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’INTRODUCTION
Tetracyclines are a class of antibiotics with broad spectrum
antibacterial activity.
1 Since the isolation of its ﬁrst member,
chlorotetracycline (1, Figure 1), from the culture broth of
Streptomyces,
2 several generations of tetracycline analogs have
been discovered and used to treat infections caused by a wide
range of pathogens. These tetracyclines include oxytetracycline
(2),
3 tetracycline (3),
4 doxycycline (4),
5 and minocycline (5),
6
all discovered before the early 1970s, as well as the recently
approved analog tigecycline (6).
7
After a half century’s use of tetracyclines, a high rate of
resistance has emerged leading to dramatically decreased
eﬃcacy.
8 There are two main tetracycline-resistance mechan-
isms: (1) active drug eﬄux (tetA tetD, and tetK tetL) and
(2)ribosomalprotection(tetM tetO).
9Theeﬄuxmechanismis
mainly observed in Gram-negative organisms such as Escherichia
coli and Pseudomonas spp.,
9,10 while ribosomal protection is
more common in Gram-positive organisms such as Staphylococ-
cus aureus and Streptococcus spp.
11
Since the discovery of the ﬁrst generation of natural tetra-
cyclines (chlorotetracycline, oxytetracycline, and tetracycline),
several generations of non-natural tetracycline antibiotics have
been produced to overcome tetracycline resistance. These in-
clude the clinically important doxycycline, minocycline, and
tigecycline, which are derived from fermentation products
through semisynthesis. However, due to the structural complex-
ity and chemical sensitivity of the tetracycline scaﬀold, chemical
modiﬁcations of tetracyclines in the past 50 years have been
largely limited to substitution at C7 and C9, and very few
modiﬁcations at C4, C5, and C6.
The total synthesis approach, recently developed by Myers
et al.,
12 can modify positions inaccessible (or diﬃcult to
access) by semisynthetic methods. Its unique “right-to-left”
(ring A to D) mode of construction provides the most eﬃcient
means to widely vary substitutions, as well as ring structures, in
the D-ring region.
12,17 Structure activity relationships (SAR) of
tetracycline analogs accumulated in the last few decades
14 and
the recently solved tetracycline 30S ribosome cocrystal
structure
15 indicate that the “southeast” portion of the molecule
is directly involved in interactions (mainly H-bonding) with the
bacterial ribosome and should be largely conserved in order to
retain high levels of ribosomal binding. In contrast, the “north-
west” portion of the molecule does not directly interact with the
ribosomeandcanbemodiﬁedwithoutsubstantiallossofactivity.
Structural variations in the D-ring region have emerged as one
of the most promising approaches to modify tetracyclines for
improvedpotencyandpharmacologicalproperties
13asshownby
previous generationsof tetracyclines such as tigecycline, which is
highlypotentandcapableofovercomingtetracyclineresistance.
7
Myers et al.
12,17 recently reported a series of pentacyclic
analogs with promising antibacterial activity against both Gram-
positiveandGram-negativeorganisms.Theseanalogswerebased
on a “pentacycline” scaﬀold (9, Figure 2),
12,17 which has an
additional benzene ring (E-ring) fused in a linear fashion to the
C8 and C9 carbons on the tetracycline D-ring. The added E-ring
notonly produces a uniquetetracyclinescaﬀoldbutalso presents
several additional derivatization sites believed to have minimum
eﬀect on ribosomal binding as expected from the binding mode
of tetracycline with the 30S ribosome. We believe this unique
pentacyclic scaﬀold, coupled with optimal substitutions and
substitution patterns, has the potential to uncover new tetracy-
cline analogs that are potent, are capable of overcoming tetra-
cyclineresistance,andhaveimprovedpharmacologicalproperties
such as oral bioavailability. We therefore decided to expand the
pentacyclineseriestoincludeamuchwiderrangeofsubstitutions
and substitution patterns. We evaluated the antibacterial activity
ofthenewpentacyclineanalogsagainstawiderangeoforganisms
including Gram-positive, Gram-negative, and tetracycline-resis-
tant strains. We also studied in vivo eﬃcacy and pharmacokinetic
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ABSTRACT: Employing a highly eﬃcient total synthesis
approach,wesynthesizedandevaluatedforantibacterialactivity
diverse and novel pentacycline analogs with systematic varia-
tions at C7, C8, C9, and C10. Certain substitution groups, as
well as substitution patterns at various positions, were found to
be preferred for increased antibacterial activity. A number of
pentacycline analogs displayed potent activity in vitro and in vivo, especially against Gram-positive organisms. Several analogs have
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properties of several new pentacycline analogs in appropriate
mouse, rat, and monkey models.
’CHEMISTRY
We applied Myers’ general synthetic approach
12,17 for the
pentacyclines (9) as outlined in Figure 2, involving the coupling
of various D E ring precursors (7) and enone 8
16 via Michael 
Dieckmann annulations. Several subseries of pentacyclines with
systematic modiﬁcations at C7 C10 were designed and synthe-
sized according to Schemes 1 10.
Several 10-substituted pentacycline analogs with no substitu-
tionatC7(7-Hpentacyclines)orwithadimethylaminogroupat
C7 (7-dimethylamino pentacyclines) were reported recently
by Myers et al.
12,17 and showed promising antibacterial activity
against both Gram-positive and Gram-negative organisms. In
order to study the eﬀect of diﬀerent substitutions and substitu-
tion patterns on the antibacterial activity of the pentacyclines,
we expanded the 7,10-disubstituted pentacycline class to include
additional C7 substituents (Cl, F, and CH3O), as well as a wide
range of C10 substituents (Scheme 1).
Thus, 6-bromophthalide (10) was treated with lithium diiso-
propylamide (LDA) and methyl crotonate, followed by treat-
ment with boron triﬂuoride diethyl etherate according to the
Broom and Sammes procedures
18 to yield 7-bromonaphthol 11
(22% yield over two steps). Naphthol 11 was methylated with
dimethylsulfate to give naphthalene 12, which was converted to
phenyl ester 13 by saponiﬁcation with aqueous sodium hydro-
xide, acid chloride formation with oxalyl chloride, and reaction
with phenol (86% yield over three steps). The methyl ether
of compound 13 was cleaved with BBr3, and the resulting
phenol was protected using di-tert-butyl dicarbonate ((Boc)2O),
4-dimethylaminopyridine (DMAP), and diisopropylethylamine
(DIEA), aﬀording the D E ring precursor 14a (89% yield over
two steps). Michael Dieckmann annulation
12 was carried out
bydeprotonationof14awithLDAinthepresenceofenone8and
N,N,N0,N0-tetramethylethylenediamine (TMEDA) in tetrahydro-
furan (THF) at  78 C, yielding the desired hexacyclic inter-
mediate 15a (47% yield). Deprotonation with phenyllithium and
lithium halogen exchange with n-butyllithium at  78 C, fol-
lowed by reaction with N,N-dimethylformamide (DMF) con-
verted 15a to aldehyde 16a in 84% yield. Reductive amination of
aldehyde 16a with a series of amines using sodium triacetoxybor-
ohydride gave secondary and tertiary amines 17a. The secondary
amineintermediateswerealsofurtherderivatizedbyacylationand
sulfonylation. Finally, desylilation with aqueous hydroﬂuoric acid
(HF) gaveintermediates18a, which weresubjectedtopalladium-
catalyzedhydrogenationtoyieldthedesired7-H-10-aminomethyl
pentacyclineanalogs19aafterreverse-phaseHPLCpuriﬁcationin
about 45 55% overall yields.
A series of 7-chloro, 7-ﬂuoro, and 7-dimethylamino-10-ami-
nomethyl pentacycline analogs were also prepared starting from
naphthalene 13 according to Scheme 1. Thus, to prepare the
7-chloro D E ring precursor (14b) required for the 7-chloro
pentacyclines (19b), compound 13 was regioselectively chlori-
natedwithN-chlorosuccinimide(NCS)toyieldphenyl7-bromo-
4-chloro-1-methoxy-3-methylnaphthalene-2-carboxylate, which
was demethylated and protected with (Boc)2O to give D E ring
precursor 14b (80% yield over three steps). The 7-ﬂuoro D E
ring precursor (14c) was prepared as follows. Intermediate 13
wasregioselectivelyiodinatedwithN-iodosuccinimide(NIS)and
triﬂuoroacetic acid (TFA) in reﬂuxing acetonitrile to give phenyl
7-bromo-4-iodo-1-methoxy-3-methylnaphthalene-2-carboxylate.
Selectivemetal iodineexchangewithn-butyllithiumat 100C
followed by quenching with N-ﬂuorobenzenesulfonimide
(NFSI)
19 yielded phenyl 7-bromo-4-ﬂuoro-1-methoxy-3-methyl-
naphthalene-2-carboxylate (51% yield over two steps), which was
convertedtoD Eringprecursor14cbythetwo-stepsequenceof
demethylationandBocprotection(78%yieldovertwosteps).For
the preparation of the 7-dimethylamino D E ring precursor
(14d), intermediate 13 was nitrated with a mixture of concen-
trated nitric acid and sulfuric acid in methylene chloride to yield
Figure 1. Structures of known tetracyclines.
Figure 2. Synthesis of pentacyclines via Michael Dieckmann annulations.3706 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
Journal of Medicinal Chemistry ARTICLE
phenyl 7-bromo-1-methoxy-3-methyl-4-nitronaphthalene-2-car-
boxylate. The methyl ether was cleaved with BBr3, and the nitro
group was reduced with zinc dust to give phenyl 4-amino-7-
bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate.Reductive
dimethylation with formaldehyde followed by Boc protection
provided D E ring precursor 14d in high overall yield. The
7-methoxy D E ring precursor (14e) was prepared as follows.
Oxidation of phenyl 4-dimethylamino-7-bromo-1-hydroxy-3-
methylnaphthalene-2-carboxylate with PhI(OAc)2 in metha-
nol/1,4-dioxane followed by treatment with zinc dust in acetic
acid aﬀorded phenyl 4-methoxy-7-bromo-1-hydroxy-3-methyl-
naphthalene-2-carboxylate,
20whichwasprotected with(Boc)2O
to give the desired D E ring precursor 14e (80% yield over two
steps).Finalanalogs(7-chloro,7-ﬂuoro,and7-dimethylamino-10-
aminomethyl pentacyclines, 19b 19e) were then prepared from
these D E ring precursors (14b 14e) using similar procedures
as described for the synthesis of 19a in moderate to good yields.
To study the eﬀect of diﬀerent alkylamino groups at C7, a set
of 7-alkylamino-10-azetidinomethyl pentacyclines were synthe-
sized according to Scheme 2. Phenyl 7-bromo-1-methoxy-3-
methyl-4-nitronaphthalene-2-carboxylate (20) was reduced to
aniline 21 with zinc dust in 86% yield. Diallylation with excess
phenyllithium and allylbromide led to diallylamine 22 (82%
yield), which was demethylated with BBr3 and protected with
(Boc)2O to yield D E ring precursor 23c (46% yield over
two steps). Additionally, D E ring precursor 23b was derived
from intermediate 21 by monoallylation with phenyllithium and
allylbromide, demethylation with BBr3, and protection of the
hydroxyl and secondary amino groups with (Boc)2O (39% yield
over three steps). Furthermore, intermediate 20 was demethy-
lated with BBr3 and reduced with Zn dust as described above for
the synthesis of analogs 19d. The resulting hydroxyaniline was
then protected as the tri-Boc intermediate by treatment with
excess (Boc)2O in DMF, followed by monodeprotection with
dilute TFA in methylene chloride to yield the di-Boc-protected
intermediate (34% yield). Methylation of the resulting carba-
mate by deprotonation with lithium bis(trimethylsilyl)amide
(LHMDS) followed by treatment with iodomethane yielded
D E ring precursor 23a (67% yield over two steps). These
threeD Eringprecursors(23a 23c)werethenannulatedwith
enone 8 to give the bromo intermediates (24a 24c)i ng o o d
yields. Formylation aﬀorded aldehydes 25a 25c, which were
reductively aminated with azetidine and deprotected to yield the
ﬁnal products 26a 26c in moderate yields.
Scheme 3 outlines the preparation of a series of 7-alkoxy-10-
azetidinomethyl pentacycline analogs. Oxidation
20 of phenyl
Scheme 1. Synthesis of 7-R-10-Aminomethyl Pentacycline Analogs
a
aReagents:(a)LDA,thenmethylcrotonate,THF;(b)BF3 Et2O,CH2Cl2;(c)(CH3)2SO4,Cs 2CO3,acetone;(d)NaOH,H2O,EtOH;(e)(COCl)2,
DMF,CH2Cl2,thenPhOH,DMAP,pyridine,CH2Cl2;(f)for14a,(1)BBr3,CH 2Cl2;(2)(Boc)2O,DMAP,DIEA,CH2Cl2;for14b,(1)NCS,CH3CN;
(2) BBr3,C H 2Cl2; (3) (Boc)2O, DMAP, CH2Cl2; for 14c, (1) NIS, TFA, CH3CN; (2) n-BuLi, then NFSI, THF; (3) BBr3,C H 2Cl2; (4) (Boc)2O,
DMAP, CH2Cl2; for 14d, (1) HNO3,H 2SO4,C H 2Cl2; (2) BBr3,C H 2Cl2; (3) Zn dust, HOAc, THF; (4) HCHO, Na(OAc)3BH, CH3CN, THF;
(5) (Boc)2O, DMAP, CH2Cl2;f o r14e, starting with phenolic precursor of 14d, (1) PhI(OAc)2,C H 3OH, 1,4-dioxane, then Zn dust, HOAc; (2) (Boc)2O,
DMAP, CH2Cl2; (g) enone 8, TMEDA, LDA, THF; (h) PhLi, n-BuLi, then DMF, THF; (i) RR0NH, Na(OAc)3BH, HOAc, 1,2-dichloroethane;
(j) acylation or sulfonylation when RNH2 was used in step i; (k) aq HF, CH3CN; (l) H2,P d  C, CH3OH.3707 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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4-dimethylamino-7-bromo-1-hydroxy-3-methylnaphthalene-2-
carboxylate (27) with PhI(OAc)2 in the presence of allyl alcohol
followed by treatment with zinc dust in acetic acid aﬀorded the
corresponding 4-allyloxy naphthol, which was protected with
(Boc)2O under standard conditions to yield the desired D E
ring precursor 28 (80% yield over two steps). Michael 
Dieckmann annulation with enone 8 gave intermediate 29
(47%yield).Formylationandreductiveaminationwithazetidine
yielded the allyl-protected intermediate 30 in good yields. Deal-
lylation with Pd(PPh3)4 and N,N-dimethylbarbituric acid gave
the naphthol intermediate 32 (86% yield). Compound 32 was
reacted with isocyanates followed by deprotections to give
carbamate analogs 33 in moderate overall yields. Intermediate
32wasalsoalkylatedwithaseriesofalcoholsunderMitsunobu
21
conditions (PPh3, diisopropyl azodicarboxylate (DIAD)) to
yield the 7-alkoxy intermediates 34. Desilylation with aqueous
HF, enol ether cleavage with HCl, and hydrogenation gave the
desired 7-alkoxy-10-azetidinomethyl pentacycline analogs 35
(25% yield over four steps). Intermediate 30 was also depro-
tected to give analog 31.
Intermediate 30 was also treated with OsO4 and N-methyl-
morpholine-N-oxide(NMO)togivethe1,2-diol36(Scheme4).
Oxidative cleavage of 36 with NaIO4 yielded aldehyde 37.
Reductive amination followed by deprotection gave the desired
7-aminoexthoxy-10-azetidinomethyl pentacycline analogs 40 in
moderate overall yields. Intermediate 36 was also deprotectedto
yield analog 38 (28% yield over three steps).
The eﬀect of substitutions at C8 was probed with a set of
8-amino, 8-methoxy, and 8-aminomethyl pentacycline analogs
preparedaccordingtoSchemes5,6,and7.Thus,4-bromophtha-
lide41(Scheme5)wasconvertedto5-bromonaphthol42under
similar conditions to those used for the preparation of 7-bromo-
naphthol 11 in 27% overall yield. Naphthol 42 was benzylated
withbenzylbromideandpotassiumcarbonatetogivecompound
43 (77% yield), which was transformed to the corresponding
phenylester44byhydrolysisandesterformationunderstandard
conditions (73% over two steps). Buchwald amination
22 of 44
withBocNH2 (74% yield),debenzylation byhydrogenation, and
reprotection with (Boc)2Oa ﬀorded the tri-Boc-protected inter-
mediate 45 (49% yield over two steps). Benzylic bromination
under radical conditions using NBS and dibenzoyl peroxide
(BPO) gave the desired D E ring precursor 46 in 81% yield.
Lithium halogen exchange of benzyl bromide 46 in the pre-
sence of enone 8 at  100 C in THF gave the desired cyclized
product 47 in 53% yield. Aqueous HF treatment of 47 followed
by hydrogenation in the presence or absence of aldehydes
yielded the desired 8-amino pentacycline analogs 49 (29% yield
over two steps).
Scheme 2. Synthesis of 7-Alkylamino-10-azetidinomethyl Pentacycline Analogs
a
aReagents:(a)Zndust,HOAc,THF;(b)PhLi,thenallylbromide,THF;(c)BBr3,CH 2Cl2;(d)(Boc)2O,DMAP,DIEA,CH2Cl2;(e)(Boc)2O,DMAP,
DMF;(f)TFA,CH2Cl2;(g)LHMDS,CH3I,THF;(h)enone8,TMEDA,LDA,THF;(i)PhLi,n-BuLi,thenDMF,THF;(j)azetidine,Na(OAc)3BH,
HOAc, 1,2-dichloroethane; (k) aq HF, acetonitrile; (l) H2,P d  C, CH3OH.3708 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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An 8-methoxy-pentacycline analog was synthesized according
to Scheme 6. Bromonaphthalene 44 was treated with bis-
(pinacolato)diboron, potassium acetate, and PdCl2(dppf) 
CH2Cl2 in hot 1,4-dioxane, followed by oxidation with H2O2
to yield the corresponding naphthol (67% yield),
23 which was
methylated to give compound 50 (74% yield). Debenzylation
by hydrogenation and protection with (Boc)2O gave intermedi-
ate 51 (90% yield over two steps), which was brominated with
NBS and 2,20-azobis(2-methylpropionitrile) (AIBN) to aﬀord
the desired D E ring precursor 52 (82% yield). Lithium halo-
gen exchange with n-butyllithium in the presence of enone 8
at 100CinTHFyieldedthedesiredcyclizedproduct53(61%
yield), which was deprotected to give the desired 8-methoxy
analog 54 (16% yield over two steps).
For the 8-aminomethyl pentacycline analogs (Scheme 7),
naphthol 42 was methylated with dimethylsulfate and cesium
carbonate to give compound 55, which was converted to the
desired D E ring precursor 57 through hydrolysis, phenyl ester
formation, demethylation, and Boc protection under conditions
described previously (76% overall yield). Michael Dieckmann
annulation of 57 with enone 8 yielded bromo intermediate 58,
which was subjected to formylation, reductive amination, desi-
lylation, and hydrogenation to yield the desired 8-aminomethyl
pentacycline analogs 61 in moderate yields.
To probe the eﬀect of substitutions at C9, a set of 9-amino-
pentacycline analogs were prepared according to Scheme 8.
5-Bromonaphthalide (62) was converted to 6-bromonaphthol
63 in 20% yield over two steps. Benzylation, hydrolysis, and
phenyl ester formation yielded intermediate 64 (46% yield over
three steps). Buchwald amination withBocNH2 gave compound
65 (64% yield), which was debenzylated by hydrogenation and
reprotected with (Boc)2O to yield compound 66 (90% over two
steps). Radical bromination of 66 using NBS and BPO aﬀorded
the desired D E ring precursor 67 (74% yield). Lithium 
halogen exchange of benzyl bromide 67 with n-butyllithium in
the presence of enone 8 at  100 C in THF gave the cyclized
compound 68 (20% yield). Aqueous HF treatment, followed by
hydrogenation in the presence or absence of aldehydes yielded
the desired 9-amino pentacycline analogs 69 (34 36% yield).
The eﬀect of C10 substitutions was explored with a set of
10-ﬂuoro pentacycline analogs prepared according to Scheme 9.
Bromonaphthalene14dwastreatedwithn-butyllithiumfollowed
byNFSItoaﬀordD Eringprecursor70(60%yield),whichwas
cyclized with enone 8 to give compound 71d in low yield (9%).
Bromo intermediates 15a, 15b, and 15e were also converted to
the corresponding ﬂuoro intermediates 71a, 71b, and 71c in
moderate yields under similar conditions. Desilylation and
hydrogenation of 71a 71d yielded the desired 10-ﬂuoro penta-
cycline analogs 72a 72d in 60 70% yields over two steps.
Scheme 10 outlines the synthesis of a series of 10-aryl
pentacyclines. Suzuki coupling of bromo intermediate 15a with
aryl boronic acids aﬀorded intermediates 73 in good yields.
Scheme 3. Synthesis of 7-Alkoxy-10-azetidinomethyl Pentacycline Analogs
a
aReagents: (a) PhI(OAc)2, allyl alcohol, 1,4-dioxane, then Zn dust, HOAc; (b) (Boc)2O, DMAP, DIEA, CH2Cl2; (c) enone 8, TMEDA, LDA, THF;
(d) PhLi, n-BuLi, then DMF, THF; (e) azetidine, Na(OAc)3BH, HOAc, 1,2-dichloroethane; (f) aq HF, CH3CN; (g) H2,P d  C, CH3OH;
(h) Pd(PPh3)4, N,N-dimethylbarbituric acid, CH2Cl2; (i) RNCO, 2,6-lutidine, CH2Cl2; (j) ROH, PPh3, DIAD, THF; (k) HCl, CH3OH.3709 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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These were deprotected as described above to yield the desired
10-aryl pentacycline analogs 75 in moderate yields.
’RESULTS AND DISCUSSION
The synthesized pentacycline analogs were evaluated for
antibacterial activity using a panel of tetracycline-sensitive and
tetracycline-resistant Gram-positive and Gram-negative bacteria
strains,andtheirminimuminhibitoryconcentrations(MICs)are
shown in Tables 1 4.
Table 1 shows the MIC data for analogs with the C10
substituent ﬁxed as an azetidinomethyl group in combination
with various C7 substituents (7-substituted-10-azetidinomethyl
Scheme 4. Synthesis of 7-(2-Aminoethoxy)-10-azetidinomethyl Pentacycline Analogs
a
aReagents: (a) OsO4, NMO,H2O, THF;(b) NaIO4,H 2O, THF;(c) RR0NH, Na(OAc)3BH,HOAc, 1,2-dichloroethane; (d) aq HF, CH3CN;(e) H2,
Pd C, CH3OH.
Scheme 5. Synthesis of 8-Amino Pentacycline Analogs
a
aReagents:(a)LDA,HMPA,thenmethylcrotonate,THF;(b)BF3 Et2O,CH2Cl2;(c)BnBr,K2CO3,acetone;(d)NaOH,H2O,EtOH;(e)(COCl)2,
DMF, CH2Cl2, then PhOH, DMAP, pyridine, CH2Cl2; (f) BocNH2,P d 2(dba)3,P ( t-Bu)3, NaOPh, toluene; (g) H2,P d  C, CH3OH; (h) (Boc)2O,
DMAP, CH2Cl2; (i) NBS, BPO, CCl4; (j) enone 8, n-BuLi, THF; (k) aq HF, THF; (l) H2,P d  C, HCl, CH3OH; (m) aldehyde, H2,P d  C, HCl,
CH3OH.3710 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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pentacyclines). While the 7-Cl analog (19b-1) was slightly less
potent than the parent compound (19a-9) and the 7-F analog
(19c-5) was equipotent to 19a-9, the 7-CH3O and 7-(CH3)2N
analogs (19e-6 and 26d) were more potent than the parent
against most Gram-positive strains, with the 7-CH3O analog
(19e-6) being the most potent compound in the series. Higher
alkoxygroupsatC7(31and35a)didnotimprovepotency,while
alkoxy groups containing additional polar or basic groups (35b,
38, 40a, and 33a) greatly reduced potency against most strains
in the panel. Among the 7-amino pentacyclines (26a 26d),
the 7-(CH3)2N analog (26d) was the most potent overall. It is
clear that tertiary amines (26c and 26d) at C7 are preferred
over secondary amines (26a and 26b). Potency against Gram-
negativestrainsdecreaseswith increasing alkyl group size among
the 7-alkoxy and 7-alkylamino analogs. The 7-alkoxy analogs
appear to have better activity against Gram-negative organisms.
It is important to note that several analogs, especially the
7-CH3O analog (19e-6), displayed good potency against all
Gram-positive resistant strains (tetK and tetM) in the panel
(MIC = 0.0625 2 μg/mL) and their tetM activity is usually
better than that of minocycline. However, these analogs are not
as potent as tigecycline against most strains in the panel.
Table 2 outlines the antibacterial activity of analogs in which
the C10 substitution was varied while keeping C7 constant as H.
Amongthe10-arylanalogs, compounds75aand75b(10-phenyl
and10-(3-pyridinyl))hadsimilaractivitytotheunsubstitutedparent
compound (19a-1) against most strains except S. pneumoniae,
while the p-dimethylaminophenyl analog (75c) had almost no
Scheme 7. Synthesis of 8-Aminomethyl Pentacycline Analogs
a
aReagents:(a)(CH3)2SO4,Cs 2CO3,acetone;(b)NaOH,H2O,EtOH;(c)(COCl)2,DMF,CH2Cl2,thenPhOH,DMAP,pyridine,CH2Cl2;(d)BBr3,
CH2Cl2; (e) (Boc)2O, DMAP, DIEA, CH2Cl2; (f) enone 8, TMEDA, LDA, THF; (g) PhLi, n-BuLi, then DMF, THF; (h) RR0NH, Na(OAc)3BH,
HOAc, 1,2-dichloroethane; (i) aq HF, CH3CN; (j) H2,P d  C, CH3OH.
Scheme 6. Synthesis of an 8-Methoxy Pentacycline Analog
a
aReagents: (a) bis(pinacolato)diboron, KOAc, PdCl2(dppf) CH2Cl2, 1,4-dioxane, then H2O2, HOAc, THF; (b) CH3I, K2CO3, acetone; (c) H2,
Pd C,CH3OH; (d) (Boc)2O, DMAP,CH2Cl2; (e) NBS,AIBN, CCl4;(f) enone 8, n-BuLi, THF;(g) aqHF, CH3CN; (h) H2,P d  C,HCl, CH3OH.3711 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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activity across the board. On the other hand, the various 10-
aminomethyl analogs, especially the 10-(CH3)2NCH2 analog
(19a-6), displayed good antibacterial activity, particularly against
the Gram-positive strains. Aromatic aminomethyl substituents
(19a-8),aswellasnonbasicaminomethylgroupsatC10(19a-19),
lead to decreased potency. It is clear that small basic alkylamines
(C1 C6) arepreferredattheC10benzylicpositionforimproved
activityagainst both Gram-positive and Gram-negative organisms.
Introduction of additional polar or basic groups decreased activity
in general (19a-12 to 19a-16). It is interesting that while the 3-F-
azetidinomethyl analog (19a-17) hadsimilar activity tothe parent
compound (19a-1) against Gram-positive strains and better
activityagainstGram-negativestrains,the3,3-di-F-azetidinomethyl
analog (19a-18) had almost no activity against Gram-negative
strains. It is likely that the azetidine nitrogen is only weakly basic
due to the gem,gem-diﬂuoro substitutions.
Table3showstheantibacterial activity ofanalogswithvarious
combinations of C7 and C10 substituents. All 10-aminomethyl
pentacycline analogs bearing a F, Cl, CH3O, or (CH3)2N group
at C7 had good potency in general, especially against Gram-
positive bacteria. While the 7-CH3O-10-azetidinomethyl analog
(19e-6) was the most active analog and the 7-Cl analog (19b-1)
had the least activity among this 10-aminomethyl pentacycline
series, the variation at C7 from F to Cl, CH3O, and (CH3)2N
did not drastically alter the analogs’ potency. As for the C10
substituents, the analogs were able to maintain good potency as
Scheme 9. Synthesis of 10-Fluoro Pentacycline Analogs
a
aReagents: (a) n-BuLi, then NFSI, THF; (b) enone 8, TMEDA, LDA, THF; (c) aq HF, CH3CN; (d) H2,P d  C, CH3OH; (e) PhLi, n-BuLi, then
NFSI, THF.
Scheme 8. Synthesis of 9-Amino Pentacycline Analogs
a
aReagents: (a) LDA, then methyl crotonate, THF; (b) BF3 Et2O, CH2Cl2; (c) BnBr, K2CO3, acetone; (d) NaOH, H2O, EtOH; (e) (COCl)2, DMF,
CH2Cl2, then PhOH, DMAP, pyridine, CH2Cl2; (f) BocNH2,P d 2(dba)3,P ( t-Bu)3,C s 2CO3, toluene; (g) H2,P d  C, EtOAc, CH3OH; (h) (Boc)2O,
DMAP, CH2Cl2; (i) NBS, BPO, CCl4; (j) enone 8, n-BuLi, THF; (k) aq HF, CH3CN; (l) H2,P d  C, HCl, CH3OH; (m) aldehyde, H2,P d  C, HCl,
CH3OH.3712 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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long as a small alkylaminomethyl group (C1 C6) is present, as
alsoindicatedbydatainTable2.HeterosubstitutionsonthisC10
moietydecreaseoverall activityasshown byanalog19d-2.While
the10-ﬂuoroanalogs(72a 72d) maintainedpotencyagainstmost
Gram-positive strains, they are much less active than the corre-
sponding10-aminomethylanalogsagainstthetwoS.pneumoniae
strains and all the Gram-negative strains. Although the 7-CH3O-
10-azetidinylmethyl analog (19e-6) had comparable activity to
tigecycline against most Gram-positive strains (except EF159),
most other analogs were less potent in general, especially against
Gram-negative organisms.
The antibacterial activity of the 8-aminomethyl, 8-amino,
8-CH3O, and 9-amino pentacycline analogs is shown in Table 4.
Most had similar or decreased activity relative to the parent
compound (19a-1). Analogs with an 8-aminomethyl group
(61a 61c) had decreased activity against the tetM strains
(SA161, EF159, and SP160) but maintained activity against
the tetK strain (SA158). While analogs with an amino group at
C8 or C9 (49a 49c, 69a, 69b) had decreased potency overall,
the 8-methoxy analog (54) maintained activity against the
S. aureus and E. faecalis strains but had signiﬁcantly decreased
activity against the S. pneumoniae strains. As data in previous
tables has shown, a proper combination of substitutions at the
C7 and C10 positions, particularly a methoxy group at C7 and
a small aminomethyl group at C10, is preferred for increased
overall potency. Since analogs in Table 4 do not have any
Table 1. In Vitro Antibacterial Activity of 7-Substituted-10-Azetidinomethyl Pentacyclines
aStrainswereobtainedfromtheAmericanTypeCultureCollection(ATCC,Manassas,VA)unlessotherwisenoted.Theﬁrstsevenstrainsfromtheleft
are Gram-positive strains. The last seven strains are Gram-negative strains. Strains with “tetA”, “tetK”,o r“tetM” noted underneath are tetracycline-
resistant strains. SA, Staphylococcus aureus; EF, Enterococcus faecalis; SP, Streptococcus pneumoniae; EC, Esherichia coli; AB, Acinetobacter baumannii; PA,
Pseudomonas aeruginosa; ECl, Enterobacter cloacae; KP, Klebsiella pneumoniae.
bObtained from Micromyx (Kalamazoo, MI).
cObtained from Marilyn
Roberts’ laboratory at the University of Washington.
dSee ref 17.
Scheme 10. Synthesis of 10-Aryl Pentacycline Analogs
a
aReagents: (a) ArB(OH)2, PdCl2(dppf) CH2Cl2,N a 2CO3,H 2O, toluene; (b) aq HF, CH3CN; (c) H2,P d  C, CH3OH.3713 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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substitution at C10, it is possible that additional substitution at
C10 would result in analogs with increased activity.
Pharmacokinetic (PK) measurements in Sprague Dawley
rats and in vivo eﬃcacy studies in a mouse septicemia model
were performed on a selected set of pentacycline analogs
(Table 5). The 7-H analogs appear to have lower clearances
and higher AUC’s than the 7-CH3O and 7-F analogs. While
compounds 19a-17 and 19c-5 are closely related analogs, diﬀer-
ing only in the position of the ﬂuorine atom, their Vz and other
PK parameters are quite diﬀerent. Due to the extremely poor
exposure of 19c-5, its exceptionally large Vz probably has little
meaning. In terms of oral bioavailability, three out of the four
analogs with oral bioavailability (%F) of greater than 10% are
compounds with ﬂuorine either at C7 or on the C10 side chain
(19a-17, 19c-6, and 19e-7), with both 19a-17 and 19e-7 having
oralbioavailabilityofabout18%.Compound19a-17alsoshowed
similar oral bioavailability in cynomolgus monkeys. A number
of analogs displayed very good in vivo eﬃcacy in the mouse
septicemia model with PD50 values ranging from less than 0.3 to
0.62 mg/kg when dosed intravenously, while both tetracycline
and tigecycline had a similar PD50 of 0.35 mg/kg in the same
model. Compound 19a-17 was also dosed orally in the septice-
mia model and showed a PD50 of 12.2 mg/kg. As a comparison,
tetracycline had an oral bioavailability of 12% and an oral PD50
of 8.1 mg/kg in these models, while tigecycline had almost no
oral bioavailability in the rats.
’CONCLUSIONS
Employing a highly eﬃcient total synthesis approach, we have
prepared diverse and novel pentacycline analogs with systematic
variations at C7, C8, C9, and C10. The in vitro and in vivo
antibacterial activities of these pentacycline analogs were eval-
uated, and their structure activity relationships (SAR) were
analyzed. All pentacycline analogs retain a varying degree of
activity against most strains used in the screening panel, espe-
cially Gram-positive organisms. This provides additional evi-
dencethatthe“northwest”portionofthemoleculeisnotdirectly
involved in binding with the ribosome. It is observed that certain
combinations of substitutions at both C7 and C10 can enhance
the pentacyclines’ overall potency. For example, analogs with a
methoxy group at C7 and a small basic alkylaminomethyl group
atC10arethemostpotentpentacyclinesagainstbothsusceptible
and resistant Gram-positive organisms, while nonbasic substitu-
ents at C10 generally do not improve potency. These observa-
tions should prove to be valuable for further SAR studies of
pentacyclines and other tetracycline classes. Although all penta-
cycline analogs prepared so far are less potent in vitro than
tigecycline, a number of analogs showed in vivo eﬃcacy compar-
able to tigecycline when dosed intravenously in a mouse septi-
cemia model. Several analogs had promising oral bioavailability
in rats and cynomolgus monkeys, while tigecycline had almost
no oral bioavailability in rats. Moreover, compound 19a-17,a
Table 2. In Vitro Antibacterial Activity of 7-H-10-Substituted Pentacyclines
aStrainswereobtainedfromtheAmericanTypeCultureCollection(ATCC,Manassas,VA)unlessotherwisenoted.Theﬁrstsevenstrainsfromtheleft
are Gram-positive strains. The last seven strains are Gram-negative strains. Strains with “tetA”, “tetK”,o r“tetM” noted underneath are tetracycline-
resistant strains. SA, Staphylococcus aureus; EF, Enterococcus faecalis; SP, Streptococcus pneumoniae; EC, Esherichia coli; AB, Acinetobacter baumannii; PA,
Pseudomonas aeruginosa; ECl, Enterobacter cloacae; KP, Klebsiella pneumoniae.
bObtained from Micromyx (Kalamazoo, MI).
cObtained from Marilyn
Roberts’ laboratory at the University of Washington.
dSee ref 17.3714 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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Table 3. In Vitro Antibacterial Activity of 7,10-Disubstituted Pentacyclines
aStrainswereobtainedfromtheAmericanTypeCultureCollection(ATCC,Manassas,VA)unlessotherwisenoted.Theﬁrstsevenstrainsfromtheleft
are Gram-positive strains. The last seven strains are Gram-negative strains. Strains with “tetA”, “tetK”,o r“tetM” noted underneath are tetracycline-
resistant strains. SA, Staphylococcus aureus; EF, Enterococcus faecalis; SP, Streptococcus pneumoniae; EC, Esherichia coli; AB, Acinetobacter baumannii; PA,
Pseudomonas aeruginosa; ECl, Enterobacter cloacae; KP, Klebsiella pneumoniae.
bObtained from Micromyx (Kalamazoo, MI).
cObtained from Marilyn
Roberts’ laboratory at the University of Washington.
Table 4. In Vitro Antibacterial Activity of 8-Substituted and 9-Substituted Pentacyclines
aStrainswereobtainedfromtheAmericanTypeCultureCollection(ATCC,Manassas,VA)unlessotherwisenoted.Theﬁrstsevenstrainsfromtheleft
are Gram-positive strains. The last seven strains are Gram-negative strains. Strains with “tetA”, “tetK”,o r“tetM” noted underneath are tetracycline-
resistant strains. SA, Staphylococcus aureus; EF, Enterococcus faecalis; SP, Streptococcus pneumoniae; EC, Esherichia coli; AB, Acinetobacter baumannii; PA,
Pseudomonas aeruginosa; ECl, Enterobacter cloacae; KP, Klebsiella pneumoniae.
bObtained from Micromyx (Kalamazoo, MI).
cObtained from Marilyn
Roberts’ laboratory at the University of Washington.
dSee ref 17.3715 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
Journal of Medicinal Chemistry ARTICLE
10-(3-ﬂuoroazetidino)methyl pentacycline analog, showed pro-
mising in vivo eﬃcacy comparable to tetracycline when dosed
orally in the mouse septicemia model. We believe pentacycline
analogs such as compound 19a-17, or future analogs derived
from this unique scaﬀold, have the potential to be further
developed as oral and iv agents against resistant Gram-positive
pathogens. This study demonstrates that the total synthesis
approach can give access to novel and potent tetracycline
analogs, such as the pentacyclines and azatetracyclines,
24 that
would be inaccessible through semisynthetic methods.
’EXPERIMENTAL SECTION
Chemistry. All commercially available solvents, including anhy-
drous solvents, and reagents were used without further purification.
All reactions under dry conditions were performed under nitrogen
atmospheres. Reductive aminations with amine salts were performed in
the presence of equal equivalents of triethylamine in addition to other
reagents.
1H and
13C NMR (nuclear magnetic resonance) spectra were
recorded on a 400 MHz JEOL ECX-400 spectrometer. Thin layer
chromatography (TLC) analysis was performed on Merck silica-gel
60 F254 and visualized under UV light. Flash chromatography was per-
formedonMercksilicagel60(40 43μm).Purityoftestedcompounds
was determined to be g95% by reverse-phase analytical HPLC/MS
analysis (high performance liquid chromatography/mass spectrometry)
performed on a Waters Alliance system (column, SunFire C18, 5 μm,
4.6   50 mm
2; solvent A, water with 0.1% formic acid; solvent B,
acetonitrile with 0.1% formicacid; MS detector, Waters 3100). Reverse-
phase preparative HPLC was performed on a Waters Autopurification
system (for purification of intermediates, column, SunFire Prep C18
OBD, 5 μm, 19   50 mm
2; flow rate, 20 mL/min; solvent A, water with
0.1% formic acid; solvent B, acetonitrile with 0.1% formic acid; fraction
collection, mass-directed; for purification of final products, column,
Polymerx RP-1 100A, 10 μm, 150   21.20 mm
2; flow rate, 20 mL/min;
solvent A, water with 0.05 N HCl; solvent B, acetonitrile; fraction
collection, mass-directed).
Methyl 7-Bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate
(11). A solution of n-butyllithium in hexanes (2.50 M, 48.4 mL,
121.1 mmol, 1.2 equiv) was added to a solution of diisopropylamine
(17.0 mL, 121.1 mmol, 1.2 equiv) in THF (400 mL) at  78 C. The
solutionwasvigorouslystirredat 78Cfor30min,warmedto0Cfor
5 min, and cooled back to  78 C. A solution of 6-bromophthalide
25
(10, 21.5 g, 100.9 mmol, 1.0 equiv) in THF (200 mL) was added slowly
via a cannula. The resulting dark solution was allowed to slowly warm
to 50Cover3h.Methylcrotonate(11.8mL,111.0mmol,1.1equiv)
was added slowly, and the resulting mixture was allowed to warm to rt
Table 5. Pharmacokinetic Proﬁles and in Vivo Eﬃcacy of Pentacyclines
aMeasuredinSprague Dawleyrats(n=3).Animalswerefastedovernight(minimumof12h)andgivenasingleoral(10mg/kg)oriv(1mg/kg)dose
followed by a sampling scheme for 24 48 h. Sterile water was used as vehicle. PK parameters were calculated by noncompartmental analysis using
WinNonlin. ND = not determined.
bSA, Staphylococcus aureus.
cDetermined in a mouse septicemia model (SA100, ATCC 13709). See Experimental
Section for details. Numbers in parentheses are 95% CI values.3716 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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without removing the cooling bath. The reaction mixture was poured
into 1 N HCl (600 mL) and extracted with ethyl acetate (200 mL   3).
The organic extracts were combined and dried over anhydrous magne-
sium sulfate. The dried solution was filtered, and the filtrate was
concentrated and dried under high vacuum, providing an orange foamy
solid (27.5 g), which was used for the next reaction without further
treatment.
The above crude product was dissolved in methylene chloride
(250 mL). BF3 Et2O (2.52 mL, 20.2 mmol, 0.2 equiv) was added
dropwiseatrt.Theresultingbrownishmixturewasstirredatrtfor1hand
poured into 0.5 N HCl (600 mL). The organic layer was separated, and
the aqueous layer was extracted with methylene chloride (200 mL   2).
The organic extracts were combined and dried over anhydrous magne-
sium sulfate. The dried solution was ﬁltered, and the ﬁltrate was
concentrated, providingathickbrownish oil. Puriﬁcationbyﬂash column
chromatography(5%f10%ethylacetate hexanes)aﬀordedcompound
11 as an oﬀ-white solid (6.32 g, 22%, two steps):
1H NMR (400 MHz,
CDCl3) δ 12.68 (s, 1 H), 8.52 (s, 1 H), 7.63 7.61 (d, J = 8.5 Hz, 1 H),
7.52 7.50(d,J=8.5 Hz,1 H),7.07 (s,1H),4.01 (s,3H),2.63(s,3 H).
Methyl 7-Bromo-1-methoxy-3-methylnaphthalene-2-carboxylate
(12). Cesium carbonate powder (9.06 g, 27.8 mmol, 1.3 equiv) and
dimethyl sulfate (2.43 mL, 25.7 mmol, 1.2 equiv) were added to a
solution of 11 (6.31 g, 21.0 mmol, 1.0 equiv) in acetone (60 mL). The
mixture was heated at reflux for 1 h, cooled to rt, and filtered through
a short pad of Celite. The Celite cake was washed thoroughly with
acetone. The filtrate was concentrated to afford 12 as a white solid,
whichwasusedforthenextreactiondirectlywithoutfurtherpurification.
Phenyl 7-Bromo-1-methoxy-3-methylnaphthalene-2-carboxylate
(13). A mixture of ethanol (10 mL) and 4 N aqueous sodium hydroxide
(10 mL) was added to compound 12. The suspension was stirred at
85 C overnight. The resulting clear solution was cooled to rt, acidified
with 4 N HCl (pH 3, 11 mL), and extracted with methylene chloride
(30 mL   4). The combined organic extracts were dried over magne-
sium sulfate, filtered, and concentrated to afford the carboxylic acid as
a pale solid.
Oxalyl chloride (2.24 mL, 25.7 mmol, 1.2 equiv) was added to a
solution of the above carboxylic acid in anhydrous methylene chloride
(100 mL) at rt, followed by a couple of drops of DMF (gas evolution).
The mixture was stirred at rt for 1 h and the volatiles evaporated under
reduced pressure. The residue was dried under high vacuum to give the
crude acid chloride. This was redissolved in dry methylene chloride
(100 mL). Pyridine (3.46 mL, 42.8 mmol, 2.0 equiv), phenol (2.11 g,
22.5mmol,1.05equiv),andDMAP(catalyticamount)wereadded.The
reaction mixture was stirred forseveral hours atrt, diluted with 1 N HCl
(100 mL), and extracted with methylene chloride (50 mL   3). The
combined organic extracts were washed with brine (40 mL) and dried
over anhydrous magnesium sulfate. The dried solution was ﬁltered, and
the ﬁltrate was concentrated. The residue was puriﬁed by ﬂash column
chromatography (5% f 10% ethyl acetate hexanes) to aﬀord the
desired product 13 as a white solid (6.86 g, 86%, three steps):
1H NMR
(400 MHz, CDCl3) δ 8.22 (d, J = 1.8 Hz, 1 H), 7.60 7.52 (m, 2 H),
7.44 7.39 (m, 3 H), 7.27 7.24 (m, 3 H), 4.05 (s, 3 H), 2.53 (s, 3 H).
Phenyl7-Bromo-1-[(tert-butoxycarbonyl)oxy]-3-methylnaphthalene-
2-carboxylate (14a). A solution of BBr3 in methylene chloride (1.0 M,
5.83 mL, 5.83 mmol, 2.0 equiv) was added slowly over 4 min to
a solution of compound 13 (1.08 g, 2.91 mmol, 1.0 equiv) in methylene
chloride (60 mL) at  70 C. The resulting orange solution was allowed
to warm to  45 C over 5 h and poured into saturated aqueous sodium
bicarbonate (100 mL). The mixture was stirred at rt for 10 min and
extracted with methylene chloride (60 mL   3). The organic extracts
were combined and dried over anhydrous magnesium sulfate. The dried
solution was filtered, and the filtrate was concentrated, providing the
naphthol intermediate as a white solid, which was used in the next
reaction without further purification.
(Boc)2O(670mg,3.20mmol,1.1equiv),DIEA(1.01mL,5.82mmol,
2.0 equiv), and DMAP (20 mg, 0.16 mmol, 0.05 equiv) were added to a
solution of the above intermediate in methylene chloride (60 mL). The
mixture was stirred at rt overnight and concentrated under reduced
pressure. The residue was puriﬁed by ﬂash column chromatography
(5% ethyl acetate hexanes) to aﬀord the desired product 14a as
a white solid (1.19 g, 89%, two steps):
1H NMR (400 MHz, CDCl3)
δ 8.03 (d, J = 1.8 Hz, 1 H), 7.63 7.55 (m, 3 H), 7.43 7.39 (m, 2 H),
7.28 7.24 (m, 3 H), 2.60 (s, 3 H), 1.44 (s, 9 H);
13C NMR (100 MHz,
CDCl3) δ 164.7, 151.2, 150.5, 144.9, 134.0, 133.4, 131.6, 129.5, 128.9,
126.9, 126.7, 126.3, 124.5, 124.0, 121.7, 120.9, 84.6, 27.5, 20.7.
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-9-bromo-4a-{[tert-butyl(dimethyl)-
silyl]oxy}-15-(dimethylamino)-5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,-
14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-Butyl Carbonate
(15a). Michael Dieckmann Cyclization, General Procedure A. A
solution of LDA (1.8 M, 4.30 mL, 7.74 mmol, 3.0 equiv) in heptane/
ethylbezene/THF was added dropwise via a syringe to a solution of
compound 14a (2.36 g, 5.16 mmol, 2.0 equiv), enone 8 (1.24 g, 2.58
mmol,1.0equiv),andTMEDA(2.32mL,15.5mmol,6.0equiv)inTHF
(100 mL) at  78 C. The resulting red-orange solution was allowed to
warmto 10Cover2handdilutedwithaqueouspotassiumphosphate
buffer (pH 7.0, 0.2 M, 50 mL) and saturated aqueous ammonium
chloride. The mixture was extracted with ethyl acetate (200 mL   2).
The organic extracts were combined, dried over anhydrous sodium
sulfate,andfiltered.Thefiltratewasconcentratedunderreducedpressure
to give the crude product, which was purified by flash column chroma-
tography (5% f 10% ethyl acetate hexanes) to afford the Michael 
Dieckmanncyclizationproduct15aas anorangesolid(1.02 g, 47%):
1H
NMR(400MHz,CDCl3)δ 15.98(brs,1 H),8.24(brs,1H),7.64 (s,2
H),7.51 7.49(m,3H),7.39 7.33(m,3H),5.37(d,J=12.0Hz,1H),
5.34(d,J=12.0Hz,1H),3.96(d,J=10.5Hz,1H),3.11 3.06(m,2H),
2.93 (t, J = 15.5 Hz, 1 H), 2.56 (dd, J = 11.0, 5.0 Hz, 1 H), 2.49 (s, 6 H),
2.49 2.46 (m, 1 H), 2.14 (d, J = 14.0 Hz, 1 H), 1.59 (s, 9 H), 0.82
(s, 9 H), 0.27 (s, 3 H), 0.12 (s, 3 H); MS (ESI) m/z 845.70 (M þ H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]oxy}-
15-(dimethylamino)-9-formyl-5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,-
14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-Butyl Carbonate
(16a). Formylation, General Procedure B. A solution of phenyllithium
in di-n-butyl ether (1.8 M, 0.20 mL, 0.36 mmol, 2.0 equiv) was added
dropwisetoasolutionofcompound15a(153mg,0.18mmol,1.0equiv)
in THF (9 mL) at  78 C. The resulting red solution was stirred at
 78 C for 5 min. n-Butyllithium (94 μL, 2.5 M/hexanes, 0.24 mmol,
1.3 equiv) was added dropwise at  78 C. The reaction was stirred at
 78 C for 5 min. Dry DMF (69 μL, 0.90 mmol, 5.0 equiv) was added.
The deep red reaction mixture was stirred at  78 C for 1 h. Saturated
aqueous ammonium chloride (10 mL) was added dropwise at  78 C.
Aqueouspotassiumphosphatebuffer(pH7.0,0.2M,10mL)wasadded.
The reaction mixture was allowed to warm to rt and extracted with
methylene chloride (30 mL   3). The organic extracts were combined,
dried over anhydrous sodium sulfate, and filtered. The filtrate was
concentrated under reduced pressure. The residue was purified by
preparative reverse-phase HPLC to afford the desired product 16a
(121mg,84%)asayellowsolid:Rf=0.15(25%ethylacetate hexanes);
1H NMR (400 MHz, CDCl3) δ 15.98 (br s, 1 H), 10.17 (s, 1 H), 8.60
(br s,1H),8.06(dd, J=8.4, 1.6 Hz,1H),7.88 (d,J=8.4Hz,1H),7.62
(s, 1 H),7.52 7.50 (m, 2 H),7.41 7.34 (m, 3 H),5.38 (d, J =12.4 Hz,
1 H), 5.35 (d, J = 12.4 Hz, 1 H), 3.98 (d, J = 10.4 Hz, 1 H), 3.18 3.13
(m, 2 H), 3.03 2.96 (m, 1 H), 2.61 2.56 (m, 1 H), 2.51 (s, 6 H),
2.50 2.48 (m, 1 H), 2.18 (d, J = 14.4 Hz, 1 H), 1.62 (s, 9 H), 0.84 (s, 9
H), 0.29 (s, 3 H), 0.15 (s, 3 H);
13C NMR (100 MHz, CDCl3) δ 191.5,
187.2, 181.7, 167.5, 140.5, 138.7, 135.0, 134.7, 129.5, 128.5, 128.48,
128.45, 128.42, 126.8, 126.0, 123.9, 120.7, 108.5, 108.4, 84.9, 81.8, 72.5,
61.2, 46.4, 41.8, 39.9, 28.4, 27.7, 26.0, 22.7, 19.0,  2.6,  3.8; MS (ESI)
m/z 795.7 (M þ H).3717 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-[(dimethylamino)methyl]-
3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydro-
pentacene-2-carboxamide (19a-6). Reductive Amination, General
Procedure C. Dimethylamine (44 μL, 2.0 M/THF, 0.088 mmol, 7.0
equiv), acetic acid (5 μL, 0.088 mmol, 7.0 equiv), and sodium triacetox-
yborohydride(19mg,0.088mmol,7.0equiv)wereaddedtoasolutionof
aldehyde 16a (10 mg, 0.012 mmol, 1.0 equiv) in 1,2-dichloroethane
(1 mL) at rt. After being stirred for 2 h, the reaction mixture was poured
into aqueous potassium phosphate buffer (pH = 7.0, 10 mL). The
mixture was extracted with methylene chloride (15 mL   3). The
combined organic extracts were dried over anhydrous sodium sulfate
and filtered. The filtrate was concentrated to give the crude product.
Desilylation, General Procedure D. Concentrated aqueous hydro-
fluoricacid(48wt%,0.3mL)wasaddedtoasolutionoftheabovecrude
product in acetonitrile (0.6 mL) in a polypropylene reaction vessel at rt.
The mixture was vigorously stirred at rt overnight and poured into
aqueous dipotassium hydrogen phosphate (3.6 g in 25 mL water). The
mixture was extracted with ethyl acetate (20 mL   3). The combined
organic extracts were dried over anhydrous sodium sulfate and filtered.
Thefiltratewasconcentratedto givethe crudeproductasayellowsolid.
Hydrogenation, General Procedure E. Methanol (3 mL) was added
totheabovecrudeproduct.10%Pd C(catalyticamount)wasaddedin
one portion at rt. An atmosphere of hydrogen was introduced by briefly
evacuating the flask and flushing with hydrogen (1 atm). The reaction
mixture was stirred at rt for 4 h and filtered through a pad of Celite. The
filtratewasconcentratedtogivethecrudeproduct,whichwaspurifiedby
preparative reverse-phase HPLCto yieldthe desiredproduct (19a-6)as
ayellowsolid(3.6mg,HClsalt,51%,threesteps):
1HNMR(400MHz,
CD3OD)δ8.48(brs,1H),7.83(d,J=7.9Hz,1H),7.74(d,J=6.9Hz,
1 H), 7.16 (br s, 1 H), 4.49 (br s, 2 H), 4.10 (br s, 1 H), 3.03 2.95
(m, 9 H), 2.87 (s, 6 H), 2.64 2.57 (m, 1 H), 2.25 2.22 (m, 1 H),
1.60 1.58 (m, 1 H); MS (ESI) m/z 522.50 (M þ H).
The following compounds were prepared similarly to 19a-6 using
aldehyde16aandtherespectiveaminesaccordingtogeneralprocedures
C, D, and E.
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-[(methylamino)methyl]-
3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydro-
pentacene-2-carboxamide (19a-2).
1H NMR (400 MHz, CD3OD) δ
8.51 (s, 1 H), 7.86 (d, J = 8.5 Hz, 1 H), 7.71 (dd, J = 1.8, 8.5 Hz, 1 H),
7.21 (s, 1 H), 4.37 (s, 2 H), 4.10 (s, 1 H), 3.17 2.96 (m, 9 H), 2.77
(s, 3 H), 2.67 (t, J = 13.4 Hz, 1 H), 2.28 2.21 (m, 1 H), 1.69 1.57
(m, 1 H); MS (ESI) m/z 508.45 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-
1,13-dioxo-10-[(propylamino)methyl]-1,4,4a,5,5a,6,13,14a-octahydro-
pentacene-2-carboxamide (19a-3).
1H NMR (400 MHz, CD3OD) δ
8.52 (s, 1 H), 7.86 (d, J = 8.5 Hz, 1 H), 7.74 (dd, J = 1.8, 8.5 Hz,
1 H), 7.21 (s, 1 H), 4.38 (s, 2 H), 4.11 (s, 1 H), 3.17 2.96 (m, 11 H),
2.67 (t, J = 13.4 Hz, 1 H), 2.28 2.20 (m, 1 H), 1.82 1.71 (m, 2 H),
1.69 1.57 (m, 1 H), 1.04 (t, J = 7.9 Hz, 3 H); MS (ESI) m/z 536.50
(M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-10-
[(isobutylamino)methyl]-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydro-
pentacene-2-carboxamide (19a-4).
1H NMR (400 MHz, CD3OD) δ
8.53 (s, 1 H), 7.84 (d, J = 8.5 Hz, 1 H), 7.74 (dd, J = 1.8, 8.5 Hz, 1 H),
7.19 (s, 1 H), 4.39 (s, 2 H), 4.10 (s, 1 H), 3.17 2.90 (m, 9 H), 2.66
(t, J = 14.0 Hz, 1 H), 2.28 2.18 (m, 1 H), 2.12 2.00 (m, 1 H),
1.70 1.57 (m, 1 H), 1.03 (d, J = 6.7 Hz, 6 H); MS (ESI) m/z 550.49
(M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-10-
{[(2-methoxyethyl)amino]methyl}-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19a-5).
1H NMR (400 MHz,
CD3OD) δ 8.51 (s, 1 H), 7.84 (d, J = 8.5 Hz, 1 H), 7.72 (dd, J = 1.8, 8.5
Hz, 1 H), 7.18 (s, 1 H), 4.41 (s, 2 H), 4.11 (s, 1 H), 3.67 (t, J = 4.9 Hz,
2 H), 3.41 (s, 3 H), 3.28 3.24 (m, 2 H), 3.15 2.92 (m, 9 H), 2.65
(t, J = 14.0 Hz, 1 H), 2.27 2.18 (m, 1 H), 1.69 1.54 (m, 1 H); MS
(ESI) m/z 552.47 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-{[ethyl(methyl)amino]-
methyl}-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19a-7).
1H NMR (400 MHz,
CD3OD)δ8.49(brs,1H),7.83(d,J=7.3Hz,1H),7.75(d,J=7.8Hz,
1 H), 7.16 (br s, 1 H), 4.59 (m, 1 H), 4.41 (m, 1 H), 4.10 (br s, 1 H),
3.30 2.95 (m, 11 H), 2.78 (s, 3 H), 2.64 2.58 (m, 1 H), 2.28 2.18
(m, 1 H), 1.60 1.58 (m, 1 H), 1.38 (m, 3 H); MS (ESI) m/z 536.59
(M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-{[methyl(phenyl)amino]-
methyl}-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19a-8).
1H NMR (400 MHz,
CD3OD)δ8.28(s,1H),7.80(d,J=8.2Hz,1H),7.51 7.43(m, 6H),
7.13 (s, 1 H), 4.96 (s, 2 H), 4.08 (s, 1 H), 3.41 (s, 3 H), 3.03 2.96 (m,
9 H), 2.64 (t, J = 14.6 Hz, 1 H), 2.20 2.19 (m, 1 H), 1.67 1.57 (m,
1 H); MS (ESI) m/z 584.54 (M þ H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-
3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydro-
pentacene-2-carboxamide (19a-9).
1H NMR (400 MHz, CD3OD) δ
8.44 (s, 1 H), 7.70 (d, J = 8.7 Hz, 1 H), 7.68 (dd, J = 1.8, 8.7 Hz, 1 H),
7.13 (s, 1 H), 4.55 (s, 2 H), 4.29 4.22 (m, 2 H), 4.12 4.08 (m, 3 H),
3.10 2.96(m,9H),2.63 2.55(m,2H),2.50 2.46(m,1H),2.26 2.21
(m, 1 H), 1.65 1.56 (m, 1 H); MS (ESI) m/z 534.51 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-
1,13-dioxo-10-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,13,14a-octahy-
dropentacene-2-carboxamide (19a-10).
1HN M R( 4 0 0M H z ,
CD3OD) δ 8.49 (s, 1 H), 7.81 7.78 (m, 2 H), 7.15 (s, 1 H), 4.54
(s, 2 H), 4.10 (s, 1 H), 3.49 (m, 2 H), 3.22 (m, 2 H), 3.03 2.95 (m,
9H ) ,2 . 6 3  2.58 (m, 1 H), 2.25 2.17 (m, 3 H), 2.02 1.98 (m, 2 H),
1.64 1.54 (m, 1 H); MS (ESI) m/z 548.58 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-
1,13-dioxo-10-(piperidin-1-ylmethyl)-1,4,4a,5,5a,6,13,14a-octahy-
dropentacene-2-carboxamide (19a-11).
1H NMR (400 MHz,
CD3OD) δ 8.50 (s, 1 H), 7.84 7.76 (m, 2 H), 7.17 (s, 1 H), 4.45
(s, 2 H), 4.10 (s, 1 H), 3.46 3.44 (m, 2 H), 3.10 2.96 (m, 11 H),
2.65 2.59 (m, 1 H), 2.25 2.17 (m, 1 H), 1.92 1.79 (m, 5 H),
1.60 1.52 (m, 2 H); MS (ESI) m/z 562.54 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-
10-[(3-hydroxyazetidin-1-yl)methyl]-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19a-12).
1H NMR (400 MHz,
CD3OD)δ8.49(s,1H),7.85(d,J=8.5Hz,1H),7.72 7.66(m, 1H),
7.19 (s, 1 H), 4.74 4.51 (m, 3 H), 4.42 4.28 (m, 2 H), 4.10 (s, 1 H),
4.08 3.94 (m, 2 H), 3.17 2.91 (m, 9 H), 2.66 (t, J = 14.7 Hz, 1 H),
2.28 2.18 (m, 1 H), 1.67 1.57 (m, 1H); MS (ESI) m/z 550.54
(M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-10-
[(3-methoxyazetidin-1-yl)methyl]-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19a-13).
1H NMR (400 MHz,
CD3OD)δ8.48(s,1H),7.84(d,J=8.5Hz,1H),7.76 7.70(m, 1H),
7.20 7.15 (m, 1 H), 4.61 (s, 3 H), 4.47 4 . 2 8( m ,3H ) ,4 . 1 6( s ,1H ) ,
4.12 4.01(m,2H),3.17 2.92(m,9H),2.69 2.56(m,1H),2.33 2.23
(m, 1 H), 1.68 1.53 (m, 1 H); MS (ESI) m/z 564.57 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-{[3-(dimethylamino)-
azetidin-1-yl]methyl}-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,-
5a,6,13,14a-octahydropentacene-2-carboxamide (19a-14).
1HNMR
(400MHz,CD3OD)δ8.57(s,1H),7.89 7.76(m,2H),7.19(s,1H),
4.91 4.74 (m, 4 H), 4.59 4.41 (m, 3 H), 4.15 (s, 1 H), 3.15 2.95 (m,
9H),2.91(s,6H),2.68 2.56(m,1H),2.32 2.23(m,1H),1.67 1.54
(m, 1 H); MS (ESI) m/z 577.60 (M þ H).
(4S,4aS,5aR,14aS)-10-{[3-(Acetylamino)azetidin-1-yl]methyl}-4-
(dimethylamino)-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,-
13,14a-octahydropentacene-2-carboxamide (19a-15).
1H NMR
(400 MHz, CD3OD) δ 8.52 8.48 (m, 1 H), 7.89 7.82 (m, 1 H),3718 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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7.74 7.66 (m, 1 H), 7.23 7.16 (m, 1 H), 4.67 4.53 (m, 3 H),
4.47 4.21 (m, 4 H), 4.10 (s, 1 H), 3.16 2.92 (m, 9 H), 2.72 2.60
(m, 1 H), 2.27 2.18 (m, 1 H), 2.00 (s, 3 H), 1.69 1.56 (m, 1 H); MS
(ESI) m/z 591.58 (M þ H).
(4S,4aS,5aR,14aS)-10-[(3-Cyanoazetidin-1-yl)methyl]-4-(dimethy-
lamino)-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19a-16).
1HN M R( 4 0 0
MHz, CD3OD) δ 8.51 (s, 1 H), 7.88 (d, J = 8.5 Hz, 1 H), 7.69 (dd,
J =1.8,8.5 Hz,1H),7.22(s, 1H),4.64(s,2 H),4.59 4.37(m, 3H),
4.10 (s, 1 H), 4.08 3.95 (m, 1 H), 3.12 2.93 (m, 10 H), 2.73 2.62
(m, 1 H), 2.28 2.18 (m, 1 H), 1.70 1.56 (m, 1 H); MS (ESI) m/z
559.47 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-[(3-fluoroazetidin-1-yl)-
methyl]-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19a-17). Prepared from
aldehyde 16a (1.08 g, 1.36 mmol, 1.0 equiv) and 3-fluoroazetidine
according to General Procedures C, D, and E. The final product was
purified by preparative reverse-phase HPLC using water (with 0.5%
trifluoroacetic acid (TFA)) and acetonitrile as the mobile phases
(474 mg, 45%, three steps, TFA salt).
To a solution of the above TFA salt of compound 19a-17 (269 mg,
0.345 mmol, 1 equiv) in methanol (5 mL) was added methanesulfonic
acid (44.8 μL, 0.691 mmol, 2 equiv). The solvent was removed under
reduced pressure; the residue was dissolved in water (3.75 mL) and
acetonitrile (1.25 mL) and then freeze-dried to provide the desired
product as the dimesylate salt (256 mg, 100%):
1H NMR (400
MHz, CD3OD) δ 8.55 8.47 (m, 1 H), 7.87 (d, J = 8.5 Hz, 1 H),
7.73 7.65 (m, 1 H), 7.21 (s, 1 H), 5.58 5.28 (m, 1 H), 4.72 4.27
(m, 6 H), 4.09 (s, 1 H), 3.18 2.92 (m, 10 H), 2.74 2.62 (3, 7 H),
2.27 2.18(m,1H),1.71 1.57(m,1H);MS(ESI)m/z552.18552.35
(M þ H).
(4S,4aS,5aR,14aS)-10-[(3,3-Difluoroazetidin-1-yl)methyl]-4-(dimethy-
lamino)-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19a-18).
1H NMR (400 MHz,
CD3OD)δ8.55 (s,1H),7.86(d,J=8.5Hz,1H),7.82 7.74(m,1H),
7.20 (s, 1 H), 4.90 4.52 (m, 5 H), 4.15 (s, 1 H), 4.11 3.70 (m, 1 H),
3.14 2.93 (m, 9 H), 2.68 2.56 (m, 1 H), 2.32 2.21 (m, 1 H),
1.67 1.52 (m, 1 H); MS (ESI) m/z 570.54 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-
-10-{[methyl(methylsulfonyl)amino]methyl}-1,13-dioxo-1,4,4a,5,5a,6,
13,14a-octahydropentacene-2-carboxamide (19a-19). Methylamine
(68 μL, 8.0 M/ethanol, 0.54 mmol, 7.0 equiv), acetic acid (31 μL, 0.54
mmol, 7.0 equiv), and sodium triacetoxyborohydride (115 mg, 0.54
mmol,7.0equiv)wereaddedtoasolutionofaldehyde16a(62mg,0.078
mmol, 1.0 equiv) in 1,2-dichloroethane (4 mL) at rt. After being stirred
for5h,thereactionmixturewasquenchedbysaturatedaqueoussodium
bicarbonate (10 mL) and aqueous potassium phosphate buffer (pH 7.0,
0.2 M, 10 mL). The mixture was extracted with methylene chloride
(15mL 3).Thecombinedorganicextractsweredriedoveranhydrous
sodium sulfate, filtered, and concentrated to give the methylamino
intermediate.
2,6-Lutidine (4.3 μL, 0.037 mmol, 3.0 equiv) and methanesulfonyl
chloride (2.9 μL, 0.037 mmol, 3.0 equiv) were added to a solution of
the above methylamino intermediate (10 mg, 0.012 mmol, 1.0 equiv) in
anhydrous methylene chloride (0.6 mL). The reaction was stirred at
rt for 6 h and concentrated. The residue was puriﬁed by preparative
reverse-phase HPLC to aﬀord the desired methylsulfonamide inter-
mediate, which was subjected to desilylation and hydrogenation accord-
ing to General Procedures D and E to yield compound 19a-19 (2.4 mg,
34%, yellow solid):
1H NMR (400 MHz, CD3OD) δ 8.31 (s, 1 H), 7.75
(d,J=8.2Hz,1H),7.66(d,J=8.2Hz,1H),7.13(s,1H),4.46(s,2H),
4.08 (s, 1 H), 3.08 2.95 (m, 12 H), 2.77 (s, 3 H), 2.64 (t, J = 14.6 Hz,
1H), 2.24 2.19 (m, 1H), 1.67 1.57 (m, 1H); MS (ESI) m/z 586.44
(M þ H).
Phenyl 7-Bromo-4-chloro-1-methoxy-3-methylnaphthalene-2-car-
boxylate. A suspension of NCS (396 mg, 2.96 mmol, 1.1 equiv) and
compound13(1.00g,2.69mmol,1.0equiv)inacetonitrile(27mL)was
heatedatrefluxforovernight.Thereactionmixturewascooledtort,and
solvents were evaporated. The crude product (white solid) was dried
under high vacuum and used directly for the next step.
Phenyl 7-Bromo-1-[(tert-butoxycarbonyl)oxy]-4-chloro-3-methyl-
naphthalene-2-carboxylate (14b). A solution of BBr3 in methylene
chloride (1.0 M, 5.38 mL, 5.38 mmol, 2.0 equiv) was added slowly to a
solution of the above crude compound (2.69 mmol, 1.0 equiv) in
methylene chloride (30 mL) at  65 C. The resulting red solution was
stirred at  65 C for 55 min and was poured into saturated aqueous
sodium bicarbonate (100 mL). The mixture was stirred at rt for 30 min
and extracted with methylene chloride (60 mL   4). The organic
extracts were combined and dried over anhydrous magnesium sulfate.
The dried solution was filtered, and the filtrate was concentrated,
providing the naphthol intermediate as a white solid:
1H NMR (400
MHz, CDCl3)δ12.06 (s,1H),8.58(d,J=2.4Hz,1H),8.13(d,J=9.2
Hz, 1 H), 7.78 (dd, J = 2.4, 9.2 Hz, 1 H), 7.50 7.46 (m, 2 H), 7.34 (t,
J = 7.3 Hz, 1 H), 7.25 7.22 (m, 2 H), 2.90 (s, 3 H); MS (ESI) m/z
389.03, 391.03 (M   H).
(Boc)2O (616 mg, 2.82 mmol, 1.05 equiv) and DMAP (10 mg,
0.08 mmol, 0.03 equiv) were added to a solution of the above naphthol
intermediateinmethylenechloride(30mL).Themixturewasstirredfor
40 min at rt and concentrated. The residue was puriﬁed by ﬂash column
chromatography (1% f 5% ethyl acetate hexanes) to aﬀord com-
pound 14b (white solid, 1.06 g, 80%, three steps):
1H NMR (400 MHz,
CDCl3) δ 8.06 (d, J = 9.2 Hz, 1 H), 8.02 (d, J = 1.8 Hz, 1 H), 7.63 (dd,
J=1.8,9.2Hz,1H),7.42 7.38(m,2H),7.27 7.22(m,3H),2.63(s,3
H), 1.43 (s, 9 H);
13C NMR (100 MHz, CDCl3) δ 164.0, 150.8, 150.3,
142.7,132.3,131.2,130.7,129.9,129.5,127.3,126.5,126.3,125.4,124.5,
121.9, 121.5, 84.8, 27.4, 18.3; MS (ESI) m/z 489.18, 491.10 (M   H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-9-bromo-4a-{[tert-butyl-
(dimethyl)silyl]oxy}-12-chloro-15-(dimethylamino)-5-hydroxy-4,6-di-
oxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl
tert-Butyl Carbonate (15b). Compound 14b (1.06 g, 2.16 mmol, 1.5
equiv) was reacted with enone 8 (694 mg, 1.44 mmol, 1.0 equiv)
according to General Procedure A to yield compound 15b as a yellow
solid (773 mg, 61%):
1H NMR (400 MHz, CDCl3) δ 15.74 (br s, 1 H),
8.19 (br s,1H),8.04 (d,J=9.2Hz, 1H),7.66(dd, J=1.8, 9.2 Hz,1H),
7.43 7.41(m,2H),7.31 7.24(m,3H),5.30,5.26(ABq,J=12.2Hz,2
H),3.87(d,J=10.4Hz,1H),3.59(dd,J=4.3,15.9Hz,1H),3.04 2.98
(m,1H),2.60(t,J=15.3Hz,1H),2.54 2.39(m,8H),2.14(d,J=14.0
Hz, 1 H), 1.50 (s, 9 H), 0.75 (s, 9 H), 0.20 (s, 3 H), 0.06 (s, 3 H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]-
oxy}-12-chloro-15-(dimethylamino)-9-formyl-5-hydroxy-4,6-dioxo-
4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-
ButylCarbonate(16b).Compound15b(704mg,0.72mmol,1.0equiv)
wasconvertedtocompound16baccordingtoGeneralProcedureB(371
mg,yellowsolid,62%):
1HNMR(400MHz,CDCl3)δ15.79(brs,1H),
10.18 (d, J = 4.2 Hz, 1 H), 8.62 (br s, 1 H), 8.38 (br s, 1 H), 8.14 (br s,
1 H), 7.51 7.37 (m, 5 H), 5.37 (br s, 2 H), 3.97 (br s, 1 H), 3.73 (d, J =
14.0Hz,1H),3.14(brs,1H),2.27 2.54(m,9H),2.25(d,J=9.8Hz,1
H),1.60(s,9H),0.84(s,9H),0.29(s,3H),0.15(s,3H);MS(ESI)m/z
829.46 (M þ H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-7-chloro-4-(dimethy-
lamino)-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-oc-
tahydropentacene-2-carboxamide (19b-1). Compound 16b (20 mg,
0.024 mmol, 1.0 equiv) was subjected to reductive amination with
azetidine (6.5 μL, 0.096 mmol, 4.0 equiv), desilylation, and hydrogena-
tion according to General Procedures C, D, and E to yield compound
19b-1 as a yellow solid (1.6 mg, from half of the crude desilylated
intermediate, 24%, three steps):
1H NMR (400 MHz, CD3OD) δ 8.59
(s, 1 H), 8.32 (d, J = 8.7 Hz, 1 H), 7.85 (dd, J = 1.4, 8.7 Hz, 1 H), 4.603719 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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(s,2H),4.27(q,J=9.6Hz,2H),4.16 4.10(m,3H),3.61(dd, J=4.1,
16.0 Hz, 1 H), 3.14 2.97 (m, 8 H), 2.61 2.46 (m, 3 H), 2.28 (ddd,
J = 2.8, 5.0, 13.7 Hz, 1 H), 1.74 1.64 (m, 1 H); MS (ESI) m/z 568.37
(M þ H).
Phenyl 7-Bromo-4-fluoro-1-methoxy-3-methylnaphthalene-2-car-
boxylate. NIS (2.57 g, 11.4 mmol, 1.3 equiv) and TFA (0.20 mL,
2.63 mmol, 0.3 equiv) were added to a suspension of compound 13
(3.26 g,8.78 mmol, 1.0equiv) in acetonitrile (90mL)atrt. Themixture
was then stirred at 80 C for 25 h. The reaction mixture was cooled to
rt, and solvents were evaporated. The resulting off-white solid was
dissolved in methylene chloride (250 mL) and the methylene chloride
solution was washed with saturated aqueous sodium bicarbonate
(200 mL). The aqueous layer was extracted with methylene chloride
(50 mL   2). The combined organic phase was dried over magnesium
sulfate, filtered, and concentrated to afford the iodo intermediate as
a pale yellow solid (4.51 g):
1H NMR (400 MHz, CDCl3) δ 8.24 (d,
J = 1.8 Hz, 1 H), 8.17 (d, J = 9.2 Hz, 1 H), 7.66 (dd, J = 1.8, 9.2 Hz,
1 H), 7.48 7.44 (m, 2 H), 7.32 7.27 (m, 3 H), 4.08 (s, 3 H), 2.76
(s, 3 H).
To a solution of the above iodo intermediate in THF (135 mL) at
 100 C (liquid nitrogen/ethanol bath) was added n-butyllithium
(4.25 mL, 1.6 M/hexanes, 6.80 mmol, 1.0 equiv) dropwise. After the
mixturewasstirredatthattemperaturefor5min,asolutionofNFSI(N-
ﬂuorobenzenesulfonimide, 2.57 g, 8.16 mmol, 1.2 equiv) in THF
(17 mL) was added dropwise via a cannula. The resulting reaction
mixturewaswarmedslowlyto 78Candkeptatthattemperaturefor1
h.Phosphatebuﬀer(pH7.0,200mL)wasaddedtoquenchthereaction.
The resulting mixture was warmed to rt and extracted with ethyl acetate
(200 mL). The organic layer was separated, washed with saturated
aqueous sodium bicarbonate (150 mL) and brine (100 mL), dried over
magnesium sulfate, ﬁltered, and concentrated to aﬀord a yellow solid,
which was puriﬁed by ﬂash column chromatography (0 f 1% ethyl
acetate hexanes) to aﬀord phenyl 7-bromo-4-ﬂuoro-1-methoxy-3-
methylnaphthalene-2-carboxylate (pale yellow solid, 1.30 g, 51%, two
steps):
1HNMR(400MHz,CDCl3)δ8.25(t,J=1.8Hz,1H),7.93(d,
J = 9.2 Hz, 1 H), 7.66 (dd, J = 1.8, 9.2 Hz, 1 H), 7.48 7.44 (m, 2 H),
7.32 7.27 (m, 3 H), 4.06 (s, 3 H), 2.48 (d, J = 2.3 Hz, 3 H); MS (ESI)
m/z 387.09 (M   H).
Phenyl 7-Bromo-1-[(tert-butoxycarbonyl)oxy]-4-fluoro-3-methyl-
naphthalene-2-carboxylate (14c). A solution of BBr3 in methylene
chloride (1.0 M, 3.67 mL, 3.67 mmol, 1.1 equiv) was added slowly to a
solution of phenyl 7-bromo-4-fluoro-1-methoxy-3-methylnaphthalene-
2-carboxylate (1.30 g, 3.34 mmol, 1.0 equiv) in methylene chloride
(40mL)at 78C.Theresultingredsolutionwasstirredat 78Cfor
45 min and was poured into saturated aqueous sodium bicarbonate
(250 mL). The mixture was stirred at rt for 30 min and extracted with
methylene chloride (300 mL   1, 120 mL   3). The organic extracts
were combined and dried over anhydrous magnesium sulfate. The dried
solution was filtered, and the filtrate was concentrated, providing the
crude product as an off-white solid.
(Boc)2O (765 mg, 3.51 mmol, 1.05 equiv) and DMAP (10 mg, 0.08
mmol, 0.02 equiv) were added to a solution of the above crude product
in methylene chloride (40 mL). The reaction mixture was stirred for
50 min at rt and concentrated. The residue was puriﬁed by ﬂash column
chromatography (1% f 3% ethyl acetate hexanes) to aﬀord com-
pound 14c (oﬀ-white solid, 1.23 g, 78%, two steps):
1H NMR (400
MHz,CDCl3)δ8.02(s,1H),7.84(d,J=8.7Hz,1H),7.60(dd,J=1.8,
8.7 Hz, 1 H), 7.41 7.38 (m, 2 H), 7.26 7.24 (m, 3 H), 2.48 (d, J = 2.8
Hz,3H),1.43(s,9H);
13CNMR(100MHz,CDCl3)δ163.6(d,J=2.9
Hz,1C),154.0(d,J=249.2 Hz,1C),151.1,150.3,140.4(d,J=3.8 Hz,
1C),131.8,129.4,127.3 (d,J=4.8Hz,1C),126.3,124.6 (d,J=4.8 Hz,
1C),124.4,123.3(d,J=20.1Hz,1C),122.3(d,J=5.8Hz,1C),122.0,
121.5, 117.8 (d, J = 19.2 Hz, 1 C), 84.6, 27.4, 12.0 (d, J = 5.8 Hz, 1 C);
MS (ESI) m/z 473.16 (M   H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-9-bromo-4a-{[tert-butyl(dimethyl)-
silyl]oxy}-15-(dimethylamino)-12-fluoro-5-hydroxy-4,6-dioxo-4,4a,6,-
13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-Butyl
Carbonate (15c). Compound 14c (1.23 g, 2.59 mmol, 1.2 equiv) was
reacted with enone 8 (1.04 g, 2.16 mmol, 1.0 equiv) according to
General Procedure A to afford product 15c as a yellow solid (1.05 g,
56%; 481 mg of starting material 14c and 262 mg of enone 8 were
recovered):
1HNMR(400MHz,CDCl3)δ15.96(s,1H),8.24(s,1H),
7.89 (d, J = 8.5 Hz, 1 H), 7.70 (dd, J = 1.8, 8.5 Hz, 1 H), 7.51 7.50 (m,
2 H), 7.39 7.31 (m, 3 H), 5.39, 5.35 (ABq, J = 12.2 Hz, 2 H), 3.97 (d,
J = 10.4 Hz, 1 H), 3.48 (dd, J = 4.3, 15.3 Hz, 1 H), 3.14 3.07 (m, 1 H),
2.64 2.48 (m, 9 H), 2.23 (d, J = 14.0 Hz, 1 H), 1.61 (s, 9 H), 0.85 (s, 9
H), 0.30 (s, 3 H), 0.17 (s, 3 H); MS (ESI) m/z 863.43 (M þ H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]-
oxy}-15-(dimethylamino)-12-fluoro-9-formyl-5-hydroxy-4,6-dioxo-
4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-
ButylCarbonate(16c).Compound15c(1.05g,1.22mmol,1.0equiv)was
converted to compound 16c according to General Procedure B (685 mg,
69%, yellow solid):
1H NMR (400 MHz, CDCl3) δ 15.88 (s, 1 H), 10.18
(s,1H),8.58(s,1H),8.17(d,J=8.5Hz,1H),8.11(dd,J=1.2,8.5Hz,1
H),7.50 7.48(m,2H),7.39 7.32(m,3H),5.37,5.34(ABq,J=12.2Hz,
2H),3.94(d,J=10.4Hz,1H),3.52(dd,J=4.3,15.3Hz,1H),3.14 3.08
(m, 1 H), 2.66 2.51 (m, 9 H), 2.22 (d, J = 14.6 Hz, 1 H), 1.59 (s, 9 H),
0.82(s,9H),0.26(s,3H),0.13(s,3H);MS(ESI)m/z813.50(MþH).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-7-
fluoro-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-oc-
tahydropentacene-2-carboxamide (19c-5). Compound 16c was sub-
jected to reductive amination with azetidine (39 μL, 0.57 mmol, 3.0
equiv), desilylation, and hydrogenation according to General Proce-
dures C, D, and E to yield the desired product 19c-5 as a yellow solid
(57 mg, 47%, three steps):
1H NMR (400 MHz, CD3OD) δ 8.53 (s,
1 H), 8.06 (d, J = 8.2 Hz, 1 H), 7.82 (dd, J = 1.8, 8.7 Hz, 1 H), 4.59 (s,
2 H), 4.27 (q, J = 9.6 Hz, 2 H), 4.16 4.10 (m, 3 H), 3.37 (dd, J = 4.1,
14.6 Hz, 1 H), 3.12 2.97 (m, 8 H), 2.63 2.55 (m, 1 H), 2.53 2.45
(m,1H),2.38(t,J=14.6Hz,1H),2.27(ddd,J=2.8,5.0,13.7Hz,1H),
1.72 1.62 (m, 1 H); MS (ESI) m/z 552.40 (M þ H).
The following compounds were prepared similarly from compound
16c and the respective amines.
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-[(ethylamino)methyl]-
7-fluoro-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19c-1).
1HN M R( 4 0 0M H z ,
CD3OD)δ 8.45(s,1H),7.94(d,J =8.4Hz,1H),7.77(d,J =8.4Hz,
1 H),4.32(s,2H),4.04(s,1 H),3.28 3.23 (m, 1 H), 3.12 3.07(m,
2H ) ,2 . 9 7  2.89 (m, 8 H), 2.32 2.18 (m, 2 H), 1.61 1.52 (m, 1 H),
1.29 (t, J = 7.2 Hz, 3 H); MS (ESI) m/z 540.2 (M þ H).
(4S,4aS,5aR,14aS)-10-[(Cyclopropylamino)methyl]-4-(dimethyla-
mino)-7-fluoro-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,-
14a-octahydropentacene-2-carboxamide (19c-2).
1H NMR (400
MHz, CD3OD) δ 8.59 (s, 1 H), 8.08 (d, J = 8.7 Hz, 1 H), 7.86 (d,
J = 8.7 Hz, 1 H), 4.53 (s, 2 H), 4.10 (s, 1 H), 3.38 (dd, J = 4.6, 15.6 Hz,
1 H), 3.12 2.97 (m, 8 H), 2.88 2.83 (m, 1 H), 2.40 (t, J = 14.2 Hz,
1 H), 2.28 2.24 (m, 1 H), 1.72 1.62 (m, 1 H), 0.97 0.91 (m, 4 H);
MS (ESI) m/z 552.35 (M þ H).
(4S,4aS,5aR,14aS)-10-[(tert-Butylamino)methyl]-4-(dimethylamino)-
7-fluoro-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19c-3).
1HN M R( 4 0 0M H z ,
CD3OD)δ8.60(s,1H),8.08(d,J=8.7Hz,1H),7.88(dd,J=1.8,8.7
Hz, 1 H), 4.42 (s, 2 H), 4.12 (s, 1 H), 3.38 (dd, J = 4.1, 14.6 Hz, 1 H),
3.12 2.98 (m, 8 H), 2.88 2.83 (m, 1 H), 2.39 (t, J =1 4 . 2H z ,1H ) ,
2.28 (ddd, J = 2.8, 5.0, 13.7 Hz, 1 H), 1.72 1.63 (m, 1 H), 1.51 (s, 9
H); MS (ESI) m/z 568.41 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-[(dimethylamino)methyl]-
7-fluoro-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octa-
hydropentacene-2-carboxamide(19c-4).
1HNMR(400MHz,CD 3OD)3720 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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δ 8.53 (s, 1 H), 8.03 (d, J = 8.4 Hz, 1 H), 7.83 (d, J = 8.4 Hz, 1 H),
4.55 4.48 (m, 2 H), 4.09 (s, 1 H), 3.34 3.25 (m, 1 H), 3.07 2.94 (m, 8
H),2.88(s,3H),2.87(s,3H),2.36 2.23 (m, 2 H), 1.67 1.55 (m, 1 H);
MS (ESI) m/z 540.3 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-7-fluoro-10-[(3-fluoroazetidin-
1-yl)methyl]-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19c-6).
1H NMR (400 MHz,
CD3OD)δ8.57 8.54(m,1H),8.07(d,J=8.7Hz,1H),7.88 7.82(m,
1 H), 5.55 5.34 (m, 1 H), 4.73 4.30 (m, 6 H), 4.12 (s, 1 H), 3.37 (dd,
J=4.1,15.6Hz,1H),3.13 2.97(m,8H),2.38(t,J=14.6Hz,1H),2.28
(ddd, J = 2.8, 5.0, 13.7 Hz, 1 H), 1.72 1.62 (m, 1 H); MS (ESI) m/z
570.36 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-7-fluoro-3,12,14,14a-tetra-
hydroxy-1,13-dioxo-10-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19c-7).
1H NMR (400 MHz,
CD3OD) δ 8.61 (s,1 H),8.09 (d,J=8.4 Hz,1 H),7.92 (d,J=8.8 Hz, 1
H), 4.63 (s, 2 H), 4.14 (s, 1 H), 3.55 3.41 (m, 2 H), 3.36 3.33 (m, 1
H), 3.28 3.00 (m, 10 H), 2.44 2.21 (m, 4 H), 2.19 2.05 (m, 2 H),
1.74 1.61 (m, 1 H); MS (ESI) m/z 566.1 (M þ H).
Phenyl 7-Bromo-1-methoxy-3-methyl-4-nitronaphthalene-2-car-
boxylate (20). A mixture of freshly mixed nitric acid (68 70%) and
concentrated sulfuric acid (4:5 v/v, 0.6 mL) was added dropwise to a
solution of compound 13 (2.74 g, 7.38 mmol, 1.0 equiv) in methylene
chloride (25 mL) at 0 C. The resulting yellow solution was stirred at
0 C for 25 min. Additional nitric acid (68 70%) and concentrated
sulfuric acid (4:5 v/v, 0.66 mL) were added dropwise. The reaction
mixture was stirred at 0 C for 1.5 h and neutralized with 6 N aqueous
sodium hydroxide (5.5 mL). Saturated aqueous sodium bicarbonate
(100 mL) was added. The organic layer was separated, and the aqueous
layer was extracted with methylene chloride (80 mL   2). The organic
extracts were combined and dried over anhydrous magnesium sulfate.
The dried solution was filtered, and the filtrate was concentrated,
providing the title compound 20 as a light yellow solid:
1H NMR
(600 MHz, CDCl3) δ 8.30 (s, 1 H), 7.72 (d, J = 8.7 Hz, 1 H), 7.55 (d,
J = 8.7 Hz, 1 H), 7.44 7.42 (m, 2 H), 7.30 7.28 (m, 1 H), 7.24 7.22
(m, 2 H), 4.09 (s, 3 H), 2.48 (s, 3 H).
Phenyl 4-Amino-7-bromo-1-hydroxy-3-methylnaphthalene-2-car-
boxylate. A solution of BBr3 in methylene chloride (1.0 M, 14.8 mL,
14.8mmol,2.0equiv)wasaddedslowlyover7mintoasolutionofphenyl
7-bromo-1-methoxy-3-methyl-4-nitronaphthalene-2-carboxylate (20)i n
methylene chloride (74 mL) at  70 C. The resulting red solution was
allowedtowarmto 45 Cin2handwaspouredintosaturatedaqueous
sodium bicarbonate (200 mL). The mixture was stirred at rt for 30 min
and extracted with methylene chloride (300 mL   2). The aqueous layer
was further extracted with ethyl acetate (150 mL   2). The organic
extractswerecombinedanddriedoveranhydrousmagnesiumsulfate.The
driedsolutionwasfilteredthroughashortplugofsilicagel,andthefiltrate
was concentrated, providing the crude product as a yellow solid (2.62 g).
Zinc dust (1.93 g, 29.52 mmol, 4.0 equiv) was added slowly to a
solution of the above intermediate in a mixture of THF (30 mL) and
acetic acid (6 mL) in one portion at 0 C. The mixture was stirred
vigorouslyfor60h atrt. Thereaction mixture wasﬁlteredthrough apad
of Celite. The Celite cake was washed thoroughly with ethyl acetate.
The ﬁltrate was washed with saturated aqueous sodium bicarbonate
(350 mL) and brine (100 mL). The organic phase was dried over
anhydrous magnesium sulfate. The dried solution was ﬁltered, and the
ﬁltrate was concentrated, providing the title compound as a yellow solid
(2.73 g, quantitative).
Phenyl 7-Bromo-1-[(tert-butoxycarbonyl)oxy]-4-(dimethylamino)-
3-methyl-2-naphthoate(14d).Formicacid(37wt%inwater,0.78mL,
10.5 mmol, 5.4 equiv), acetic acid (0.60 mL, 10.5 mmol, 5.4 equiv),
and sodium triacetoxyborohydride (2.23 g, 10.5 mmol, 5.4 equiv)
were added to a solution of phenyl 4-amino-7-bromo-1-hydroxy-3-
methylnaphthalene-2-carboxylate (730 mg, 1.96 mmol, 1.0 equiv) in
acetonitrile (35 mL) and THF (20 mL). The reaction mixture was
stirred at rt for 3.5 h and quenched by slowly adding saturated aqueous
sodium bicarbonate (80 mL). The resulting clear mixture was extracted
withethylacetate(50mL 3).Theorganicextractswerecombinedand
driedoveranhydrousmagnesiumsulfate.Thedriedsolutionwasfiltered,
and the filtrate was concentrated to give the crude intermediate phenyl
7-bromo-1-hydroxy-4-(dimethylamino)-3-methyl-2-naphthoate (27).
(Boc)2O(470mg,2.16mmol,1.1equiv),DIEA(0.61mL,3.50mmol,
1.8 equiv), and DMAP (20 mg, 0.16 mmol, 0.08 equiv) were added to a
solution of the above intermediate 27 in methylene chloride (35 mL).
The reaction mixture was stirred for 1 h at rt, diluted with methylene
chloride (100 mL), and washed with a mixture of brine and saturated
aqueous sodium bicarbonate (1:1, 100 mL). The organic phase was
separated and dried over magnesium sulfate. The dried solution was
ﬁltered, and the ﬁltrate was concentrated. The residue was puriﬁed by
ﬂash column chromatography (1% f 5% ethyl acetate hexanes) to
aﬀordcompound 14das a yellowfoamy solid(976mg,quantitative, two
steps):
1H NMR (600 MHz, CDCl3) δ 8.14 8.10 (m, 2 H), 7.68 7.66
(m, 1 H), 7.52 7.55 (m, 2 H), 7.39 7.37 (m, 3 H), 3.05 (s, 6 H), 2.58
(s, 3 H), 1.57 (s, 9 H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]-
oxy}-12,15-bis(dimethylamino)-9-formyl-5-hydroxy-4,6-dioxo-4,4a,-
6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-Butyl
Carbonate (16d). Compound 14d (760 mg, 1.52 mmol, 2.0 equiv) was
reacted with enone 8 (366 mg, 0.76 mmol, 1.0 equiv) according to
GeneralProcedureAtoaffordthecyclizedproduct15d(430mg,64%)as
a yellow solid, which was converted to compound 16d according to
General Procedure B (214 mg, 53%, yellow solid): Rf = 0.45 (35% ethyl
acetate hexanes);
1H NMR (400 MHz, CDCl3) δ 15.85 (br s, 1H),
10.17 (s, 1H), 8.60 (br s, 1H), 8.24 (d, J = 8.8 Hz, 1H), 8.06 (dd, J =8 . 8 ,
1.2 Hz, 1H), 7.51 (dd, J = 8.0, 1.2 Hz, 2H), 7.40 7.33 (m, 3H), 5.39 (d,
J=12.0Hz,1H),5.35(d,J=12.0Hz,1H),4.04(d,J=10.4Hz,1H),3.36
(dd, J = 15.6, 4.0 Hz, 1H), 3.03 (br s, 6H), 3.08 2.97 (m, 1H), 2.71 (t,
J = 15.2 Hz, 1H), 2.63 2.54 (m, 8H), 2.23 (d, J = 10.0 Hz,1H), 1.61 (s,
9H), 0.86 (s, 9H), 0.30 (s, 3H), 0.17 (s, 3H);
13C NMR (100 MHz,
CDCl3) δ 191.7, 187.2, 182.5, 181.7, 167.5, 151.3, 145.3, 143.6, 138.4,
134.9, 134.4, 129.8, 128.5, 128.4, 127.3, 125.8, 125.4, 121.3, 108.3, 84.7,
81.7, 72.5, 61.0, 46.4, 43.2, 41.8, 35.7, 28.2, 27.6, 26.0, 22.7, 18.9,  2.6,
 3.8; HRMS ESI (m/z)[ Mþ H]
þ calcd for C46H56N3O10Si,
838.3735; found, 838.3721.
(4S,4aS,5aR,14aS)-4,7-Bis(dimethylamino)-3,12,14,14a-tetrahy-
droxy-10-[(methylamino)methyl]-1,13-dioxo-1,4,4a,5,5a,6,13,14a-oc-
tahydropentacene-2-carboxamide (19d-1). Compound 16d was
subjectedtoreductiveaminationwithmethylamine(33wt%inethanol,
14μL,0.11mmol,7.0equiv),desilylation,andhydrogenationaccording
toGeneralProceduresC,D,andEtoyieldcompound19d-1asayellow
solid (4.4 mg, 41% for three steps):
1H NMR (400 MHz, CD3OD) δ
8.72 (br s, 1 H), 8.47 (br s, 1 H), 8.02 (br s, 1 H), 4.42 (br s, 2 H), 4.17
(br s, 1 H), 3.66 3.54 (m, 8 H), 3.26 3.20 (m, 1 H), 3.06 2.90 (m, 7
H), 2.77 (s, 3 H), 2.69 (m, 1 H), 2.42 (br s, 1 H), 1.70 (br s, 1 H); MS
(ESI) m/z 551.45 (M þ H).
The following compounds were prepared similarly from compound
16d and the respective amines.
(4S,4aS,5aR,14aS)-4,7-Bis(dimethylamino)-3,12,14,14a-tetrahydroxy-
10-{[(2-methoxyethyl)amino]methyl}-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19d-2).
1H NMR (400 MHz,
CD3OD)δ8.65(brs,1H),8.37(brs,1H),7.94(brs,1H),4.37(brs,2
H),4.08 (brs,1H),3.59 3.45 (m,10H),3.30 (s,4H),2.96 2.86 (m,
8H),2.61(m,1H),2.34(m,1H),1.62(m,1H);MS(ESI)m/z595.48
(M þ H).
(4S,4aS,5aR,14aS)-4,7-Bis(dimethylamino)-10-[(dimethylamino)-
methyl]-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide(19d-3).
1HNMR(400MHz,
CD3OD) δ 8.76 (s, 1 H), 8.50 (br s, 1 H), 8.07 (br s, 1 H), 4.57 (s, 23721 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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H), 4.18 (s, 1 H), 3.68 3.56 (m, 7 H), 3.06 2.90 (m, 14 H),
2.71 2.70 (m, 1 H), 2.43 (m, 1 H), 1.70 (m, 1 H); MS (ESI) m/z
565.54 (M þ H).
(4S,4aS,5aR,14aS)-4,7-Bis(dimethylamino)-3,12,14,14a-tetrahydroxy-
1,13-dioxo-10-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,13,14a-octahy-
dropentacene-2-carboxamide (19d-4).
1H NMR (400 MHz,
CD3OD) δ 8.76 (s, 1 H), 8.45 (br s, 1 H), 8.08 (d, J =6 . 4H z ,1
H), 4.62 (s, 2 H), 4.17 (s, 1 H), 3.63 3.51 (m, 10 H), 3.30 2.95 (m,
9 H), 2.69 (m, 1 H), 2.40 (m, 1 H), 2.18 2.01 (m, 4 H), 1.69 (m, 1
H); MS (ESI) m/z 591.56 (M þ H).
Phenyl 7-Bromo-1-hydroxy-4-methoxy-3-methylnaphthalene-2-car-
boxylate. PhI(OAc)2 (2.20 g, 6.84 mmol, 2.0 equiv) was added in one
portiontoasolutionofphenyl7-bromo-1-hydroxy-4-(dimethylamino)-3-
methyl-2-naphthoate (27, 1.37 g, 3.42 mmol, 1.0 equiv) in a mixture of
methanol(20mL)and1,4-dioxane(20mL)at0C.Thereactionmixture
was stirred at 0 C for 8 min. Acetic acid (4 mL) and zinc dust (1.34 g,
20.5 mmol, 6.0 equiv) were added at 0 C. The reaction mixture was
stirred at 0 C for 10 min and filtered through a pad of Celite. The Celite
cake was washed thoroughly with ethyl acetate. The filtrate was washed
with 6 N aqueous sodium hydroxide (11 mL), saturated aqueous sodium
bicarbonate (120 mL), and brine (50 mL). The organic phase was dried
over anhydrous magnesium sulfate. The dried solution was filtered, and
the filtrate was concentrated, providing the title compound as a yellow
solid:
1H NMR (400 MHz, CDCl3) δ 12.10 (s, 1 H),8.06 (d, J = 9.2 Hz,
1 H),8.02 (d,J= 1.8Hz, 1 H),7.63(dd,J= 1.8, 9.2 Hz, 1 H), 7.42 7.38
(m,2H),7.27 7.22(m,3H),2.63(s,3H),1.43(s,9H);MS(ESI)m/z
385.21 (M   H).
Phenyl 7-Bromo-1-[(tert-butoxycarbonyl)oxy]-4-methoxy-3-meth-
yl-2-naphthoate (14e). (Boc)2O (784 mg, 3.59 mmol, 1.05 equiv) and
DMAP (12 mg, 0.10 mmol, 0.03 equiv) were added to a solution of
phenyl 7-bromo-1-hydroxy-4-methoxy-3-methylnaphthalene-2-carbox-
ylate in methylene chloride (30 mL). The mixture was stirred at rt for
25 min and concentrated. The residue was purified by flash column
chromatography (5% f 10% ethyl acetate hexanes) to afford the Boc-
protected product 14e (white solid, 1.33 g, 80%, two steps):
1H NMR
(400MHz,CDCl3)δ8.02(d,J=1.8Hz,1H),7.94(d,J=8.7Hz,1H),
7.62(dd,J=1.8,8.7Hz,1H),7.43 7.39(m,2H),7.27 7.24(m,3H),
3.84(s,3H),2.51(s,3H),1.43(s,9H);
13CNMR(100MHz,CDCl3)
δ 164.4, 152.4, 151.3, 150.5, 140.5, 131.5, 129.5, 128.1, 127.8, 126.3,
125.3, 124.8, 124.7, 124.2, 121.6, 121.4, 84.6, 61.7, 27.5, 13.4.
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-9-bromo-4a-{[tert-butyl(dimethyl)-
silyl]oxy}-15-(dimethylamino)-5-hydroxy-12-methoxy-4,6-dioxo-4,4a,-
6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-Butyl
Carbonate (15e). Compound 14e (1.56 g, 3.20 mmol, 1.5 equiv) was
reactedwithenone8(1.03g,2.13mmol,1.0equiv)accordingtoGeneral
ProcedureAtoyieldcompound15easayellowsolid(829mg,45%):
1H
NMR(400MHz,CDCl3)δ15.94(brs,1H),8.23(brs,1H),7.94(d,J=
8.5 Hz, 1 H), 7.67 (dd, J = 2.4, 8.5 Hz, 1 H), 7.50 7.48 (m, 2 H),
7.39 7.32 (m,3H),5.37, 5.33(ABq,J=12.2Hz,2 H),3.98(d,J=11 .0
Hz,1 H),3.85(s,3H),3.48(dd,J=4.9,15.3Hz,1 H),3.06 2.98(m,1
H), 2.62 2.44 (m, 9 H), 2.20 (d, J = 14.0 Hz, 1 H), 1.58 (s, 9 H), 0.82
(s, 9 H), 0.27 (s, 3 H), 0.13 (s, 3 H); MS (ESI) m/z 875.55 (M þ H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]-
oxy}-15-(dimethylamino)-9-formyl-5-hydroxy-12-methoxy-4,6-dioxo-
4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-
ButylCarbonate(16e).Compound15e(589mg,0.67mmol,1.0equiv)
wasconvertedtocompound16eaccordingtoGeneralProcedureB(366
mg,66%,yellowsolid):
1HNMR(400MHz,CDCl3)δ15.90(brs,1H),
10.17(s,1H),8.58(brs,1H),8.18(d,J=8.5Hz,1H),8.08(dd,J=1.2,
8.5Hz,1H),7.50 7.48(m,2H),7.39 7.32(m,3H),5.37,5.33(ABq,
J = 12.2 Hz, 2 H), 3.97 (d, J = 11.0 Hz, 1 H), 3.89 (s, 3 H), 3.54 (dd,
J=4.3,15.3Hz,1H),3.07 3.02(m,1H),2.67 2.45(m,9H),2.21(d,
J=14.0Hz,1H),1.59(s,9H),0.82(s,9H),0.27(s,3H),0.13(s,3H);
MS (ESI) m/z 825.80 (M þ H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-
3,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19e-6). Compound 16e (273
mg, 0.33 mmol, 1.0 equiv) was subjected to reductive amination with
azetidine(45μL,0.66mmol,2.0equiv)toaffordcompound17e-6(MS
(ESI) m/z 866.76 (M þ H)), followed by desilylation and hydrogena-
tion according to General Procedures C, D, and E to yield compound
19e-6asayellowsolid(156mg,74%,threesteps):
1HNMR(400MHz,
CD3OD) δ 8.51 (d, J=1.8 Hz, 1H), 8.07 (d, J=8.7 Hz, 1 H),7.80 (dd,
J = 1.8, 8.7 Hz, 1 H), 4.59 (s, 2 H), 4.27 (q, J = 10.0 Hz, 2 H), 4.17 (s, 1
H), 4.15 4.10 (m, 2 H), 3.79 (s, 3 H), 3.39 (dd, J = 4.1, 15.6 Hz, 1 H),
3.08 2.98 (m, 8 H), 2.63 2.56 (m, 1 H), 2.53 2.45 (m, 1 H),
2.37 2.30 (m, 2 H), 1.69 1.60 (m, 1 H); MS (ESI) m/z 564.42
(M þ H).
The following compounds were prepared similarly from compound
16e and the respective amines.
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-7-
methoxy-1,13-dioxo-10-[(propylamino)methyl]-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19e-1).
1H NMR (400 MHz,
CD3OD) δ 8.56 (d, J=1.8 Hz, 1H), 8.11 (d, J=8.7 Hz, 1 H),7.81 (dd,
J = 1.8, 8.7 Hz, 1 H),4.40 (s, 2 H),4.13 (s, 1 H), 3.81 (s, 3 H), 3.41 (dd,
J = 4.1, 15.6 Hz, 1 H), 3.09 2.97 (m, 10 H), 2.38 (t, J = 13.7 Hz, 1 H),
2.28 (ddd, J = 2.8, 4.6, 13.7 Hz, 1 H), 1.82 1.74 (m, 2 H), 1.72 1.62
(m, 1 H), 1.04 (t, J = 7.3 Hz, 3 H); MS (ESI) m/z 566.42 (M þ H).
(4S,4aS,5aR,14aS)-10-[(Cyclopropylamino)methyl]-4-(dimethyl-
amino)-3,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-1,4,4a,5,5a,
6,13,14a-octahydropentacene-2-carboxamide (19e-2).
1H NMR
(400 MHz, CD3OD) δ 8.56 (d, J = 1.8 Hz, 1 H), 8.11 (d,
J = 8.7 Hz, 1 H), 7.82 (dd, J = 1.8, 8.7 Hz, 1 H), 4.52 (s, 2 H), 4.13 (s,
1H),3.80(s,3H),3.41(dd,J=4.6,15.6Hz,1H),3.06 2.97(m,8H),
2.86 2.81 (m, 1 H), 2.38 (t, J = 13.7 Hz, 1 H), 2.30 2.25 (m, 1 H),
1.72 1.62 (m, 1 H), 0.94 0.92 (m, 4 H); MS (ESI) m/z 564.53
(M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-
10-[(isobutylamino)methyl]-7-methoxy-1,13-dioxo-1,4,4a,5,5a,6,13,-
14a-octahydropentacene-2-carboxamide (19e-3).
1H NMR (400
MHz, CD3OD) δ 8.59 (d, J = 1.8 Hz, 1 H), 8.12 (d, J = 8.7 Hz, 1 H),
7.81 (dd, J= 1.8, 8.7 Hz, 1 H),4.41 (s, 2 H),4.08 (s, 1 H), 3.81 (s, 3 H),
3.42 (dd, J = 4.1, 15.6 Hz, 1 H), 3.07 2.94 (m, 10 H), 2.41 (t, J = 13.7
Hz, 1 H), 2.29 2.24 (m, 1 H), 2.11 2.01 (m, 1 H), 1.73 1.64 (m, 1
H), 1.04 (d, J = 6.4 Hz, 6 H); MS (ESI) m/z 580.48 (M þ H).
(4S,4aS,5aR,14aS)-10-[(tert-Butylamino)methyl]-4-(dimethylamino)-
3,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19e-4).
1H NMR (400 MHz,
CD3OD) δ 8.59 (s, 1 H), 8.13 (d, J = 8.2 Hz, 1 H), 7.82 (d, J = 8.2 Hz,
1H),4.39(s,2H),4.12(s,1H),3.82(s,3H),3.42(dd,J=3.2,15.6Hz,
1 H), 3.05 2.97 (m, 8 H), 2.40 (t, J = 14.6 Hz, 1 H), 2.29 2.25
(m, 1 H), 1.73 1.63 (m, 1 H), 1.50 (s, 9 H); MS (ESI) m/z 580.64
(M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-[(dimethylamino)methyl]-
3,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-oc-
tahydropentacene-2-carboxamide (19e-5).
1H NMR (400 MHz,
CD3OD) δ 8.57 (s, 1 H), 8.14 (d, J = 8.7 Hz, 1 H), 7.81 (dd, J =1 . 8 ,
8.7 Hz, 1 H), 4.52 (s, 2 H), 4.12 (s, 1 H), 3.82 (s, 3 H), 3.42 (dd, J =4 . 1 ,
15.6 Hz, 1 H), 3.05 2.97 (m, 8 H), 2.91 (s, 6 H), 2.40 (dd, J = 13.7, 15.1
Hz,1H),2.30 2.25(m,1H),1.73 1.63(m,1H);MS(ESI)m/z552.55
(M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-[(3-fluoroazetidin-1-yl)-
methyl]-3,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-1,4,4a,5,5a,-
6,13,14a-octahydropentacene-2-carboxamide (19e-7).
1H NMR
(400 MHz, CD3OD, TFA salt) δ 8.53 (d, J = 1.8 Hz, 1 H), 8.11 (d,
J = 8.7 Hz, 1 H), 7.75 (dd, J = 1.8, 8.7 Hz, 1 H), 5.51 5.36 (m, 1 H),
4.65 (s, 2 H), 4.65 4.53 (m, 1 H), 4.42 4.34 (m, 1 H), 4.10 (s, 1 H),
3.80 (s, 3 H), 3.40 (dd, J = 4.1, 15.1 Hz, 1 H), 3.06 2.94 (m, 8 H), 2.383722 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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(t, J = 15.1 Hz, 1 H), 2.28 2.24 (m, 1 H), 1.72 1.62 (m, 1 H); MS
(ESI) m/z 582.38 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-7-
methoxy-1,13-dioxo-10-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (19e-8).
1H NMR (400 MHz,
CD3OD) δ 8.58 (s,1 H),8.12 (d,J=8.2 Hz,1 H),7.85 (d,J=8.2 Hz, 1
H), 4.59 (s, 2 H), 4.12 (s, 1 H), 3.81 (s, 3 H), 3.56 3.51 (m, 2 H), 3.41
(dd, J = 4.1, 15.1 Hz, 1 H), 3.27 3.21 (m, 2 H), 3.06 2.97 (m, 8 H),
2.38 (t, J = 14.6 Hz, 1 H), 2.29 2.21 (m, 3 H), 2.05 2.02 (m, 2 H),
1.72 1.62 (m, 1 H); MS (ESI) m/z 578.59 (M þ H).
Phenyl 4-Amino-7-bromo-1-methoxy-3-methylnaphthalene-
2-carboxylate (21). Acetic acid (2 mL) and zinc dust (622 mg, 9.52 mmol,
4 equiv) were added to a solution of compound 20 (990 mg, 2.38 mmol,
1.0 equiv) in THF (10 mL) at rt. The reaction mixture was stirred at rt for
15 h. More zinc dust (311 mg, 4.76 mmol, 2 equiv) was added. The reaction
mixture was stirred for another 5 h and filtered through a Celite pad. The
Celite cake was washed with ethyl acetate. The filtrate was washed with
saturated aqueous sodium bicarbonate and brine. The organic phase was
dried over sodium sulfate and filtered. The filtrate was concentrated. The
residue was purified by flash column chromatography (20% ethyl aceta-
te hexanescontaining10%methylenechloride)toaffordtheanilineproduct
21 (791 mg, 86%) as a yellow solid.
Phenyl 4-[Allyl(tert-butoxycarbonyl)amino]-7-bromo-1-[(tert-butoxy-
carbonyl)oxy]-3-methyl-2-naphthoate (23b). A solution of phenyllithium
in di-n-butyl ether (1.8 M, 0.61 mL, 1.10 mmol, 1.2 equiv) was added
dropwisetoasolutionofaniline21(354mg,0.92mmol,1.0equiv) inTHF
(18 mL) at  78 C. After 5 min, allylbromide (0.11 mL, 1.28 mmol, 1.4
equiv) wasaddeddropwiseat 78C.Thereactionmixturewasallowedto
warm up to rt over 1 h 40 min, and saturated aqueous ammonium chloride
was added. The resulting mixture was stirred for 5 min and extracted with
ethyl acetate (40 mL  3). The combined organic extracts were dried over
anhydrous sodium sulfate and filtered. The filtrate was concentrated, and
the residue was purified by flash column chromatography (0% f 5% ethyl
acetate/hexanes) to afford the monoallyl intermediate (325 mg, 83%) as
a colorless solid:
1H NMR (400 MHz, CDCl3) δ8.26(d, J= 1.8 Hz, 1 H),
7.99(d,J=9.2Hz,1H),7.60(dd,J=1.8,9.2Hz,1H),7.49 7.44(m,2H),
7.32 7.28(m,3H),6.11 6.01(m,1H),5.39 5.34(m,1H),5.21 5.18
(m, 1 H), 4.06 (s, 3 H), 3.69 (dt, J = 6.0, 1.4 Hz, 2 H), 2.49 (s, 3 H);
13C
NMR (100 MHz, CDCl3) δ166.6, 150.6, 148.5, 139.7, 136.0, 130.4, 129.7,
129.3, 128.2, 126.3, 126.2, 125.6, 125.1, 123.4, 121.5, 120.3, 116.4, 63.8,
53.0, 15.1.
A solution of BBr3 in methylene chloride (1.0 M, 0.61 L, 0.61 mmol,
2.0 equiv) was added dropwise to a solution of the above monoallyl
intermediate (130 mg, 0.30 mmol, 1.0 equiv) in methylene chloride
(3 mL) at  30 C. The resulting yellow solution was stirred between
 30to 25Cfor1.5handwaspouredintosaturated aqueoussodium
bicarbonate. The mixture was warmed to rt and extracted with methy-
lene chloride (25 mL   3). The organic extracts were combined, dried
over anhydrous sodium sulfate, and ﬁltered. The ﬁltrate was concen-
trated to give the crude product:
1H NMR (400 MHz, CDCl3) δ 11.77
(s, 1 H), 8.58 (d, J = 1.8 Hz, 1 H), 7.94 (d, J = 9.2 Hz, 1 H), 7.71 (dd,
J = 1.8, 9.2 Hz, 1 H), 7.50 7.46 (m, 2 H), 7.36 7.32 (m, 1 H),
7.26 7.23 (m, 2 H), 6.13 6.03 (m, 1 H), 5.39 5.34 (m, 1 H),
5.21 5.18 (m, 1 H), 3.60 (dt, J = 5.5, 1.4 Hz, 2 H), 2.73 (s, 3 H).
(Boc)2O (96 mg, 0.44 mmol, 2.0 equiv) and DMAP (3 mg, 0.02
mmol, 0.1 equiv) were added to a solution of the above intermediate in
DMF(1mL).Thereactionwasstirredatrtovernight,dilutedwithethyl
acetate (50 mL), and washed with water (30 mL   4). The organic
phase was dried over anhydrous sodium sulfate. The dried solution
was ﬁltered and concentrated. The residue was puriﬁed by ﬂash column
chromatography (5% f 7% ethyl acetate hexanes) to aﬀord com-
pound 23b (colorless oil, 88 mg, 47%, two steps, 3:1 rotamers):
1H
NMR (400 MHz, CDCl3) δ 8.09 (m, 1 H), 7.68 7.67 (m, 2 H),
7.49 7.45 (m, 2 H), 7.34 7.28 (m, 3 H), 6.02 5.90 (m, 1 H),
5.09 5.04 (m, 2 H), 4.21 (d, J = 6.9 Hz, 1.5 H), 4.12 (d, J = 6.9 Hz,
1 H), 2.49 (s, 0.75 H), 2.48 (s, 2.25 H), 1.57 (s, 2.25 H), 1.48 (s, 9 H),
1.25 (s, 6.75 H).
Phenyl 7-Bromo-4-(diallylamino)-1-methoxy-3-methyl-2-naphtho-
ate(22).Asolutionofphenyllithiumindi-n-butylether(1.8M,0.35mL,
0.64 mmol, 1.2 equiv) was added dropwise to a solution of aniline 21
(206mg,0.53mmol,1.0equiv)inTHF(10mL)at 78C.After3min,
allylbromide (0.16 mL, 1.86 mmol, 1.5 equiv) was added dropwise at
 78C.Thereactionmixturewasallowedtowarmuptortover30min.
The reaction was recooled to  78 C. Additional phenyllithium in di-n-
butyl ether (0.35 mL, 1.8 M/di-n-butyl ether, 0.636 mmol, 1.2 equiv) and
allylbromide(0.16mL,1.86mmol,1.5equiv)wereadded.Thereactionwas
allowed to warm to rt over 40 min and quenched with saturated aqueous
ammonium chloride. The mixture was stirred for 5 min and extracted
with ethyl acetate (40 mL   3). The organic extracts were combined and
dried over anhydrous sodium sulfate. The dried solution was filtered and
the filtrate was concentrated. The residue was purified by flash column
chromatography (0% f 2% ethyl acetate/hexanes) to afford the diallyl
compound 22 (205 mg, 82%) as a pale yellow oil:
1H NMR (400 MHz,
CDCl3) δ8.25 (d, J= 1.8 Hz, 1 H), 8.06 (d, J= 9.2 Hz, 1 H), 7.60 (dd, J=
1.8,9.2Hz,1H),7.49 7.44(m,2H),7.32 7.28(m,3H),5.82 5.91(m,
2H),5.14 5.04(m,4H),4.06(s,3H),3.84 3.75(m,4H),2.51(s,3H).
Phenyl 7-Bromo-1-[(tert-butoxycarbonyl)oxy]-4-(diallylamino)-3-
methyl-2-naphthoate (23c). A solution of BBr3 in methylene chloride
(1.0M,2.22mL,2.22mmol,2.0equiv)wasaddeddropwisetoasolution
of compound 22 (517 mg, 1.11 mmol, 1.0 equiv) in methylene chloride
(11 mL) at  40 C. The resulting light orange suspension was stirred
between 40and 30Cfor1handwaspouredintosaturatedaqueous
sodium bicarbonate. The mixture was warmed to rt and stirred for
30min.Themixturewasextractedwithmethylenechloride(60mL 3).
The organic extracts were combined and dried over anhydrous magne-
siumsulfate.Thedriedsolutionwasfilteredandconcentrated.Thecrude
product was used directly for the next reaction.
(Boc)2O (291 mg, 1.33 mmol, 1.2 equiv), DIEA (0.23 mL, 1.33
mmol,1.2equiv),andDMAP(16mg,0.13mmol,0.1equiv)wereadded
to a solution of the above intermediate in methylene chloride (20 mL).
The mixture was stirred at rt for 20 min and concentrated. The res-
idue was puriﬁed by ﬂash column chromatography (0% f 5% ethyl
acetate hexanes) to aﬀord compound 23c (pale yellow solid, 280 mg,
46%, two steps):
1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 9.2 Hz,
1H),8.02(d,J=1.8Hz,1H),7.62(dd,J=1.8,9.2Hz,1H),7.47 7.43
(m, 2 H), 7.31 7.27 (m, 3 H), 5.90 5.80 (m, 2 H), 5.15 5.04 (m,
4 H), 2.54 (s, 3 H), 1.48 (s, 9 H).
Phenyl 7-Bromo-4-[(tert-butoxycarbonyl)(methyl)amino]-1-[(tert-
butoxycarbonyl)oxy]-3-methyl-2-naphthoate (23a). Phenyl 4-amino-
7-bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate(2.0g,5.37mmol,
1.0 eq, crude) was dissolved in DMF (30 mL). (Boc)2O (2.34 g, 10.75
mmol, 2.0 equiv) and DMAP (30 mg, 0.24 mmol, 0.04 equiv) were
added. The brownish reaction mixture was stirred at rt for 3.5 h. The
reaction mixture was diluted with ethyl acetate (300 mL) and washed
with brine (150 mL   3). The organic phase was dried over magnesium
sulfate.Thedriedsolutionwasfiltered,andthefiltratewasconcentrated.
TLC analysis indicated incomplete reaction. The residue was then
redissolved in DMF (30 mL). (Boc)2O (2.34 g, 10.75 mmol, 2.0 equiv)
and DMAP (20 mg, 0.16 mmol, 0.03 equiv) were added. The mixture
was stirred at rt for 42 h. The reaction mixture was diluted with ethyl
acetate (300 mL) and washed with water (200 mL   2) and brine
(200 mL). The organic phase was dried over magnesium sulfate.
The dried solution was filtered, and the filtrate was concentrated. The
residue was purified by flash column chromatography (15% f 25%
ethyl acetate hexanes) to afford the tri-Boc-protected product (white
solid,1.24g,34%):
1HNMR(400MHz,CDCl3)δ8.10(t,J=1.4Hz,1
H), 7.69 (d, J = 1.4 Hz, 2 H), 7.47 7.43 (m, 2 H), 7.32 7.25 (m, 3 H),
2.47 (s, 3 H), 1.46 (s, 9 H), 1.32 (s, 18 H).3723 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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TFA (0.71 mL, 9.22 mmol, 5.0 equiv) was added to a solution of
theabovetri-Boc-protectedcompound(1.24g,1.84mmol,1.0equiv)in
methylene chloride (60 mL) at 0 C. The solution was stored in a
refrigerator (4 C) overnight. Saturated aqueous sodium bicarbonate
was added slowly at 0 C, and the mixture was warmed to rt. The
mixture was extracted with methylene chloride (50 mL   3). The
organic extracts were combined and dried over anhydrous magnesium
sulfate. The dried solution was ﬁltered, and the ﬁltrate was con-
centrated, providing the O-Boc and N-mono-Boc intermediate as a
white foamy solid.
The above crude compound was dissolved in THF (30 mL). A
solutionofLHMDSinTHF(1.0M,2.76mL,2.76mmol,1.5equiv)was
addeddropwisetothereactionat 78C.Theresultingorangemixture
was stirred at  78 C for 20 min. Iodomethane (0.23 mL, 3.68 mmol,
2.0 equiv) was added slowly. The reaction mixture was slowly warmed
to rt and stirred overnight. Saturated ammonium chloride was added.
The reaction mixture was extracted with ethyl acetate (100 mL   1,
50 mL   2). The organic extracts were combined and dried over
anhydrous magnesium sulfate. The dried solution was ﬁltered, and the
ﬁltrate was concentrated. The residue was puriﬁed by ﬂash column
chromatography (10% f 20% ethyl acetate hexanes) to give com-
pound 23a (6.5:1 rotamers, yellow foamy solid, 724 mg, 67%, two
steps):
1H NMR (400 MHz, CDCl3) δ 8.06 8.05(m, 1 H), 7.66 7.59
(m, 2 H), 7.42 7.36 (m, 2 H), 7.26 7.21 (m, 3 H), 3.15 (s, 2.6 H),
3.147 (s, 0.4 H), 2.43 (s, 2.6 H), 2.427 (s, 0.4 H), 1.42 (s, 9 H), 1.38
(s, 1.2 H), 1.21 (s, 7.8 H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-9-bromo-12-[(tert-butoxycarbonyl)
(methyl)amino]-4a-{[tert-butyl(dimethyl)silyl]oxy}-15-(dimethylamino)-
5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno-
[2,3-d]isoxazol-7-yl tert-Butyl Carbonate (24a). Compound 23a (772
mg, 1.32 mmol, 2.0 equiv) was reacted with enone 8 (318 mg, 0.66
mmol, 1.0 equiv) according to General Procedure A to yield compound
24a (560 mg, 87%, a mixture of rotamers) as a yellow solid:
1H NMR of
the major rotamer (400 MHz, CDCl3) δ 15.82 (br s, 1 H), 8.29 (br s, 1
H), 7.74 (dd, J = 1.8, 8.5 Hz, 1 H), 7.64 (dd, J = 8.5 Hz,
1 H), 7.55 7.51 (m, 2 H), 7.42 7.35 (m, 3 H), 5.36, 5.39 (ABq,
J = 12.2 Hz, 2 H), 3.93 (d, J = 10.7 Hz, 1 H), 3.15 (s, 3 H), 3.12 3.09
(m, 1 H), 3.04 2.98 (m, 1 H), 2.62 2.46 (m, 9 H), 2.19 2.15 (m,
1 H), 1.61 (s, 9 H), 1.27 (s, 9 H), 0.82 (s, 9 H), 0.28 (s, 3 H), 0.15 (s,
3 H); MS (ESI) m/z 974.62 (M þ H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-12-[(tert-butoxycarbonyl)(methyl)-
amino]-4a-{[tert-butyl(dimethyl)silyl]oxy}-15-(dimethylamino)-9-
formyl-5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropen-
taceno[2,3-d]isoxazol-7-yl tert-Butyl Carbonate (25a). Compound
24a (93 mg, 0.096 mmol, 1.0 equiv) was converted to compound 25a
according to General Procedure B. The crude product was purified by
preparative reverse-phase HPLC (45 mg, 51%, a mixture of rotamers,
yellow solid):
1H NMR (400 MHz, CDCl3) δ 15.84, 15.97 (s, 1 H),
10.21, 10.19 (s, 1 H), 8.69, 8.65 (s, 1 H), 8.16 8.14 (m, 1 H),
7.90 7.84 (m, 1 H), 7.53 7.50 (m, 2 H), 7.42 7.35 (m, 3 H), 5.38
(s, 2 H), 4.02, 3.99 (d, J = 10.4 Hz, 1 H), 3.28, 3.19 (s, 3 H), 3.28 2.99
(m,2H),2.68 2.49(m, 9H),2.18 2.14 (m, 1H),1.62,1.61(s,9H),
1.27, 1.24(s,9 H),0.85, 0.82 (s,9 H),0.26, 0.25 (s,3 H), 0.16(s,3 H);
MS (ESI) m/z 924.68 (M þ H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-
3,12,14,14a-tetrahydroxy-7-(methylamino)-1,13-dioxo-1,4,4a,5,5a,6,-
13,14a-octahydropentacene-2-carboxamide (26a). Compound 25a
was subjected to reductive amination with azetidine, followed by
desilylation and hydrogenation according to general procedures C, D,
and E to yield compound 26a (23% over three steps):
1H NMR (400
MHz,CD3OD)δ8.68(brs,1H),8.17(brd,J=7.3Hz,1H),8.01(brs,
J = 7.3 Hz, 1 H), 4.62 (br s, 2 H), 4.27 4.25 (m, 2 H), 4.17 4.12 (m,
3 H), 3.20 2.98 (m, 12 H), 2.60 2.38 (m, 4 H), 1.62 1.72 (m, 1 H);
MS (ESI) m/z 563.50 (M þ H).
(4aS,13aR,14aS,15S)-12-[Allyl(tert-butoxycarbonyl)amino]-3-
(benzyloxy)-9-bromo-4a-{[tert-butyl(dimethyl)silyl]oxy}-15-(dimethy-
lamino)-5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropen-
taceno[2,3-d]isoxazol-7-yl tert-Butyl Carbonate (24b). Prepared from
compound23baccordingtoGeneralProcedureA:
1HNMR(400MHz,
CDCl3) δ 15.90, 15.82 (s, 1 H), 8.32 8.26 (m, 1 H), 7.74 7.69 (m, 1
H), 7.65 7.62 (m, 1 H), 7.52 7.50 (m, 2 H), 7.41 7.33 (m, 3 H),
6.04 5.87 (m, 1 H), 5.40 5.34 (m, 2 H), 5.09 4.95 (m, 2 H), 4.56 
4.45(m,1H),3.96 3.81(m,2H),3.22 3.09(m,1H),3.01 2.91(m,
1H),2.62 2.35(m,9H),2.19 2.10(m,1H),1.61,1.60(s,9H),1.27,
1.26 (s, 9 H), 0.84, 0.81 (s, 9 H), 0.29, 0.28 (s, 3 H), 0.15, 0.14 (s, 3 H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-9-bromo-4a-{[tert-butyl(dimethyl)
silyl]oxy}-12-(diallylamino)-15-(dimethylamino)-5-hydroxy-4,6-dioxo-
4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-
Butyl Carbonate (24c). Prepared from compound 23c according to
General Procedure A:
1H NMR (400 MHz, CDCl3) δ 15.88 (br s, 1 H),
8.25 (br s,1 H),7.80 (d, J = 9.2 Hz,1 H),7.66 (dd, J = 1.8, 9.2Hz,1 H),
7.52 7.50 (m, 2 H), 7.41 7.34 (m, 3 H), 5.96 5.89 (m, 1 H),
5.79 5.72 (m, 1 H), 5.36 (s, 2 H), 5.19 4.99 (m, 4 H), 4.00 (d,
J = 10.4 Hz, 1 H), 3.86 3.67 (m, 4 H), 3.45 (dd, J = 4.3, 15.3 Hz, 1 H),
3.00 2.92(m,1H),2.62 2.48(m,9H),2.18(d,J=14.6Hz,1H),1.60
(s, 9 H), 1.26 (s, 9 H), 0.85 (s, 9 H), 0.29 (s, 3 H), 0.15 (s, 3 H).
(4aS,13aR,14aS,15S)-12-[Allyl(tert-butoxycarbonyl)amino]-3-
(benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]oxy}-15-(dimethylamino)-
9-formyl-5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropen-
taceno[2,3-d]isoxazol-7-yl tert-Butyl Carbonate (25b). Prepared from
compound24baccordingtoGeneralProcedureB:
1HNMR(400MHz,
CDCl3) δ 15.86, 15.79 (s, 1 H), 10.21, 10.19 (s, 1 H), 8.66 8.62 (m, 1
H), 8.14 8.10 (m, 1 H), 7.90 7.81 (m, 1 H), 7.52 7.50 (m, 2 H),
7.41 7.30 (m, 3 H), 6.05 5.87 (m, 1 H), 5.41 5.32 (m, 2 H), 5.10 
4.95(m,2H),4.60 4.48(m,1H),4.06 3.84(m,2H),3.28 3.15(m,
1 H), 3.04 2.94 (m, 1 H), 2.76 2.44 (m, 9 H), 2.21 2.12 (m, 1 H),
1.62,1.61(s,9H),1.27,1.26(s,9H),0.84,0.82(s,9H),0.29,0.28(s,3
H), 0.16, 0.14 (s, 3 H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]-
oxy}-12-(diallylamino)-15-(dimethylamino)-9-formyl-5-hydroxy-4,6-
dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-
yl tert-Butyl Carbonate (25c). Prepared from compound 24c according
to General Procedure B:
1H NMR (400 MHz, CDCl3) δ 15.85 (br s, 1
H), 10.18 (s, 1 H), 8.61 (br s, 1 H), 8.23 (d, J = 8.5 Hz, 1 H), 8.07 (dd,
J = 1.2, 8.5 Hz, 1 H), 7.52 7.50 (m, 2 H), 7.41 7.34 (m, 3 H),
5.99 5.89(m,1H),5.83 5.73(m,1H),5.39,5.35(ABq,J=12.2Hz,2
H),5.20 5.01(m,4H),4.00(d,J=10.4Hz,1H),3.94 3.71(m,4H),
3.52 (dd, J = 4.3, 15.9 Hz, 1 H), 3.02 2.97 (m, 1 H), 2.67 2.46 (m,
9H),2.20(d,J=14.0Hz,1H),1.61(s,9H),0.86(s,9H),0.30(s,3H),
0.16 (s, 3 H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-
3,12,14,14a-tetrahydroxy-1,13-dioxo-7-(propylamino)-1,4,4a,5,5a,6,-
13,14a-octahydropentacene-2-carboxamide (26b). Prepared from
compound 25b according to General Procedures C, D, and E:
1H
NMR(400MHz,CD3OD)δ8.69(d,J=1.4Hz,1H),8.14(dd,J=1.4,
8.7Hz,1H),8.00(d,J=8.7Hz,1H),4.63(brs,2H),4.31 4.24(m,2
H), 4.16 4.12 (m, 3 H), 3.63 2.98 (m, 11 H), 2.68 2.34 (m, 4 H),
1.94 1.86 (m, 2 H), 1.72 1.42 (m, 1 H), 1.06 1.00 (m, 3 H); MS
(ESI) m/z 591.47 (M þ H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-
7-(dipropylamino)-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,-
6,13,14a-octahydropentacene-2-carboxamide (26c). Prepared from
compound 25c according to General Procedures C, D, and E:
1H NMR
(400 MHz, D2O) δ 8.35 (br s, 1 H), 8.05 (d, J = 8.2 Hz, 1 H), 7.61 (d,
J = 8.2 Hz, 1 H), 4.31 (br s, 2 H), 3.98 3.86 (m, 5 H), 3.58 3.40 (m, 2
H), 3.12 (dd, J = 3.7, 15.6 Hz, 1 H), 2.96 2.85 (m, 2 H), 2.76 (s, 3 H),
2.72 2.71(m,2H),2.67(s,3H),2.42 2.26(m,2H),2.22 2.14(m,1
H), 2.06 2.00 (m, 1 H), 1.52 1.43 (m, 1 H), 1.34 1.18 (m, 2 H),3724 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
Journal of Medicinal Chemistry ARTICLE
1.06 0.80 (m, 2 H), 0.55 (t, J = 7.3 Hz, 3 H), 0.42 (t, J = 7.1 Hz, 3 H);
MS (ESI) m/z 633.50 (M þ H).
Phenyl 4-(Allyloxy)-7-bromo-1-[(tert-butoxycarbonyl)oxy]-3-meth-
yl-2-naphthoate (28). PhI(OAc)2 (2.58 g, 8.00 mmol, 2.0 equiv) was
addedinoneportiontoasolutionof27(1.60g,4.00mmol,1.0equiv)in
a mixture of allylalcohol (20 mL) and 1,4-dioxane (20 mL) at 0 C. The
reaction mixture was stirred at 0 C for 30 min. Acetic acid (4 mL) and
zincdust(1.57g,24.0mmol,6.0equiv)wereaddedat0C.Thereaction
mixture was stirred at 0 C for 25 min and filtered through a pad of
Celite. The Celite cake was washed thoroughly with ethyl acetate. The
filtrate was washed with 6 N aqueous sodium hydroxide (11 mL),
saturated aqueous sodium bicarbonate (120 mL), and brine (50 mL).
The organic phase was dried over anhydrous magnesium sulfate. The
dried solution was filtered, and the filtrate was concentrated, providing
the allyloxy intermediate as an orange solid.
(Boc)2O (917 mg, 4.20 mmol, 1.05 equiv) and DMAP (catalytic
amount)wereaddedtoasolutionoftheaboveintermediateinmethylene
chloride (40 mL). The mixture was stirred for 10 min at rt and
concentrated. Theresidue was puriﬁed by ﬂashcolumnchromatography
(1% f 4% ethyl acetate hexanes) to aﬀord compound 28 (white solid,
1.64 g, 80%, two steps):
1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1 H),
7.92 (d, J = 8.7 Hz, 1 H), 7.60 (dd, J = 1.8, 8.7 Hz, 1 H), 7.42 7.38 (m,
2 H), 7.26 7.18 (m, 3 H), 6.16 6.07 (m, 1 H), 5.46 (d, J = 17.4 Hz, 1
H),5.28(d,J=10.5Hz,1H),4.41(d,J=5.5Hz,2H),2.50(s,3H),1.43
(s, 9 H);
13C NMR (100 MHz, CDCl3) δ 164.4, 151.3, 151.2, 150.4,
140.5,133.1,131.4, 129.5, 128.3,127.7, 126.3, 125.2,125.0,124.6, 124.3,
121.6, 121.4, 118.0, 84.5, 75.0, 27.4, 13.7.
(4aS,13aR,14aS,15S)-12-(Allyloxy)-3-(benzyloxy)-9-bromo-4a-{[tert-
butyl(dimethyl)silyl]oxy}-15-(dimethylamino)-5-hydroxy-4,6-dioxo-
4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-
Butyl Carbonate (29). Compound 28 (150 mg, 0.29 mmol, 1.5 equiv)
was reacted with enone 8 (94 mg, 0.19 mmol, 1.0 equiv) according to
General Procedure A to give compound 29 as a yellow solid (83 mg,
47%):
1HNMR(400MHz,CDCl3)δ15.93(brs,1H),8.23(brs,1H),
7.92(d,J=9.2Hz,1H),7.67(dd,J=1.8,9.2Hz,1H),7.50 7.48(m,2
H),7.39 7.30(m,3H),6.20 6.10(m,1H),5.45(dd,J=1.2,15.1Hz,1
H),5.38 5.32(m,3H),4.47 4.38(m,2H),3.96(d,J=11.0Hz,1H),
3.49(dd,J=4.3,15.3Hz,1H),3.03 2.98(m,1H),2.60 2.44(m,9H),
2.17(d,J=14.6 Hz,1H),1.58(s,9H),0.81(s,9H),0.26(s,3H),0.12
(s, 3 H); MS (ESI) m/z 901.77 (M þ H).
(4aS,13aR,14aS,15S)-12-(Allyloxy)-9-(azetidin-1-ylmethyl)-3-
(benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]oxy}-15-(dimethylamino)-
5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno-
[2,3-d]isoxazol-7-yltert-ButylCarbonate(30).Compound29(769mg,
0.85 mmol, 1.0 equiv) was converted to the corresponding aldehyde
accordingtoGeneralProcedureB(519mg,72%,yellowsolid):
1HNMR
(400 MHz, CDCl3) δ 15.90 (br s, 1 H), 10.16 (s, 1 H), 8.58 (br s, 1 H),
8.17(d,J=8.5Hz,1H),8.07(dd,J=1.2,8.5Hz,1H),7.50 7.48(m,2
H),7.39 7.30(m,3H),6.22 6.12(m,1H),5.48(dd,J=1.2,17.1Hz,1
H),5.38 5.32(m,3H),4.51 4.45(m,2H),3.98(d,J=10.4Hz,1H),
3.55(dd,J=4.3,15.3Hz,1H),3.08 3.00(m,1H),2.65 2.45(m,3H),
2.51(s,6H),2.19(d,J=14.6Hz,1H),1.60(s,9H),0.82(s,9H),0.27
(s, 3 H), 0.13 (s, 3 H); MS (ESI) m/z 851.67 (M þ H).
The above aldehyde intermediate was then subjected to reductive
amination with azetidine according to General Procedure C to yield
compound 30 as a yellow solid:
1H NMR (400 MHz, CDCl3) δ 16.02
(brs,1H),8.00(d,J=8.5Hz,1H),7.91(brs,1H),7.57(d,J=8.5Hz,1
H),7.49 7.48(m,2H),7.38 7.30(m,3H),6.21 6.12(m,1H),5.46
(d,J=17.1Hz,1H),5.38 5.27(m,3H),4.43(d,J=5.5Hz,2H),3.98
(d,J=11.0Hz,1H),3.72(q,J=12.8Hz,2H),3.50(dd,J=4.3,15.3Hz,
1H),3.23(t,J=7.3Hz,4H),3.01 2.96(m,1H),2.62 2.43(m,3H),
2.49 (s, 6 H), 2.17 (d, J = 14.0 Hz, 1 H), 2.08 (p, J = 7.3 Hz, 2 H), 1.58
(s,9H),0.81(s,9H),0.26(s,3H),0.12(s,3H);MS(ESI)m/z892.83
(M þ H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-
3,12,14,14a-tetrahydroxy-1,13-dioxo-7-propoxy-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (31). Prepared from compound
30 by desilylation and hydrogenation according General Procedure D
andE:
1HNMR(400MHz, CD3OD)δ8.53(br s,1H),8.11 (d,J=8.7
Hz,1H),7.75(d,J=8.7Hz,1H),4.56(s,2H),4.26(q,J=9.6Hz,2H),
4.12 4.10 (m, 3 H), 3.85 3.79 (m, 2 H), 3.42 (dd, J = 4.1, 15.6 Hz, 1
H),3.12 2.96(m,8H),2.62 2.55(m,1H),2.52 2.47(m,1H),2.40
(t, J = 14.6 Hz, 1 H), 2.28 2.24 (m, 1 H), 1.94 1.85 (m, 2 H),
1.73 1.63(m,1H),1.31(t,J=7.8Hz,3H);MS(ESI)m/z592.42(M
þ H).
(4aS,13aR,14aS,15S)-9-(Azetidin-1-ylmethyl)-3-(benzyloxy)-4a-{[tert-
butyl(dimethyl)silyl]oxy}-15-(dimethylamino)-5,12-dihydroxy-4,6-
dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-
yltert-ButylCarbonate(32).Amixtureofcrudeproduct30(0.33mmol,
1.0 equiv), Pd(PPh3)4 (7.6 mg, 0.0066 mmol, 0.02 equiv) and N,N-
dimethylbarbituric acid (256 mg, 1.64 mmol, 5.0 equiv) was dissolved
in degassed methylene chloride (8 mL) under nitrogen. The resulting
orange solution was stirred at rt for 1 h and diluted with saturated
aqueoussodiumbicarbonate.Themixturewasextractedwithmethylene
chloride (15 mL   3). The organic extracts were combined, dried over
anhydrous sodium sulfate, filtered, and concentrated. The residue was
purified by preparative reverse-phase HPLC. Fractions with the desired
MW were collected and concentrated at rt under reduced pressure. The
residue was neutralized with saturated aqueous sodium bicarbonate and
extracted with methylene chloride (15 mL   3). The organic extracts
were combined, dried over anhydrous sodium sulfate, filtered, and
concentrated to afford the desired product 32 as an orange solid (263
mg, 86% over two steps):
1H NMR (400 MHz, CDCl3) δ 16.05 (br s,
1 H), 7.81 (br s, 1 H), 7.68 7.65 (m, 1 H), 7.49 7.47 (m, 2 H),
7.38 7.29(m,3H),7.12 7.10(m,1H),5.32,5.35(ABq,J=12.2Hz,2
H),3.97(d,J=11.0Hz,1H),3.67(s,2H),3.44 3.41(m,1H),3.32(t,
J=7.3Hz,4H),3.05 3.00(m,1H),2.55 2.42(m,3H),2.46(s,6H),
2.16 2.10(m, 3H),1.58(s,9H),0.81(s,9 H),0.26(s, 3H),0.12(s,3
H); MS (ESI) m/z 852.94 (M þ H).
(6aR,7aS,8S,11aS)-10-(Aminocarbonyl)-2-(azetidin-1-ylmethyl)-8-
(dimethylamino)-9,11a,12,14-tetrahydroxy-11,13-dioxo-6,6a,7,7a,8,-
11,11a,13-octahydropentacen-5-yl Methylcarbamate (33a). 2,6-Lu-
tidine (6.3 μL, 0.055 mmol, 3.0 equiv) and methylisocyanate (3.2 μL,
0.055 mmol, 3.0 equiv) were added to a solution of compound 32
(16mg,0.018mmol,1.0equiv)inmethylenechloride(1mL)atrt.The
reaction mixture was stirred at rt for 1 h. Additional methylisocyanate
(5.0 μL, 0.085 mmol, 4.7 equiv) was added. The reaction mixture was
stirred at rt for 3 h, diluted with saturated aqueous sodium bicarbonate
(10mL)andpotassiumphosphatebuffersolution(pH7.0,10mL),and
extracted with methylene chloride (15 mL   3). The organic extracts
were combined, dried over anhydrous sodium sulfate, filtered, and
concentrated to give the carbamate intermediate (MS (ESI) m/z
909.86 (M þ H)), which was subjected to desilylation and hydrogena-
tion according to General Procedures D and E to yield compound 33a
asayellowsolid:
1HNMR(400MHz,CD3OD)δ8.53(d, J=1.8Hz,1
H), 7.87 (d, J = 8.2 Hz, 1 H), 7.77 (dd, J = 1.8, 8.2 Hz, 1 H), 4.56 (s, 2
H),4.25 (q, J=9.6Hz,2H),4.14 4.08 (m, 3H),3.14 3.09 (m, 1H),
3.06 2.96 (m, 8H),2.82 (s, 3H),2.64 2.54 (m, 1H),2.52 2.43 (m,
1 H), 2.32 (dd, J= 13.7, 14.6 Hz, 1 H), 2.24 2.21 (m, 1 H), 1.68 1.58
(m, 1 H); MS (ESI) m/z 607.47 (M þ H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-
3,12,14,14a-tetrahydroxy-7-(2-methoxyethoxy)-1,13-dioxo-1,4,4a,5,-
5a,6,13,14a-octahydropentacene-2-carboxamide(35b). DIAD (27μL,
0.14 mmol, 5.0 equiv) was added dropwise to a solution of compound
32 (24mg, 0.028 mmol, 1.0 equiv), PPh3 (37 mg, 0.14 mmol, 5.0 equiv),
and 2-methoxyethanol (11 μL, 0.14 mmol, 5.0 equiv) in THF (1 mL) at
0C.Theresultingdarkredsolutionwasstirredat0Cfor1h.Saturated
aqueous sodium bicarbonate and brine (1:1, 20 mL) were added. The3725 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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mixturewasextractedwithmethylenechloride(15mL 3).Theorganic
extractswerecombined,driedoveranhydroussodiumsulfate,filtered,and
concentratedtogivethecrudeproduct(MS(ESI)m/z968.81(MþH)).
The above crude product was subjected to desilylation according to
General Procedure D, and the crude desliylated product was puriﬁed by
preparative reverse-phase HPLC. This intermediate was dissolved in
methanol(0.5 mL).ConcentratedHCl(0.5mL)was addedslowly atrt.
The reaction mixture was stirred at rt for 36 h and poured into aqueous
dipotassium hydrogenphosphate (3 g dissolved in 30 mL water). The
mixture was extracted with methylene chloride (15 mL   5). The
combined organic extracts were dried over anhydrous sodium sulfate,
ﬁltered, and concentrated. The residue was subjected to hydrogenation
accordingtoGeneralProcedure Etoyieldcompound 35b(4.3mg,25%
over four steps):
1H NMR (400 MHz, CD3OD) δ 8.51 (d, J = 1.4 Hz, 1
H),8.22(d,J=8.7Hz,1H),7.76(dd,J=1.4,8.7Hz,1H),4.57(s,2H),
4.26 (q, J = 9.6 Hz, 2 H), 4.15 4.10 (m, 3 H), 4.09 4.04 (m, 1 H),
3.99 3.94 (m, 1 H), 3.79 3.70 (m, 2 H), 3.47 (dd, J = 4.1, 15.6 Hz, 1
H), 3.45 (s, 3 H), 3.05 2.97 (m, 8 H), 2.63 2.55 (m, 1 H), 2.53 2.45
(m, 1 H), 2.36 (dd, J = 13.7, 15.1 Hz, 1 H), 2.28 2.25 (m, 1 H),
1.71 1.62 (m, 1 H); MS (ESI) m/z 608.47 (M þ H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-
3,12,14,14a-tetrahydroxy-7-isopropoxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-
octahydropentacene-2-carboxamide (35a). Prepared similarly to com-
pound 35b from compound 32 and isopropanol:
1H NMR (400 MHz,
CD3OD)δ8.52(d,J=1.8Hz,1H),8.12(d,J=8.7Hz,1H),7.73(dd,J=
1.8,8.7Hz,1H),4.56(s,2H),4.29 4.22(m,3H),4.15 4.10(m,3H),
3.42(dd,J=4.1,15.1Hz,1H),3.04 2.91(m,8H),2.62 2.55(m,1H),
2.53 2.44(m,1H),2.37(t,J=14.4Hz,1H),2.27 2.22(m,1H),1.72 
1.62 (m, 1 H), 1.32 (d, J = 6.4 Hz, 3 H), 1.27 (d, J = 6.4 Hz, 3 H); MS
(ESI) m/z 592.53 (M þ H).
(4aS,13aR,14aS,15S)-9-(Azetidin-1-ylmethyl)-3-(benzyloxy)-4a-{[tert-
butyl(dimethyl)silyl]oxy}-12-(2,3-dihydroxypropoxy)-15-(dimethyla-
mino)-5-(2-methoxyethoxy)-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahy-
dropentaceno[2,3-d]isoxazol-7-yl tert-ButylCarbonate (36). N-Methyl-
morpholine-N-oxide (60 mg, 0.52 mmol, 4.0 equiv) was added to a
solution of compound 30 (115 mg, 0.129 mmol, 1.0 equiv) in THF
(3 mL) andwater(0.6 mL). A solution ofOsO4 in water (4 wt%,30 μL,
0.04 equiv) was added. The reaction mixture was stirred at rt overnight,
diluted with aqueous Na2S2O3 (2 M, 10 mL) and brine (10 mL), and
extractedwithmethylenechloride(20mL 2).Theorganicextractswere
combined,driedoveranhydroussodiumsulfate,filtered,andconcentrated
to give compound 36: MS (ESI) m/z 926.92 (M þ H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-7-(2,3-dihydroxypropoxy)-
4-(dimethylamino)-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,-
13,14a-octahydropentacene-2-carboxamide (38). Prepared from com-
pound 36 by desilylation and hydrogenation according to General
Procedures D and E (28% over three steps):
1H NMR (400 MHz,
CD3OD) δ 8.52 (s, 1 H), 8.27 (dd, J = 2.3, 8.2 Hz, 1 H), 7.75 (d, J =8 . 2
Hz, 1 H), 4.56 (s, 2 H), 4.26 (q, J = 10.1 Hz, 2 H), 4.15 4.09 (m, 3 H),
4.06 4.02(m,1H),3.98(dd,J=3.2,9.6Hz,0.5H),3.92 3.91(m,1H),
3.84(dd,J=6.0,9.6Hz,0.5H),3.73 3.70(m,2H),3.53 3.47(m,1H),
3.05 2.97(m,8H),2.62 2.55(m,1H),2.52 2.45(m,1H),2.36(dd,
J = 14.2, 14.6 Hz, 1 H), 2.28 2.25 (m, 1 H), 1.71 1.62 (m, 1 H); MS
(ESI) m/z 624.61 (M þ H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-
3,12,14,14a-tetrahydroxy-1,13-dioxo-7-(2-oxoethoxy)-1,4,4a,5,5a,6,-
13,14a-octahydropentacene-2-carboxamide (37). NaIO4 (72 mg,
0.34 mmol, 3.0 equiv) was added to a solution of compound 36 (0.11
mmol, 1.0 equiv) in THF (1.5 mL) and water (1.5 mL) at 0 C. The
reaction mixture was stirred between 0 and 8 C for 24 h, diluted with
aqueous Na2S2O3 solution (2 M, 15 mL) and brine (15 mL), and
extracted with methylene chloride (20 mL   3). The organic extracts
were combined, dried over anhydrous sodium sulfate, filtered, and
concentrated to give compound 37.
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-
7-[2-(dimethylamino)ethoxy]-3,12,14,14a-tetrahydroxy-1,13-dioxo-
1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (40a). Pre-
pared from compound 37 and dimethylamine according to General Proce-
dures C, D, and E:
1H NMR (400 MHz, CD3OD) δ 8.56 (d, J = 1.8 Hz,
1 H), 8.15 (d, J = 8.2 Hz, 1 H), 7.83 (dd, J = 1.8, 8.2 Hz, 1 H), 4.58 (s,
2 H), 4.30 4.23 (m, 4 H), 4.15 4.09 (m, 3 H), 3.77 3.71 (m, 2 H),
3.43 3.38 (m, 1 H), 3.10 2.98 (m, 14 H), 2.63 2.55 (m, 1 H),
2.52 2.45 (m, 2 H), 2.39 2.36 (m, 1 H), 1.73 1.63 (m, 1 H); MS
(ESI) m/z 621.66 (M þ H).
Methyl 5-Bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate
(42).Asolutionofn-butyllithiuminhexane(2.5M,12.0mL,30.0mmol,
1.2 equiv) was added slowly to a stirred solution of diisopropylamine
(4.25 mL, 30.0 mmol, 1.2 equiv) in anhydrous THF (100 mL) at  78 C.
Thesolutionwasstirredat 78Cfor30min.4-Bromophthalide
26(5.38g,
25 mmol, 1 equiv) in anhydrous THF (20 mL) was added dropwise. The
mixture was then warmed to  50 C over 3 h. Methyl crotonate
(2.95mL,27.5 mmol,1.1equiv) was slowlyadded. Thereactionmixture
wasgraduallywarmedtort,stirredovernight,andpouredintodiluteHCl
(1 N, 150 mL). The mixture was extracted with ethyl acetate (50 mL  
3). The combined organic extracts were dried over anhydrous sodium
sulfate, filtered, and concentrated to give the crude intermediate.
The above crude intermediate was redissolved in methylene chloride
(65 mL). BF3 Et2O (0.63 mL, 5.00 mmol, 0.2 equiv) was added
dropwise. The reaction was stirredatrt for1h andquenched with water
(100 mL). The organic layer was separated, and the aqueous layer was
further extracted with methylene chloride (50 mL   3). The combined
organic extracts were dried over anhydrous sodium sulfate, ﬁltered, and
concentrated. The residue was puriﬁed by ﬂash chromatography (100:1
f 50:1, petroleum ether ethyl acetate) to give the desired product 42
(2.0 g, 27%) as a white solid:
1H NMR (400 MHz, CDCl3) δ 12.68
(s, 1 H), 8.29 (dd, J = 1.2, 8.4 Hz, 1 H), 7.78 (dd, J = 1.2. 8.4 Hz, 1 H),
7.41 (s, 1 H), 7.21 (t, J = 8.4 Hz, 1 H), 3.94 (s, 3 H), 2.63 (s, 3 H).
Methyl 1-(Benzyloxy)-5-bromo-3-methylnaphthalene-2-carboxy-
late (43). To a stirred solution of compound 42 (2.0 g, 6.8 mmol, 1.0
equiv) in acetone (25 mL) was added powdered potassium carbonate
(1.2 g, 8.7 mmol, 1.3 equiv) and benzylbromide (1.4 g, 8.2 mmol, 1.2
equiv). The mixture was heated at reflux for 1.5 h, cooled to rt, and
filtered through a short Celite pad. The filtrate was concentrated under
reduced pressure, and the residue was purified by flash chromatography
(100:1, petroleum ether ethyl acetate) to give the desire product 43
(2.0 g, 77%) as a white solid:
1H NMR (400 MHz, CDCl3) δ 8.01 (d,
J=8.4Hz,1H),7.80(s,1H),7.72(d,J=7.6Hz,1H),7.43 7.41(m,2
H),7.37 7.29(m,3H),7.20(t,J=8.4Hz,1H),5.05(s,2H),3.83(s,3
H), 2.45 (s, 3 H).
Phenyl 1-(Benzyloxy)-5-bromo-3-methylnaphthalene-2-carboxy-
late (44). To a solution of compound 43 (2.0 g, 5.2 mmol) in absolute
ethanol (10 mL) was added aqueous sodium hydroxide (4 N, 10 mL).
The mixture was heated at reflux overnight. The reaction was cooled to
rt, diluted with water (30 mL), and extracted with ethyl acetate (20 mL
  3, discarded). The aqueous phase was acidified with dilute HCl (1 N,
45 mL) to pH ≈ 6, and the mixture was extracted with ethyl acetate
(40mL 3).Thecombinedorganicextractsweredriedoveranhydrous
sodiumsulfate,filtered,andconcentratedunderreducedpressuretogive
the carboxylic acid intermediate as a white solid.
To a solution of the above crude product in methylene chloride
(20mL)wasaddedoxalylchloride(0.57mL,6.5mmol,1.3equiv)anda
few drops of DMF (gas evolution). The solution was stirred at rt for 30
min, and the volatiles were evaporated under reduced pressure. The
residuewasfurtherdriedunderhighvacuumtoaﬀordthecrudebenzoyl
chloride. This crude benzoyl chloride was redissolved in dry methylene
chloride (20 mL). Pyridine (0.88 mL, 10.9 mmol, 2.1 equiv), phenol
(0.54 g, 5.7 mmol, 1.1 equiv), and DMAP (catalytic amount) were
added.Thesolutionwasstirredatrtfor1h.Thesolventwasevaporated.3726 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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The residue was suspended in ethyl acetate and ﬁltered. The ﬁltrate was
washed with 1 N HCl (three times), H2O, saturated aqueous sodium
bicarbonate,andbrine,anddriedoversodiumsulfate.Thedriedsolution
was ﬁltered, and the ﬁltrate was concentrated. The residue was puriﬁed
byﬂashchromatography(100:1,petroleumether ethylacetate)togive
compound 44 (1.7 g, 73%) as an oﬀ-white solid:
1H NMR (400 MHz,
CDCl3) δ 8.11 (d, J = 8.4 Hz, 1 H), 7.94 (s, 1 H), 7.83 (dd, J = 1.2, 8.4
Hz, 1 H), 7.53 7.51 (m, 2 H), 7.42 7.35 (m, 5 H), 7.32 7.24 (m,
2 H), 7.16 (d, J = 7.6 Hz, 1 H), 5.22 (s, 2 H), 2.68 (s, 3 H).
Phenyl 5-[Bis(tert-butoxycarbonyl)amino]-1-[(tert-butoxycarbonyl)-
oxy]-3-methyl-2-naphthoate (45). To a stirred solution of compound
44 (2.0 g, 4.48 mmol, 1.0 equiv) inanhydroustoluene(20mL) wasadded
BocNH2 (786 mg, 6.7 mmol, 1.5 equiv), PhONa (779 mg, 6.7 mmol, 1.5
equiv), and Pd2(dba)33CHCl3 (125 mg, 0.11 mmol, 0.025 equiv). The
mixturewasdegassed.(tBu)3P(45mg,0.22mmol,0.05equiv) wasadded.
The mixture was heated at 95 C for 2 h. The reaction was cooled to rt,
quenched with water (50 mL), and extractedwith ethyl acetate (50 mL  
3). The combinedorganic extracts were dried oversodiumsulfate,filtered,
andconcentratedunderreducedpressure.Theresiduewaspurifiedbyflash
chromatography (100:1 f 50:1 f 20:1, petroleum ether ethyl acetate)
to give the aminated intermediate (1.6 g, 74%) as a white solid:
1HN M R
(400 MHz, CDCl3) δ 7.89 (d, J = 8.4 Hz, 1 H), 7.48 7.46 (m, 3 H),
7.42 7.31 (m, 7 H), 7.21 7.19 (m, 1 H), 7.09 (d, J = 8.4 Hz, 2 H), 5.16
(s, 2 H), 2.61 (s, 3 H), 1.51 (s, 9 H).
To a stirred solution of the above aminated intermediate (2.0 g, 4.13
mmol,1.0equiv)inmethanol(20mL)wasadded10%Pd C(300mg).
Thesuspensionwasbrieﬂyevacuatedandreﬁlledwithhydrogen,andthe
mixturewasstirredunderahydrogenatm osphere(1atm )atrtfor1h.The
reaction mixture was ﬁltered through a small Celite pad and the ﬁltrate
was concentrated under reduced pressure. The residue was redissolved
in methylene chloride (20 mL). Boc2O (1.25 g, 5.73 mmol, 1.4 equiv)
and a catalytic amount of DMAP (30 mg, 0.25 mmol, 0.06 equiv) were
added. The solution was stirred at rt for 2 h. The reaction was quenched
withbrine(50mL)andextractedwithmethylenechloride(30mL 3).
The combined organic extracts were dried, ﬁltered, and concentrated.
Theresiduewaspuriﬁedbyﬂashchromatography(50:1f15:1f10:1,
petroleum ether ethyl acetate) to give the desired product 45 (1.2 g,
49%)asawhitesolid:
1HNMR(400MHz,CDCl3)δ7.93(d,J=8.4Hz,
1 H), 7.61 (s, 1 H), 7.54 7.39 (m, 4 H), 7.32 7.26 (m, 3 H), 2.67 (s, 3
H), 1.46 (s, 9 H), 1.32 (s, 18 H).
Phenyl 5-[Bis(tert-butoxycarbonyl)amino]-3-(bromomethyl)-1-
[(tert-butoxycarbonyl)oxy]-2-naphthoate (46). To a solution of com-
pound 45(1.1g, 1.85 mmol, 1.0 equiv) incarbon tetrachloride (20mL)
was added NBS (347 mg, 1.95 mmol, 1.05 equiv) and BPO (895 mg,
3.70mmol,2.0equiv).Themixturewasrefluxedfor2h,cooledtort,and
concentrated. The residue was purified by flash chromatography
(50:1 f 15:1, petroleum ether ethyl acetate) to give the desired
product 46 (1.0 g, 81%) as a white solid:
1H NMR (400 MHz, CDCl3)
δ7.98(d,J=8.4Hz,1H),7.78(s,1H),7.62 7.56(m,1H),7.47 7.40
(m, 3 H), 7.40 7.35 (m, 2 H), 7.32 7.26 (m, 1 H), 4.92 (s, 1 H), 1.43
(s, 9 H), 1.30 (s, 18 H).
Di-tert-butyl [(4aS,13aR,14aS,15S)-3-(Benzyloxy)-7-[(tert-butoxy-
carbonyl)oxy]-4a-{[tert-butyl(dimethyl)silyl]oxy}-15-(dimethylamino)-
5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-
d]isoxazol-11-yl]imidodicarbonate (47). A solution of n-butyllithium in
hexane (2.5 M, 0.30 mL, 0.75 mmol, 3.2 equiv) was added dropwise to a
solutionof46(504mg,0.75mmol,3.2equiv)andenone8(113mg,0.23
mmol, 1.0 equiv) in dry THF (10 mL) at  100 C (liquid N2/ethanol
bath).Thereactionwasstirredat 100Cfor30min,allowedtowarmto
0 C gradually, quenched with brine (20 mL), and extracted with ethyl
acetate (20 mL   3). The combined organic extracts were dried, filtered,
and concentrated. The residue was purified by flash chromatography
(30:1f20:1f10:1,petroleumether ethylacetate)togivethedesired
product 47 (123 mg, 53%) as a yellow semisolid:
1H NMR (400 MHz,
CDCl3)δ8.33(d,J=8.4Hz,1H),7.77 7.71(m,5H),7.66 7.48(m,6
H), 7.35 (d, J = 8.8 Hz, 2 H), 5.59 (s, 2 H), 4.27 4.18 (m, 1 H),
3.40 3.29 (m, 2 H), 3.20 (d, J = 10.4 Hz, 1 H), 2.90 2.68 (m, 9 H),
2.28 2.18(m,1H),1.56(s,9H),1.50(s,18H),1.08(s,9H),0.50(s,3
H), 0.37 (s, 3 H).
(4S,4aS,5aR,14aS)-8-Amino-4-(dimethylamino)-3,12,14,14a-tetra-
hydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-car-
boxamide(49a).Preparedfromcompound47(29mg,0.030mmol)by
desilylation and hydrogenation according to General Procedures D and
E (4.3 mg, 29%, yellow solid):
1H NMR (400 MHz, CD3OD) δ 8.49
(d, J = 8.0 Hz, 1 H), 7.76 (d, J = 8.0 Hz, 1 H), 7.59 (t, J = 8.0 Hz, 1 H),
7.26 (s, 1 H), 4.16 (s, 1 H), 3.36 2.91 (m, 9 H), 2.78 2.66 (m, 1 H),
2.33 2.29 (m, 1 H), 1.71 1.61 (m, 1 H); MS (ESI) m/z 480.2
(M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-
8-(methylamino)-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropenta-
cene-2-carboxamide (49b). The Boc and TBS protection groups of
compound47(70mg,0.071mmol)wereremovedaccordingtoGeneral
Procedure D. One half of this crude product (20 mg, 0.035 mmol,
1.0 equiv) was dissolved in 1 N HCl/methanol (4 mL). Formalin
(0.06 mL, 0.74 mmol, 21 equiv) and 10% Pd C (7.0 mg) were added.
The suspension was briefly evacuated and refilled with hydrogen. The
mixture was stirred at rt under a hydrogen atmosphere (1 atm) for 3 h.
The catalyst was filtered off, and the filtrate was concentrated under
reduced pressure to yield the crude product. The crude product was
purified by preparative HPLC to give the desired product 49b (4.5 mg,
23%)asayellowsolid:
1HNMR(400MHz,CD3OD)δ8.33(t,J=8.4Hz,
1H),7.65 7.46(m,2H),7.25(s,1H),4.03(s,1H),3.15 2.85(m,12
H), 2.69 2.56 (m, 1 H),2.20 2.16 (m, 1 H),1.62 1.49 (m, 1 H);MS
(ESI) m/z 494.2 (M þ H).
(4S,4aS,5aR,14aS)-4,8-Bis(dimethylamino)-3,12,14,14a-tetrahydroxy-
1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide
(49c).Preparedfromthesameprecursor(30mg,0.053mmol,1.0equiv)
undersimilar hydrogenationconditionsused forcompound 49b, except
that the reaction was performed at 40 50 C overnight (4.0 mg, 15%,
yellowsolid):
1HNMR(400MHz,CD3OD)δ8.56(d,J=8.4Hz,1H),
8.10 (d, J = 8.4 Hz, 1 H), 7.68 (t, J = 8.4 Hz, 1 H), 7.58 (s, 1 H), 4.13 (s,
1 H), 3.46 (s, 3 H), 3.44 (s, 3 H), 3.22 2.96 (m, 9 H), 2.81 2.73 (m,
1 H), 2.30 2.25 (m, 1 H), 1.70 1.59 (m, 1 H); MS (ESI) m/z 508.0
(M þ H).
Phenyl 1-(Benzyloxy)-5-methoxy-3-methyl-2-naphthoate (50). A
mixture of compound 44 (2.2 g, 4.93 mmol, 1.0 equiv), bis-
(pinacolato)diboron (7.5 g, 29.5 mmol, 6.0 equiv), potassium acetate
(3.0 g, 30.6 mmol, 6.2 equiv), and PdCl2(dppf) CH2Cl2 (400 mg, 0.5
mmol, 0.1 equiv) in 1,4-dioxane (50 mL) was degassed and stirred at
90Cunderanitrogenatmosphereovernight.Thereactionmixturewas
cooled to rt and filtered. The filtrate was concentrated. The residue was
purified by column chromatography (100:1, petroleum ether ethyl
acetate) to afford the borate intermediate (2.1 g, 86%) as a white solid:
1H NMR (400 MHz, CDCl3) δ 8.44 (s, 1 H), 8.25 (d, J = 8.4 Hz, 1 H),
8.11(d,J=2.4Hz,1H),7.54 7.52(m,2H),7.46(dd,J=6.8,8.4Hz,1
H),7.41 7.37(m,5H),7.27 7.23(m,1H),7.17 7.15(m,2H),5.21
(s, 2 H), 2.66 (s, 3 H), 1.24 (s, 12 H).
To a solution of the above borate intermediate (2.0 g, 4.0 mmol,
1.0 equiv) in THF (20 mL) was carefully added H2O2 (30%, 2.0 mL,
17.6 mmol, 4.4 equiv), followed by acetic acid (1.2 mL, 20.0 mmol,
5.0 equiv). The reaction was stirred at rt overnight, quenched with
saturated aqueous NaHSO3 solution (until starch iodide test was
negative), and extracted with ethyl acetate (50 mL   3). The combined
organic extracts were dried, ﬁltered, and concentrated. The residue was
puriﬁed by ﬂash chromatography (50:1 f 40:1 f 10:1, petroleum
ether ethyl acetate) to give the desired naphthol intermediate (1.2 g,
78%)asawhitesolid:
1HNMR(400MHz,CDCl3)δ7.81(s,1H),7.66
(d, J = 8.4 Hz, 1 H), 7.47 (d, J = 6.8 Hz, 2 H), 7.36 7.28 (m, 5 H),3727 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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7.24 7.17 (m, 2 H), 7.09 (d, J = 7.6 Hz, 2 H), 6.78 (d, J = 7.2 Hz, 1 H),
5.51 (br s, 1 H), 5.16 (s, 2 H), 2.58 (s, 3 H).
To a stirred solution of the above naphthol intermediate (1.0 g,
2.6 mmol, 1.0 equiv) in acetone (15 mL) was added powdered
potassium carbonate (0.9 g, 6.5 mmol, 2.5 equiv) and iodomethane
(0.74 g, 5.2 mmol, 2.0 equiv). The reaction was stirred at rt overnight
and quenched with water (50 mL). After evaporation of acetone, the
residue was extracted with ethyl acetate (20 mL   3). The combined
organic extracts were dried, ﬁltered, and concentrated. The residue was
puriﬁedbyﬂashchromatography(40:1,petroleumether ethylacetate)
to give the desired product 50(760 mg, 74%) as awhite solid:
1HNMR
(400MHz,CDCl3)δ7.89(s,1H),7.65(d,J=8.4Hz,1H),7.48(d,J=
7.6 Hz, 2 H), 7.36 7.28 (m, 6 H), 7.20 7.17 (m, 1 H), 7.09 (d, J = 8.4
Hz,2H),6.82(d,J=7.6Hz,1H),5.16 (s,2H),3.94(s,3H),2.57(s,3
H).
Phenyl 1-[(tert-Butoxycarbonyl)oxy]-5-methoxy-3-methyl-2-naph-
thoate(51).Toastirredsolutionofcompound50(750mg,1.88mmol,
1.0 equiv) in methanol (10 mL) and ethyl acetate (10 mL) was added
10%Pd C(90mg).Thesuspensionwasbrieflyevacuated,refilledwith
hydrogen,andstirredunderahydrogenatmosphere(1atm)atrtfor2h.
The catalyst was filtered off, and the filtrate was concentrated under
reduced pressure. The residue was redissolved in methylene chloride
(20 mL). Boc2O (430 mg, 1.97 mmol, 1.1 equiv) and DMAP (20 mg,
0.16 mmol, 0.09 equiv) were added. The reaction was stirred at rt for
50 min, quenched with water (50 mL), and extracted with ethyl acetate
(30 mL   3). The combined organic extracts were dried, filtered, and
concentrated. The residue was purified by flash chromatography (40:1,
petroleumether ethylacetate)togivethedesiredproduct51(690mg,
90%) as a white solid:
1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1 H),
7.44 7.35(m,4H),7.24 7.20(m,3H),6.82(d,J=7.6Hz,1H),3.94
(s, 3 H), 2.60 (s, 3 H), 1.40 (s, 9 H).
Phenyl 3-(Bromomethyl)-1-[(tert-butoxycarbonyl)oxy]-5-methoxy-
2-naphthoate (52). A mixture of compound 51 (204 mg, 0.50 mmol,
1.0 equiv), NBS (99 mg, 0.56 mmol, 1.1 equiv), and AIBN (20 mg,
0.12 mmol, 0.24 equiv) in carbon tetrachloride (4 mL) was stirred at
reflux for 3 h. After evaporation of the solvent, the residue was purified
by flash chromatography (50:1, petroleum ether ethyl acetate) to give
the desired product 52 (200 mg, 82%) as a white solid:
1H NMR
(400MHz,CDCl3)δ8.28(s,1H),7.56 7.46(m,4H),7.42 7.32(m,
2H),7.35 7.30(m,1H),6.96(d,J=6.8Hz,1H),4.99(s,2H),4.03(s,
3 H), 1.49 (s, 9 H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)-
silyl]oxy}-15-(dimethylamino)-5-hydroxy-11-methoxy-4,6-dioxo-4,-
4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-
Butyl Carbonate (53). A solution of n-butyllithium in hexane (2.5 M,
0.10 mL, 0.25 mmol, 4.0 equiv) was added dropwise to a solution of
compound 52 (100 mg, 0.21 mmol, 3.3 equiv) and enone 8 (30 mg,
0.062 mmol, 1.0 equiv) in dry THF (2.5 mL) at  100 C (liquid
nitrogen/ethanol bath). The reaction was allowed to warm to 0 C
gradually over 1 h, quenched with brine (20 mL), and extracted with
ethyl acetate (20 mL   3). The combined organic extracts were dried,
filtered, and concentrated. The residue was purified by flash chroma-
tography (40:1 f 20:1, petroleum ether ethyl acetate) to give the
desiredproduct53(30mg,61%)asayellowsolid:
1HNMR(400MHz,
CDCl3) δ 7.93 (s, 1 H), 7.62 (d, J = 8.4 Hz, 1 H), 7.46 7.44 (m, 2 H),
7.40 7.28 (m, 5 H), 6.87 (d, J = 6.8 Hz, 1 H), 5.31 (s, 2 H), 3.95 (s,
3 H), 3.11 3.03 (m, 2 H), 2.92 (d, J = 10.4 Hz, 1 H), 2.51 2.38 (m,
9H),2.11 2.05(m,1H),1.73 1.65(m,1H),1.53(s,9H),0.80(s,9H),
0.22 (s, 3 H), 0.09 (s, 3 H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-
8-methoxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-
carboxamide (54). Prepared from compound 53 (30 mg, 0.038 mmol)
by desilylation and hydrogenation according the General Procedures D
andE(8.0mg,16%,yellowsolid):
1HNMR(400MHz,CD3OD)δ7.87
(d,J=8.4Hz,1H),7.43(s,1H),7.39(t,J=8.4Hz,1H),7.07(d,J=8.4
Hz,1H),4.07(s,1H),3.97(s,2H),3.09 2.89(m,9H),2.65 2.58(m,
1 H), 2.22 2.19 (m, 1 H), 1.65 1.59 (m, 1 H); MS (ESI) m/z 495.3
(M þ H).
Phenyl 5-Bromo-1-[(tert-butoxycarbonyl)oxy]-3-methylnaphtha-
lene-2-carboxylate (57). Prepared from compound 42 according to
thesamereactionsequenceusedforcompound14awithanoverallyield
of76%:
1HNMR(400MHz,CDCl3)δ8.00(s,1H),7.87(d,J=8.7Hz,
1 H), 7.80 (dd, J = 1.4, 7.8 Hz, 1 H), 7.42 7.38 (m, 2 H), 7.31 (dd, J =
7.3, 8.2 Hz, 1 H), 7.26 7.23 (m, 3 H), 2.66 (s, 3 H), 1.41 (s, 9 H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-11-bromo-4a-{[tert-butyl-
(dimethyl)silyl]oxy}-15-(dimethylamino)-5-hydroxy-4,6-dioxo-4,4a,6,-
13,13a,14,14a,15-octahydropentaceno-[2,3-d]isoxazol-7-yl tert-Butyl
Carbonate (58). Prepared from compound 57 according to General
Procedure A:
1H NMR (400 MHz, CDCl3) δ 15.99 (br s, 1 H), 8.09 (d,
J = 8.5 Hz, 1 H), 7.97 (s, 1 H), 7.86 (d, J = 6.7 Hz, 1 H), 7.51 7.48 (m,
2 H), 7.39 7.33 (m, 4 H), 5.38, 5.34 (ABq, J = 12.0 Hz, 2 H), 3.97 (d,
J = 11.0 Hz, 1 H), 3.23 3.11 (m, 2 H), 3.00 (t, J = 13.4 Hz, 1 H),
2.60 2.46 (m, 8 H), 2.22 2.16 (m, 1 H), 1.58 (s, 9 H), 0.82 (s, 9 H),
0.28 (s, 3 H), 0.14 (s, 3 H); MS (ESI) m/z 845.61 (M þ H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]oxy}-
15-(dimethylamino)-11-formyl-5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,-
14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-Butyl Carbonate
(59). Prepared from compound 58 according to General Procedure B:
1HNMR(400MHz,CDCl3)δ15.93(brs,1H),10.32(s,1H),9.04(s,
1H),8.40(d,J=8.5Hz,1H),8.07(d,J=6.7Hz,1H),7.69(dd,J=7.3,
7.9Hz,1H),7.50 7.48(m,2H),7.39 7.32(m,2H),5.37,5.33(ABq,
J=12.2Hz,2H),3.96(d,J=10.4Hz,1H),3.25 3.11(m,2H),3.00(t,
J=14.0Hz,1H),2.58 2.40(m,8H),2.20 2.15(m,1H),1.57(s,9H),
0.81(s,9H),0.26(s,3H),0.12(s,3H);MS(ESI)m/z795.58(MþH).
(4S,4aS,5aR,14aS)-8-[(Cyclopropylamino)methyl]-4-(dimethylam-
ino)-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octa-
hydropentacene-2-carboxamide (61a). Prepared from compound 59
by reductive amination with cyclopropylamine, followed by desilylation
and hydrogenation according to General Procedures C, D, and E:
1H
NMR (400 MHz, CD3OD) δ 8.47 (d, J = 8.2 Hz, 1 H), 7.83 (d, J = 8.2
Hz, 1 H), 7.54 (t, J = 8.2 Hz, 1 H), 7.46 (s, 1 H), 4.75 (s, 2 H), 4.11 (s, 1
H), 3.20 2.85 (m, 10 H), 2.69 (m, 1 H), 2.35 2.25 (m, 1 H),
1.67 1.58 (m, 1 H); MS (ESI) m/z 534.52 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-8-[(dimethylamino)methyl]-
3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydro-
pentacene-2-carboxamide (61b). Prepared from compound 59 by
reductive amination with dimethylamine, followed by desilylation and
hydrogenation according to General Procedures C, D, and E:
1H NMR
(400 MHz, CD3OD) δ 8.52 8.49 (m, 1 H), 7.86 (s, 1 H), 7.55 7.51
(m, 2 H), 4.77 (s, 2 H), 4.10 (s, 1 H), 3.19 2.90 (m, 15 H), 2.67 (m, 1
H), 2.28 (m, 1 H), 1.62 (m, 1 H); MS (ESI) m/z 522.50 (M þ H).
(4S,4aS,5aR,14aS)-8-(Azetidin-1-ylmethyl)-4-(dimethylamino)-3,-
12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydro-
pentacene-2-carboxamide (61c). Prepared from compound 59 by
reductive amination with azetidine, followed by desilylation and hydro-
genation according to General Procedures C, D, and E:
1H NMR (400
MHz, CD3OD) δ 8.45 (d, J = 8.2 Hz, 1 H), 7.80 (d, J = 5.0 Hz, 1 H),
7.52 7.48(m,2H),4.82(s,2H),4.27(s,2H),4.10(s,3H),3.19 2.96
(m, 9 H), 2.66 2.45 (m, 3 H), 2.26 (m, 1 H), 1.62 (m, 1 H); MS (ESI)
m/z 534.51 (M þ H).
Methyl 6-Bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate
(63). A solution of n-butyllithium in hexane (2.5 M, 96 mL, 0.24 mol,
1.2 equiv) was added slowly to a stirred solution of diisopropylamine
(33.8 mL, 0.24 mol, 1.2 equiv) in anhydrous THF (800 mL) at  78 C.
The mixture was stirred at  78 C for 30 min. A solution of
5-bromophthalide (62, 42.6 g, 0.2 mol, 1.0 equiv) in anhydrous THF
(200 mL) was added dropwise. The reaction mixture was then allowed
to warm to  50 C over 3 h. Methyl crotonate (23.4 mL, 0.22 mol, 1.13728 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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equiv) was slowly added. The reaction was gradually warmed to rt with
stirring overnight. The reaction mixture was poured into dilute HCl
(1 N, 150 mL) and extracted with ethyl acetate (50 mL   3). The
combined organic extracts were dried over anhydrous sodium sulfate,
filtered, and concentrated to dryness.
The above crude intermediate was redissolved in methylene chloride
(400 mL). BF3 Et2O (5.1 mL, 40 mmol, 0.2 equiv) was added
dropwise. The reaction was stirred at rt for 1 h and quenched with
water (200 mL). Theorganic layer was separated, and the aqueous layer
was extracted with methylene chloride (100 mL   3). The combined
organic layers were dried over anhydrous sodium sulfate, ﬁltered, and
concentrated. The residue was puriﬁed by ﬂash chromatography (50:1
f 30:1, petroleum ether ethyl acetate) to give the desired product 63
(12 g, 20%) as a white solid:
1H NMR (400 MHz, CDCl3) δ 12.67 (s,
1H),8.14(d,J=8.8Hz,1H),7.72(d,J=1.2Hz,1H),7.43(dd,J=1.6,
8.4 Hz, 1 H), 6.92 (s, 1 H), 3.93 (s, 3 H), 2.56 (s, 3 H).
Phenyl 1-(Benzyloxy)-6-bromo-3-methylnaphthalene-2-carboxy-
late (64). To a stirred solution of compound 63 (10.7 g, 36.3 mmol,
1.0 equiv) in acetone (250 mL) was added powdered potassium
carbonate (10.0 g, 72.5 mmol, 2.0 equiv) and benzylbromide (7.4 g,
43.5mmol,1.2equiv).Themixturewasrefluxedfor2h,cooledtort,and
concentrated.Theresiduewaspurifiedbyflashchromatography (1:0f
10:1, petroleum ether ethyl acetate) to give the benzyl ether inter-
mediate (9.1 g, 65%) as a white solid:
1H NMR (400 MHz, CDCl3) δ
7.93 7.91 (m, 2 H), 7.50 7.46 (m, 3 H), 7.43 7.34 (m, 4 H), 5.10 (s,
2 H), 3.89 (s, 3 H), 2.45 (s, 3 H).
To a solution of the above benzyl ether intermediate (12.5 g, 32.4
mmol) in absolute ethanol (50 mL) was added dilute aqueous sodium
hydroxide (4 N, 50 mL). The mixture was heated at reﬂux overnight,
cooled to rt, diluted with water (150 mL), and extracted with ethyl
acetate (50 mL   3, discarded). The aqueous phase was acidiﬁed with
dilute HCl (1 N, 220 mL) to pH ≈ 6 and extracted with ethyl acetate
(50 mL   3). The combined organic layers were dried over anhydrous
sodiumsulfate,ﬁltered,andconcentratedunderreducedpressuretogive
the carboxylic acid as a white solid.
Toasolutionofabovecrudeproductinmethylenechloride(250mL)
was added oxalyl chloride (6.13 mL, 65.0 mmol, 2.0 equiv) and a few
drops of DMF (gas evolution). The mixture was stirred at rt for 30 min,
and the volatiles were evaporated under reduced pressure. The residue
was further dried under high vacuum to aﬀord the crude benzoyl
chloride. This crude benzoyl chloride was redissolved in dry methylene
chloride (200 mL). Pyridine (5.14 g, 65.0 mmol, 2.0 equiv), phenol
(3.66 g, 39.0 mmol, 1.2 equiv), and a catalytic amount of DMAP were
added.Themixturewasstirredatrtfor1h.Thesolventwasevaporated.
The residue was suspended in ethyl acetate and ﬁltered. The ﬁltrate was
washed with 1 N HCl (three times), H2O, saturated aqueous sodium
bicarbonate, and brine. The solution was dried over sodium sulfate,
ﬁltered, and concentrated. The residue was puriﬁed by ﬂash chroma-
tography (1:0 f 10:1, petroleum ether ethyl acetate) to give com-
pound 64 (1.7 g, 71%) as an oﬀ-white solid:
1H NMR (400 MHz,
CDCl3) δ 8.00 7.97 (m, 2 H), 7.56 7.51 (m, 3 H), 7.44 7.38 (m,
6 H), 7.30 7.26 (m, 1 H), 7.18 7.15 (m, 2 H), 5.23 (s, 2 H), 2.64
(s, 3 H).
Phenyl 1-(Benzyloxy)-6-[(tert-butoxycarbonyl)amino]-3-methyl-2-
naphthoate (65). A mixture of compound 64 (3.5 g, 7.5 mmol, 1.0
equiv), BocNH2 (1.32 g, 11.3 mmol, 1.5 equiv), cesium carbonate (3.68
g, 11.3 mmol, 1.5 equiv), Pd2(dba)3 (213 mg, 0.19 mmol, 0.025 equiv),
and P(tBu)3 (77 mg, 0.38 mmol, 0.05 equiv) in toluene (50 mL) was
degassed and stirred between90 and 100 C overnight undera nitrogen
atmosphere. After cooling to rt, the mixture was added with water
(100 mL) and extracted with ethyl acetate (50 mL   3). The combined
organic layers were dried over anhydrous sodium sulfate, filtered, and
concentrated. The residue was purified by flash chromatography (30:1
f 10:1, petroleum ether ethyl acetate) to give the desired product
65 (2.3 g, 64%) as a white solid:
1H NMR (400 MHz, CDCl3) δ 8.04
(d, J = 9.2 Hz, 1 H), 7.99 (s, 1 H), 7.53 (dd, J = 1.2, 8.0 Hz, 2 H),
7.44 7.38(m,6H),7.31 7.24(m,2H),7.17(d,J=7.6Hz,2H),6.67
(s, 1 H), 5.23 (s, 2 H), 2.61 (s, 3 H), 1.56 (s, 9 H).
Phenyl 6-[Bis(tert-butoxycarbonyl)amino]-1-[(tert-butoxycarbonyl)-
oxy]-3-methyl-2-naphthoate (66). To a stirred solution of compound
65 (2.0 g, 4.13 mmol, 1.0 equiv) in methanol (15 mL) and ethyl acetate
(3 mL) was added 10% Pd C (300 mg). The suspension was briefly
evacuated and refilled with hydrogen and stirred under a hydrogen
atmosphere (1 atm) at rt for 2 h. The catalyst was filtered off, and
the filtrate was concentrated under reduced pressure. The residue was
redissolved in methylene chloride (20 mL). Boc2O (2.5 g, 11.57 mmol,
2.8 equiv) and DMAP (50 mg, 0.42 mmol, 0.10 equiv) were added. The
reaction was stirred at rt for 1 h and quenched with water (50 mL). The
mixturewasextractedwithmethylenechloride(20mL 3).Thecombined
organic layers were dried, filtered, and concentrated. The residue was
purified by flash chromatography (50:1 f 30:1, petroleum ether ethyl
acetate) to give the desired product 66 (2.2 g, 90%) as a white solid:
1HNMR(400MHz,CDCl3)δ7.91(d,J=8.8Hz,1H),7.60(s,1H),7.55
(s, 1 H), 7.45 7.41 (m, 2 H), 7.30 7.26 (m, 4 H), 2.65 (s, 3 H), 1.44
(s, 9 H), 1.39 (s, 18 H).
Phenyl 6-[Bis(tert-butoxycarbonyl)amino]-3-(bromomethyl)-1-
[(tert-butoxycarbonyl)oxy]-2-naphthoate (67). A mixture of com-
pound 66 (2.2 g, 3.81 mmol, 1.0 equiv), NBS (691 mg, 3.88 mmol,
1.02 equiv), and BPO (1.84 g, 7.60 mmol, 2.0 equiv) in carbon
tetrachloride (20 mL) was refluxed for 5 h. The reaction was cooled
to rt and quenched with water (50mL). The mixture was extracted with
methylene chloride (20 mL   3). The combined organic layers were
dried, filtered, and concentrated. The residue was purified by flash
chromatography (50:1 f 30:1, petroleum ether ethyl acetate) to give
the desired product 67 (1.9 g, 74%) as a white solid:
1H NMR (400
MHz, CDCl3) δ 7.99 (d, J = 8.8 Hz, 1 H), 7.78 (s, 1 H), 7.63 (d, J = 2.0
Hz, 1 H), 7.47 7.41 (m, 2 H), 7.40 7.33 (m, 2 H), 7.31 7.26 (m,
2 H), 4.93 (s, 2 H), 1.45 (s, 9 H), 1.40 (s, 18 H).
Di-tert-butyl [(4aS,13aR,14aS,15S)-3-(Benzyloxy)-7-[(tert-butoxy-
carbonyl)oxy]-4a-{[tert-butyl(dimethyl)silyl]oxy}-15-(dimethylamino)-
5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-
d]isoxazol-10-yl]imidodicarbonate (68). A solution of n-butyllithium in
hexane (2.5 M, 0.15 mL, 0.37 mmol, 3.6 equiv) was added dropwise to a
solution of compound 67 (250 mg, 0.37 mmol, 3.6 equiv) and enone 8
(50 mg, 0.10 mmol, 1.0 equiv) in dry THF (5.0 mL) at  100 C (liquid
nitrogen/ethanol bath). The reaction was allowed to warm to 0 C
gradually over 1 h and quenched with brine (20 mL). The mixture was
extracted with ethyl acetate (10 mL   3). The combined organic layers
were dried, filtered, and concentrated. The residue was purified by flash
chromatography (40:1 f 20:1, petroleum ether ethyl acetate) to give
the desired product 68 (20 mg, 20%) as a yellow semisolid:
1HN M R
(400 MHz, CDCl3) δ 7.97 (d, J = 9.2 Hz, 1 H), 7.41 (s,1 H), 7.38 7.36
(m, 3 H), 7.26 7.12 (m, 4 H), 5.23 (s, 2 H), 3.84 (d, J = 14.4 Hz, 1 H),
2.99 2.95 (m, 2 H), 3.01 2.92 (m, 1 H), 2.86 2.82 (m, 1 H),
2.46 2.30 (m, 9 H), 2.05 1.98 (m, 1 H), 1.44 (s, 9 H), 1.29 (s, 18
H), 0.70 (s, 9 H), 0.14 (s, 3 H), 0.08 (s, 3 H).
(4S,4aS,5aR,14aS)-9-Amino-4-(dimethylamino)-3,12,14,14a-tetra-
hydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-car-
boxamide (69a). Prepared from compound 68 (18 mg, 0.018 mmol)
according to General Procedures D and E (3.0 mg, 36%, yellow solid):
1HNMR(400MHz,CD3OD)δ8.42(d,J=8.8Hz,1H),7.61(s,1H),
7.37(d,J=8.8Hz,1H),7.14(s,1H),4.11(s,1H),3.18 2.95(m,9H),
2.68 2.61 (m, 1 H), 2.27 2.20 (m, 1 H), 1.69 1.57 (m, 1 H); MS
(ESI) m/z 480.2 (M þ H).
(4S,4aS,5aR,14aS)-4,9-Bis(dimethylamino)-3,12,14,14a-tetrahydroxy-
1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide
(69b). Compound 68 (45 mg, 0.046 mmol) was desilylated according
to General Procedure D. The crude product was dissolved in HCl/3729 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
Journal of Medicinal Chemistry ARTICLE
methanol (1 N, 6.0 mL). Formalin (0.10 mL, 1.23 mmol, 35 equiv) and
10% Pd C (20 mg) were added. The suspension was briefly evacuated
and refilled with hydrogen. The reaction was stirred under a hydrogen
atmosphere(1atm)atrtfor30min.Thecatalystwasfilteredoff,andthe
filtrate was concentrated under reduced pressure to give the crude product.
The crude product was purified by HPLC to yield the desired product
69b (6.0 mg, 34%) as a yellow solid:
1H NMR (400 MHz, CD3OD) δ
8.35 (d, J=9.2 Hz,1 H),7.40 (d, J=9.2 Hz,1 H),7.06 (s, 1H), 4.08 (s,
1H),3.26(s,6H),3.15 2.85(m,9H),2.65 2.58(m,1H),2.24 2.18
(m, 1 H), 1.68 1.54 (m, 1 H); MS (ESI) m/z 508.1 (M þ H).
Phenyl 1-[(tert-Butoxycarbonyl)oxy]-4-(dimethylamino)-7-fluoro-
3-methyl-2-naphthoate (70). A solution of n-butyllithium in hexanes
(1.6M,0.35mL,0.55mmol,1.2equiv)wasaddeddropwisetoasolution
of compound 14d (230 mg, 0.46 mmol, 1.0 equiv) in THF (10 mL)
at  100 C, forming a red solution. After 5 min, a solution of
N-fluorobenzenesulfonimide (290 mg, 0.92 mmol, 2.0 equiv) in THF
(1 mL) was added dropwise via a cannula. The reaction was allowed to
warm to  78 C and was stirred at that temperature for 1 h. Saturated
aqueous ammonium chloride (5 mL) was added dropwise at  78 C.
The reaction mixture was allowed to warm to 23 C, diluted with
additionalsaturatedaqueousammoniumchloride(30mL),andextracted
with ethyl acetate (60 mL). The organic phase was separated, washed
with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and
concentrated. The residue was purified by preparative reverse-phase
HPLC to yield compound 70 (95 mg, 60% based on recovered starting
material (50 mg)):
1H NMR (400 MHz, CDCl3) δ 8.19 (dd, J =5 . 5 ,
9.2 Hz, 1 H), 7.48 7.42 (m, 3 H), 7.34 7.27 (m, 4 H), 2.98 (s, 6 H),
2.50 (s, 3 H), 1.46 (s, 9 H); MS (ESI) m/z 440.34 (M þ H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)-
silyl]oxy}-12,15-bis(dimethylamino)-9-fluoro-5-hydroxy-4,6-dioxo-4,-
4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-
Butyl Carbonate (71d). Prepared from compound 70 (15 mg, 0.033
mmol,1.0equiv)andenone8(16mg,0.033mmol,1.0equiv)according
to General Procedure A (2.4 mg, 9%):
1H NMR (400 MHz, CDCl3) δ
15.88 (br s, 1 H), 8.13 (dd, J = 5.5, 9.2 Hz, 1 H), 7.68 (br d, J = 7.9 Hz,
1 H), 7.50 7.48 (m, 2 H), 7.39 7.30 (m, 4 H), 5.37, 5.33 (ABq,
J = 12.2 Hz, 2 H), 4.02 (d, J = 10.4 Hz, 1 H), 3.27 (dd, J = 4.3, 15.3 Hz,
1 H), 3.03 2.95 (m, 7 H), 2.65 (t, J = 15.3 Hz, 1 H), 2.58 2.49 (m, 8
H), 2.18 (d, J =14.0 Hz, 1 H), 1.57 (s, 9 H), 0.83 (s, 9 H), 0.27 (s, 3 H),
0.13 (s, 3 H); MS (ESI) m/z 828.55 (M þ H).
(4S,4aS,5aR,14aS)-4,7-Bis(dimethylamino)-10-fluoro-3,12,14,14a-
tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-
carboxamide (72d). Prepared from compound 71d (2.4 mg, 0.003
mmol, 1.0 equiv) by desilylation and hydrogenation according to
General Procedures D and E (1.1 mg, 60% for two steps):
1H NMR
(400MHz,CD3OD)δ8.25(brs,1H),8.08(brs,1H),7.57(brs,1H),
4.14 (s, 1 H), 3.44 3.39 (m, 1 H), 3.13 2.97 (m, 8 H), 2.56 2.50 (m,
1 H), 2.33 2.29 (m, 1 H), 1.74 1.64 (m, 1 H); MS (ESI) m/z 526.30
(M þ H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]oxy}-
15-(dimethylamino)-9-fluoro-5-hydroxy-12-methoxy-4,6-dioxo-4,4a,-
6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-Butyl
Carbonate(71c).Asolutionofphenyllithiumindi-n-butylether(1.8M,
66 μL, 0.12 mmol, 2.0 equiv) was added dropwise to a solution of
compound15e(52mg,0.06mmol,1.0equiv)inTHF(2mL)at 78C,
forming a dark red solution. After 5 min, a solution of n-butyllithium in
hexanes (1.6 M, 45 μL, 0.072 mmol, 1.2 equiv) was added dropwise
at  78 C followed 3 min later by the addition of N-fluorobenzenesul-
fonimide (66 mg, 0.21 mmol, 3.5 equiv). The resulting red reaction
mixture was stirred at  78 C for 1 h. Saturated aqueous ammonium
chloride solution (2 mL) was added dropwise at  78 C. The reaction
mixture was allowed to warm to 23 C, diluted with saturated aqueous
ammonium chloride solution (20 mL), and extracted with methylene
chloride (15 mL   3). The organic extracts were combined, and the
combinedsolutionwasdriedoveranhydroussodiumsulfate,filtered,and
concentrated. The residue was purified by preparative reverse-phase
HPLC to yield product 71c as a yellow solid (17 mg, 34%):
1H NMR
(400 MHz, CDCl3) δ 15.95 (br s, 1 H), 8.08 (dd, J = 5.5, 9.2 Hz, 1 H),
7.69 (br d, J = 9.2 Hz, 1 H), 7.50 7.48 (m, 2 H), 7.41 7.32 (m, 4 H),
5.37, 5.33 (ABq, J = 12.2 Hz, 2 H), 3.98 (d, J = 10.4 Hz, 1 H), 3.87 (s,
3H),3.48(dd,J=4.9,15.3Hz,1H),3.04 2.98(m,1H),2.63 2.47(m,
9H),2.19(d,J=14.0Hz,1H),1.59(s,9H),0.81(s,9H),0.26(s,3H),
0.12 (s, 3 H); MS (ESI) m/z 815.50 (M þ H).
Compounds 71a and 71b were prepared from compound 15a and
15b using similar conditions.
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]-
oxy}-15-(dimethylamino)-9-fluoro-5-hydroxy-4,6-dioxo-4,4a,6,13,13a,-
14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-Butyl Carbo-
nate (71a).
1H NMR (400 MHz, CDCl3) δ 16.01 (br s, 1 H), 7.76
(dd, J = 5.5, 9.2 Hz, 1 H), 7.68 (br d, J = 9.2 Hz, 1 H), 7.53 (s, 1 H),
7.50 7.46 (m, 2 H), 7.39 7.29 (m, 4 H), 5.37, 5.33 (ABq, J =1 2 . 2H z ,
2H),3.97(d,J=11.0Hz,1H),3.10 3.05(m,2H),2.98 2.94(m,1H),
2.58 2.46 (m, 8 H), 2.13 (d, J = 14.0 Hz, 1 H), 1.58 (s, 9 H), 0.81 (s, 9
H),0.26(s,3H),0.12(s,3H);
19FNMR(400MHz,CDCl3)δ 111.7;
MS (ESI) m/z 785.47 (M þ H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]
oxy}-12-chloro-15-(dimethylamino)-9-fluoro-5-hydroxy-4,6-dioxo-
4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-
Butyl Carbonate (71b).
1H NMR (400 MHz, CDCl3) δ 15.82 (br s,
1H),8.30(dd,J=5.5,9.2Hz,1H),7.75 7.69(m,1H),7.50 7.44(m,
3 H), 7.39 7.32 (m, 3 H), 5.37, 5.33 (ABq, J = 12.2 Hz, 2 H), 3.94 (d,
J = 11.0 Hz, 1 H), 3.66 (dd, J = 4.3, 15.9 Hz, 1 H), 3.10 3.05 (m, 1 H),
2.74 2.68(m,1H),2.61 2.45(m,8H),2.20(d,J=14.0Hz,1H),1.57
(s,9H),0.82(s,9H),0.26(s,3H),0.12(s,3H);MS(ESI)m/z819.45
(M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-fluoro-3,12,14,14a-tetra-
hydroxy-7-methoxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropenta-
cene-2-carboxamide (72c). Prepared from compound 71c (17 mg,
0.020 mmol, 1.0 equiv) by desilylation and hydrogenation according
to General Procedures D and E (8 mg, 70% for two steps):
1H NMR
(400 MHz, CD3OD) δ 8.04 (dd, J = 5.0, 9.2 Hz, 1 H), 7.92 (dd, J = 2.8,
7.3 Hz, 1 H), 7.49 (dt, J = 2.3, 8.7 Hz, 1 H), 4.11 (s, 1 H), 3.78 (s, 3 H),
3.35(dd,J=4.1,15.1Hz,1H),3.06 2.95(m,8H),2.32(t,J=14.2Hz,
1 H), 2.28 2.24 (m, 1 H), 1.65 (q, J = 11.4 Hz, 1 H); MS (ESI) m/z
513.28 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-fluoro-3,12,14,14a-tetra-
hydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-car-
boxamide (72a). Prepared from compound 71a by desilylation and
hydrogenation according to General Procedures D and E:
1H NMR
(400 MHz, CD3OD) δ 7.92 (dd, J = 2.3, 9.6 Hz, 1 H), 7.79 (dd, J = 5.5,
9.2 Hz, 1 H), 7.44 (dt, J = 2.8, 8.7 Hz, 1 H), 7.17 (s, 1 H), 4.09 (s, 1 H),
3.09 2.96 (m, 9 H), 2.65 (t, J = 13.7 Hz, 1 H), 2.21 (ddd, J = 2.8, 4.6,
13.7 Hz, 1 H), 1.68 1.58 (m, 1 H); MS (ESI) m/z 483.26 (M þ H).
(4S,4aS,5aR,14aS)-7-Chloro-4-(dimethylamino)-10-fluoro-3,12,
14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropen-
tacene-2-carboxamide (72b). Prepared from compound 71b by desi-
lylation and hydrogenation according to General Procedures D and E:
1H NMR (400 MHz, CD3OD) δ 8.28 (dd, J = 5.0, 9.2 Hz, 1 H), 8.05
(dd, J = 1.8, 9.6 Hz, 1 H), 7.62 (dt, J = 2.8, 9.2 Hz, 1 H), 4.11 (s, 1 H),
3.58(dd,J=4.6,15.6Hz,1H),3.05 2.97(m,8H),2.78(t,J=14.6Hz,
1 H), 2.27 2.24 (m, 1 H), 1.73 1.63 (m, 1 H); MS (ESI) m/z 517.23
(M þ H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]-
oxy}-15-(dimethylamino)-5-hydroxy-4,6-dioxo-9-phenyl-4,4a,6,13,13a,-
14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-Butyl Carbonate
(73a). Compound 15a (20 mg, 0.024 mmol, 1.0 equiv), phenyl boronic
acid (14 mg, 0.12 mmol, 5.0 equiv), sodium carbonate (12 mg, 0.12 mmol,
5.0 equiv), and Pd(dppf)Cl23CH2Cl2 (1.0 mg, 0.0012 mmol, 0.05 equiv)3730 dx.doi.org/10.1021/jm1015395 |J. Med. Chem. 2011, 54, 3704–3731
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were dissolved in a mixture of toluene (1 mL), 1,4-dioxane (1 mL), and
water(0.2mL).Thereactionmixturewasstirredat80Cfor1h,cooledto
rt, diluted with methylene chloride (30 mL), and washed with aqueous
potassiumphosphatebuffer(pH7.0,0.2M,10mL).Theorganicphasewas
driedoveranhydroussodiumsulfate,filtered,andconcentrated.Theresidue
was purified by preparative rever s e - p h a s eH P L Ct oa f f o r dc o m p o u n d73a
(17mg,78%) as a yellow solid:
1HNMR(400MHz,CDCl3)δ16.09(s, 1
H), 8.23 (s, 1 H), 7.83 (s, 2 H), 7.68 7.66 (m, 2 H), 7.56 (s, 1 H),
7.51 7.47 (m, 4 H), 7.41 7.32 (m, 4 H), 5.36 (s, 2 H), 4.01 (d,
J = 10.4 Hz, 1 H), 3.15 3.08 (m, 2 H), 2.97 (t, J =1 5 . 3H z ,1H ) ,
2.59 2.47(m,8H),2.15(d,J=14.0Hz,1H),1.58(s,9H),0.82(s,9H),
0.27 (s, 3 H), 0.14 (s, 3 H); MS (ESI) m/z 843.78 (M þ H).
Compounds73band73cwerepreparedfromcompound15aandthe
respective boronic acids under similar conditions.
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]-
oxy}-15-(dimethylamino)-5-hydroxy-4,6-dioxo-9-pyridin-3-yl-4,4a,6,-
13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-7-yl tert-Butyl
Carbonate (73b).
1H NMR (400 MHz, CDCl3) δ 16.03 (s, 1 H),
8.93 (d, J = 1.8 Hz, 1 H), 8.64 (dd, J = 1.2, 4.9 Hz, 1 H), 8.24 (s, 1 H),
8.02 (dt,J=7.9,1.8 Hz,1H),7.89(d, J=8.5Hz, 1H),7.79 (dd, J=8.5,
1.2 Hz, 1 H), 7.59 (s, 1 H), 7.50 7.46 (m, 3 H), 7.39 7.32 (m, 3 H),
5.37,5.34(ABq,J=12.2Hz,2H),3.98(d,J=11.0Hz,1H),3.15 3.10
(m,2H),2.98(t,J=15.3Hz,1H),2.58 2.48(m,8H),2.15(d,J=14.0
Hz, 1 H), 1.58 (s, 9 H), 0.82 (s, 9 H), 0.27 (s, 3 H), 0.13 (s, 3 H); MS
(ESI) m/z 844.74 (M þ H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]-
oxy}-15-(dimethylamino)-9-[4-(dimethylamino)phenyl]-5-hydroxy-
4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d]isoxazol-
7-yl tert-Butyl Carbonate (73c).
1H NMR (400 MHz, CDCl3) δ 16.11
(s, 1 H), 8.16 (s, 1 H), 7.83 7.77 (m, 2 H), 7.61 7.59 (m, 2 H),
7.52 7.49(m,3H),7.39 7.32(m,3H),6.92 6.90(m,2H),5.37,5.34
(ABq, J = 12.2 Hz, 2 H),4.01 (d, J = 10.4 Hz, 1 H),3.19 2.93 (m, 9 H),
2.58 2.46(m,8H),2.14(d,J=14.0Hz,1H),1.58(s,9H),0.82(s,9H),
0.27 (s, 3 H), 0.13 (s, 3 H); MS (ESI) m/z 886.90 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-
1,13-dioxo-10-phenyl-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-
carboxamide (75a). Prepared from compound 73a by desilylation and
hydrogenationaccordingtoGeneralProceduresDandE:
1HNMR(400
MHz,CD3OD)δ8.48(d,J=1.8Hz,1H),7.88(dd,J=1.8,8.7Hz,1H),
7.76(d,J=8.4Hz,1H),7.71(d,J=7.3Hz,2H),7.48(t,J=7.3Hz,2H),
7.37(t,J=7.3Hz,1H),7.09(s,1H),4.10(s,1H),3.09 2.93(m,9H),
2.58(t,J=14.2Hz,1H),2.23 2.20(m,1H),1.64 1.54 (m,1H);MS
(ESI) m/z 541.43 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-
1,13-dioxo-10-pyridin-3-yl-1,4,4a,5,5a,6,13,14a-octahydropentacene-
2-carboxamide (75b). Prepared from compound 73b by desilylation
and hydrogenation according to GeneralProcedures D andE:
1HNMR
(400 MHz, CD3OD) δ 9.33 (s, 1 H), 9.07 (d, J = 6.4 Hz, 1 H), 8.87 (d,
J = 6.4 Hz, 1 H), 8.76 (s, 1 H), 8.22 (t, J = 7.8 Hz, 1 H), 8.04 (d, J = 7.8
Hz,1H),7.92(d,J=7.8Hz,1H),7.19(s,1H),4.12(s,1H),3.12 2.97
(m,9H),2.64(t,J=13.3Hz,1H),2.25 2.23(m,1H),1.67 1.58(m,
1 H); MS (ESI) m/z 542.41 (M þ H).
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-[4-(dimethylamino)phenyl]-
3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydro-
pentacene-2-carboxamide (75c). Prepared from compound 73c by
desilylation and hydrogenation according to General Procedures D and
E:
1H NMR (400 MHz, CD3OD) δ 8.49 (s, 1 H), 7.92 7.84 (m, 3 H),
7.77 7.75(m,3H),7.08(s,1H),4.06(s,1H),3.30(s,6H),3.08 2.92
(m,9H),2.57(t,J=13.7Hz,1H),2.20 2.17(m,1H),1.60 1.51(m,
1 H); MS (ESI) m/z 584.51 (M þ H).
Susceptibility Testing. Compound stocks were prepared and
serially diluted in sterile deionized water. Tetracycline-susceptible iso-
lates SA100 (Staph. aureus ATCC 13709, Smith), SA101 (Staph. aureus
ATCC 29213), SP106 (Strep. pneumoniae ATCC 49619), EF103 (Enc.
faecalisATCC29212),EC107(E.coliATCC25922),KP109(Klebsiella
pneumoniae ATCC 13883), AB110 (Acinetobacter baumannii ATCC
19606), EC108 (Enterobacter cloacae ATCC 13047), and PA111
(Pseudomonas aeruginosa ATCC 27853) were obtained from the Amer-
ican Type Culture Collection (ATCC, Manassas, VA). Tetracycline-
resistant isolates Staph. aureus SA158 (tetK), Strep. pneumoniae SP160
(tetM), Enc. faecalis EF159 (tetM), E. coli EC155 (tetA), and K.
pneumoniae KP153 (tetA) were obtained from Marilyn Roberts’ labora-
tory at the University of Washington. Staph. aureus SA161 (tetM) was
obtained from Micromyx (Kalamazoo, MI). Minimal inhibitory con-
centration (MIC) determinations were performed in liquid medium in
96-well microtiter plates according to the methods described by the
Clinical and Laboratory Standards Institute (CLSI).
27 Cation-adjusted
MuellerHintonbrothwasobtainedfromBBL(Cat.no.212322,Becton
Dickinson,Sparks,MD),preparedfreshandkeptat4Cpriortotesting.
Defibrinated horse blood (Cat. no. A0432, PML Microbiologicals,
Wilsonville, OR) was used to supplement medium, as appropriate. All
test methods met acceptable standards based on recommended quality
control ranges for all comparator antibiotics and the appropriate ATCC
quality control strains.
PD50 Determination. In vivo efficacy was evaluated in a mouse
systemic infection model against a susceptible Staph. aureus isolate,
ATCC 13709. ATCC 13709 was mixed with 5% mucin and inoculated
by intraperitoneal injection at 2.1   10
6 cfu/mouse. Mice received the
test compounds 60 min postinfection via intravenous injection or oral
gavage (0.3 30 mg/kg, 6 mice/dose group, vehicle = sterile water).
Infectioncontrolgroupsdidnotreceivetreatment.Survivalwasassessed
overa48hperiod.Percentsurvivalwascalculated,andPD50valueswere
determined using Probit analysis.
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